

Annual

# HEDIS/ CAHPS Report

Comparative Analysis of Audited  
Results from TennCare MCOs

# Table of Contents

List of Tables.....	3	Results.....	25
List of Figures .....	4	<b>Statewide Performance.....</b>	<b>25</b>
Acknowledgements, Acronyms and Initialisms.....	7	<b>Individual Plan Performance.....</b>	<b>34</b>
Executive Summary.....	10	<b>HEDIS Trending—Statewide Weighted Rates.....</b>	<b>49</b>
Background.....	11	Effectiveness of Care Measures—	
<b>HEDIS Measures—Domains of Care .....</b>	<b>11</b>	Prevention and Screening .....	50
<b>Effectiveness of Care Measures.....</b>	<b>11</b>	Effectiveness of Care Measures—	
Prevention and Screening.....	12	Respiratory Conditions .....	60
Respiratory Conditions.....	14	Effectiveness of Care Measures—	
Cardiovascular Conditions .....	15	Cardiovascular Conditions .....	65
Diabetes.....	16	Effectiveness of Care Measures—Diabetes .....	66
Musculoskeletal Conditions .....	16	Effectiveness of Care Measures—	
Behavioral Health.....	16	Musculoskeletal Conditions.....	68
Medication Management.....	18	Effectiveness of Care Measures—Behavioral Health....	68
Overuse/Appropriateness .....	18	Effectiveness of Care Measures—	
Measures Collected Through CAHPS Health Plan		Medication Management .....	72
Survey .....	19	Effectiveness of Care Measures—	
<b>Access/Availability of Care Measures.....</b>	<b>19</b>	Overuse/Appropriateness.....	73
<b>Utilization and Risk-Adjusted Utilization .....</b>	<b>21</b>	Access/Availability of Care Measures .....	75
<b>Relative Resource Use.....</b>	<b>22</b>	Utilization and Risk-Adjusted Utilization Measures .....	80
<b>Experience of Care .....</b>	<b>22</b>	<b>APPENDIX A   Utilization Measure Results and</b>	
CAHPS Health Plan Survey 5.0H Adult Version (CPA)		<b>Benchmarks .....</b>	<b>A-1</b>
and 5.0H Child Version (CPC).....	22	<b>Utilization Additional Measure Descriptions .....</b>	<b>A-1</b>
Children With Chronic Conditions (CCC).....	23	<b>Utilization Measures: Plan-Specific Rates/     National Benchmarks .....</b>	<b>A-2</b>
<b>Health Plan Descriptive Information Measures .....</b>	<b>24</b>	<b>APPENDIX B   HEDIS 2015 National Medicaid Means</b>	
<b>Measures Collected Using Electronic Clinical Data</b>		<b>and Percentiles .....</b>	<b>B-1</b>
<b>Systems (ECDS) .....</b>	<b>24</b>	<b>APPENDIX C   MCO Population in Member Months ....</b>	<b>C-1</b>
		<b>APPENDIX D   Measure Reporting Options.....</b>	<b>D-1</b>

## List of Tables

Table CIS. Combination Vaccinations for Childhood Immunization Status (CIS) .....	13
Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures .....	26
Table 1b. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance .....	31
Table 2. Comparative Weighted State and National HEDIS Rates: Access/Availability of Care Measures .....	32
Table 3. Comparative Weighted State and National HEDIS Rates: Utilization Measures .....	33
Table 4. HEDIS 2016 Rating Color and Measure Designations .....	34
Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures .....	35
Table 5b. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance .....	42
Table 6. HEDIS 2016 Plan-Specific Rates: Access/Availability of Care Measures .....	43
Table 7. HEDIS 2016 Plan-Specific Rates: Use of Services Measures .....	44
Table 8. 2016 CAHPS Rating Color and Measure Designations .....	45
Table 9. 2016 CAHPS 5.0H Adult Medicaid Survey Results .....	45
Table 10. 2016 CAHPS 5.0H Child Medicaid Survey Results (General Population) .....	46
Table 11. 2016 CAHPS 5.0H Child Medicaid Survey Results (Children with Chronic Conditions) .....	47
Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures .....	A-2
Table B. HEDIS 2015 National Medicaid Means and Percentiles .....	B-1
Table C1. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—AG .....	C-1
Table C2. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—BC and TCS .....	C-2
Table C3. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—UHC .....	C-4
Table D. Measure reporting options: Administrative/Hybrid .....	D-1

## List of Figures

Fig. 1. Adult BMI Assessment (ABA) .....	50	Fig. 22. CIS: Combination 3 .....	55
Fig. 2. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)— BMI Percentile: 3–11 years.....	50	Fig. 23. CIS: Combination 4 .....	55
Fig. 3. WCC—BMI Percentile: 12–17 years .....	50	Fig. 24. CIS: Combination 5 .....	55
Fig. 4. WCC—BMI Percentile: Total.....	50	Fig. 25. CIS: Combination 6 .....	56
Fig. 5. WCC—Counseling for Nutrition: 3–11 years .....	51	Fig. 26. CIS: Combination 7 .....	56
Fig. 6. WCC—Counseling for Nutrition: 12–17 years .....	51	Fig. 27. CIS: Combination 8 .....	56
Fig. 7. WCC—Counseling for Nutrition: Total.....	51	Fig. 28. CIS: Combination 9 .....	56
Fig. 8. WCC—Counseling for Physical Activity: 3–11 years .....	51	Fig. 29. CIS: Combination 10 .....	57
Fig. 9. WCC—Counseling for Physical Activity: 12–17 years .....	52	Fig. 30. Immunizations for Adolescents (IMA): Meningococcal .....	57
Fig. 10. WCC—Counseling for Physical Activity: Total .....	52	Fig. 31. IMA: Tdap/Td .....	57
Fig. 11. Childhood Immunization Status (CIS): DTap.....	52	Fig. 32. IMA: Combination 1.....	57
Fig. 12. CIS: IPV .....	52	Fig. 33. Human Papillomavirus Vaccine for Female Adolescents (HPV) .....	58
Fig. 13. CIS: MMR.....	53	Fig. 34. Lead Screening in Children (LSC).....	58
Fig. 14. CIS: HiB .....	53	Fig. 35. Breast Cancer Screening (BCS) .....	58
Fig. 15. CIS: HepB .....	53	Fig. 36. Cervical Cancer Screening (CCS) .....	58
Fig. 16. CIS: VZV .....	53	Fig. 37. Chlamydia Screening in Women (CHL): 16–20 years .....	59
Fig. 17. CIS: PCV .....	54	Fig. 38. CHL: 21–24 years .....	59
Fig. 18. CIS: HepA .....	54	Fig. 39. CHL: Total.....	59
Fig. 19. CIS: RV.....	54	Fig. 40. Appropriate Testing for Children With Pharyngitis (CWP) .....	60
Fig. 20. CIS: Flu .....	54	Fig. 41. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR).....	60
Fig. 21. CIS: Combination 2 .....	55		

Fig. 42. Pharmacotherapy Management of COPD Exacerbation (PCE): Systemic Corticosteroid .....	60	Fig. 60. Persistence of Beta-Blocker Treatment After a Heart Attack (PBH) .....	65
Fig. 43. PCE: Bronchodilator .....	60	Fig. 61. Comprehensive Diabetes Care (CDC): HbA1c Testing .....	66
Fig. 44. Medication Management for People With Asthma (MMA)—Medication Compliance 50%: 5–11 years .....	61	Fig. 62. CDC: HbA1c Control (<7.0%) .....	66
Fig. 45. MMA—Medication Compliance 50%: 12–18 years .....	61	Fig. 63. CDC: HbA1c Control (<8.0%) .....	66
Fig. 46. MMA—Medication Compliance 50%: 19–50 years .....	61	Fig. 64. CDC: Retinal Eye Exam Performed .....	66
Fig. 47. MMA—Medication Compliance 50%: 51–64 years .....	61	Fig. 65. CDC: Medical Attention for Nephropathy .....	67
Fig. 48. MMA—Medication Compliance 50%: Total .....	62	Fig. 66. CDC: Blood Pressure Control (<140/90 mm Hg) ...	67
Fig. 49. MMA—Medication Compliance 75%: 5–11 years .....	62	Fig. 67. CDC: HbA1c Poor Control (>9.0%)* .....	67
Fig. 50. MMA—Medication Compliance 75%: 12–18 years .....	62	Fig. 68. Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) .....	68
Fig. 51. MMA—Medication Compliance 75%: 19–50 years .....	62	Fig. 69. Antidepressant Medication Management (AMM): Effective Acute Phase Treatment .....	68
Fig. 52. MMA—Medication Compliance 75%: 51–64 years .....	63	Fig. 70. AMM: Effective Continuation Phase Treatment ....	68
Fig. 53. MMA—Medication Compliance 75%: Total .....	63	Fig. 71. Follow-Up Care for Children Prescribed ADHD Medication (ADD): Initiation Phase .....	69
Fig. 54. Asthma Medical Ratio (AMR): 5–11 years .....	63	Fig. 72. ADD: Continuation and Maintenance Phase .....	69
Fig. 55. AMR: 12–18 years .....	63	Fig. 73. Follow-Up After Hospitalization for Mental Illness (FUH): 7-Day Follow-Up .....	69
Fig. 56. AMR: 19–50 years .....	64	Fig. 74. FUH: 30-Day Follow-Up .....	69
Fig. 57. AMR: 50–64 years .....	64	Fig. 75. Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD) .....	70
Fig. 58. AMR: Total .....	64	Fig. 76. Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD) .....	70
Fig. 59. Controlling High Blood Pressure (CBP) .....	65	Fig. 77. Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC) .....	70

Fig. 78. Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) .....	70	Fig. 98. CAP: 25 months–6 years .....	75
Fig. 79. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM): 1-5 Years .....	71	Fig. 99. CAP: 7–11 years .....	76
Fig. 80. APM: 6-11 Years .....	71	Fig. 100. CAP: 12–19 years .....	76
Fig. 81. APM: 12-17 Years .....	71	Fig. 101. Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET)—Initiation of AOD Treatment: 13–17 years .....	76
Fig. 82. APM: Total .....	71	Fig. 102. IET—Initiation of AOD Treatment: ≥18 years .....	76
Fig. 83. Annual Monitoring for Patients on Persistent Medications (MPM): ACE Inhibitors or ARBs .....	72	Fig. 103. IET—Initiation of AOD Treatment: Total .....	77
Fig. 84. MPM: Digoxin .....	72	Fig. 104. IET—Engagement of AOD Treatment: 13–17 years .....	77
Fig. 85. MPM: Diuretics .....	72	Fig. 105. IET—Engagement of AOD Treatment: ≥18 years .....	77
Fig. 86. MPM: Total .....	72	Fig. 106. IET—Engagement of AOD Treatment: Total .....	77
Fig. 87. Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)* .....	73	Fig. 107. Prenatal and Postpartum Care (PPC): Timeliness of Prenatal Care .....	78
Fig. 88. Appropriate Treatment for Children With Upper Respiratory Infection (URI) .....	73	Fig. 108. PPC: Postpartum Care .....	78
Fig. 89. Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB) .....	73	Fig. 109. Call Answer Timeliness (CAT) .....	78
Fig. 90. Use of Imaging Studies for Low Back Pain (LBP) ..	73	Fig. 110. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP): 1-5 Years .....	78
Fig. 91. Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC): 1-5 Years* .....	74	Fig. 111. APP: 6-11 Years .....	79
Fig. 92. APC: 6-11 Years* .....	74	Fig. 112. APP: 12-17 Years .....	79
Fig. 93. APC: 12-17 Years* .....	74	Fig. 113. APP: Total .....	79
Fig. 94. APC: Total* .....	74	Fig. 114. Frequency of Ongoing Prenatal Care (FPC): ≥ 81% .....	80
Fig. 95. Adults' Access to Preventive/Ambulatory Health Services (AAP): 20–44 years .....	75	Fig. 115. Well-Child Visits in the First 15 Months of Life (W15): 6 or More Visits .....	80
Fig. 96. AAP: 45–64 years .....	75	Fig. 116. Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34) .....	80
Fig. 97. Children and Adolescents' Access to Primary Care Practitioners (CAP): 12–24 months .....	75	Fig. 117. Adolescent Well-Care Visits (AWC) .....	80

## Acknowledgements, Acronyms and Initialisms<sup>1,2</sup>

AAB .....	Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis	APM.....	Metabolic Monitoring for Children and Adolescents on Antipsychotics
AAP .....	Adults' Access to Preventive/ Ambulatory Health Services	APP .....	Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics
ABA .....	Adult BMI Assessment	ARB.....	Angiotensin Receptor Blocker
ABX .....	Antibiotic Utilization	ART .....	Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis
ACE .....	Angiotensin Converting Enzyme	ASM .....	Use of Appropriate Medications for People With Asthma
ADD.....	Follow-Up Care for Children Prescribed ADHD Medication	AWC.....	Adolescent Well-Care Visits
ADHD.....	Attention-Deficit/Hyperactivity Disorder	BC.....	Volunteer State Health Plan, Inc, as BlueCare Tennessee
AHRQ.....	Agency for Healthcare Research and Quality	BCE/BCM/BCW.....	BC in the Tennessee East, Middle and West Grand Regions
AMB.....	Ambulatory Care	BCS.....	Breast Cancer Screening
AG.....	Amerigroup Community Care, Inc., as Amerigroup	BlueCare®; BlueCare Tennessee <sup>SM</sup> .....	registered or service marks of The BlueCross BlueShield Association
AGE/AGM/AGW.....	AG in the Tennessee East, Middle and West Grand Regions	BlueCross BlueShield of Tennessee; BlueCare .....	licensees of The BlueCross BlueShield Association
AMI.....	Acute Myocardial Infarction	BMI .....	Body Mass Index
AMM .....	Antidepressant Medication Management	BP .....	Blood Pressure
AMR.....	Asthma Medication Ratio	BR.....	Biased Rate
AOD.....	Alcohol or Other Drug		
APC .....	Use of Multiple Concurrent Antipsychotics in Children and Adolescents		

<sup>1</sup> The source for data contained in this publication is Quality Compass® 2015 and is used with the permission of the National Committee for Quality Assurance (NCQA). Quality Compass 2015 includes certain CAHPS data. Any data display, analysis, interpretation, or conclusion based on these data is solely that of the authors, and NCQA specifically disclaims responsibility for any such display, analysis, interpretation, or conclusion. Quality Compass is a registered trademark of NCQA. CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

<sup>2</sup> Other company and product names may be trademarks of the respective companies with which they are associated. The mention of such companies and product names is with due recognition and without intent to misappropriate such names or marks.

CAHPS® .....	refers to the Consumer Assessment of Healthcare Providers and Systems and is a registered trademark of AHRQ	FVA .....	Flu vaccinations for adults ages 18 to 64
CAP .....	Children and Adolescents' Access to Primary Care Practitioners	HbA1c.....	Hemoglobin A1c, also called Glycosylated Hemoglobin, Glycohemoglobin
CAT .....	Call Answer Timeliness	HEDIS® .....	refers to the Healthcare Effectiveness Data and Information Set and is a registered trademark of NCQA
CBP .....	Controlling High Blood Pressure	HepA .....	Hepatitis A Vaccination
CCC .....	Children With Chronic Conditions	HepB .....	Hepatitis B Vaccination
CCS .....	Cervical Cancer Screening	HiB.....	H ( <i>Haemophilus</i> ) Influenza Type B Vaccination
CDC .....	Comprehensive Diabetes Care	HPV .....	Human Papillomavirus Vaccine (also, HPV for Female Adolescents measure)
CHL .....	Chlamydia Screening in Women	HTN.....	Hypertension
CIS .....	Childhood Immunization Status	IAD .....	Identification of Alcohol and Other Drug Services
CPA .....	CAHPS Health Plan Survey 5.0H Adult Version	IET.....	Initiation and Engagement of AOD Dependence Treatment
CPC .....	CAHPS Health Plan Survey 5.0H Child Version	IMA .....	Immunizations for Adolescents
COPD.....	Chronic Obstructive Pulmonary Disease	IP; IPU.....	Inpatient; IP Utilization – General Hospital/Acute Care
CVD .....	Cardiovascular Disease	IPV.....	Polio Vaccination
CWP.....	Appropriate Testing for Children With Pharyngitis	LBP .....	Use of Imaging Studies for Low Back Pain
CY .....	Calendar Year	LDL-C .....	Low-Density Lipoprotein Cholesterol
DMARD.....	Disease-Modifying Anti-Rheumatic Drug	LSC .....	Lead Screening in Children
DTaP.....	Diphtheria, Tetanus and Acellular Pertussis Vaccination	MCO .....	Managed Care Organization
ED .....	Emergency Department	MMA.....	Medication Management for People With Asthma
ENP .....	Enrollment by Product Line	MMR.....	Measles, Mumps and Rubella Vaccination
Flu.....	Influenza	MPM .....	Annual Monitoring for Patients on Persistent Medications
FPC.....	Frequency of Ongoing Prenatal Care	MPT .....	Mental Health Utilization
FSP.....	Frequency of Selected Procedure		
FUH .....	Follow-Up After Hospitalization for Mental Illness		

## Acknowledgements, Acronyms and Initialisms

MSC .....	Medical Assistance With Smoking and Tobacco Use Cessation	SMC .....	Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia
MY .....	Measurement Year	SMD .....	Diabetes Monitoring for People With Diabetes and Schizophrenia
NA .....	Not Applicable	SPC .....	Statin Therapy for Patients With CVD
NB .....	No Benefit	SPD .....	Statin Therapy for Patients With Diabetes
NCQA .....	National Committee for Quality Assurance	SPR .....	Use of Spirometry Testing in the Assessment and Diagnosis of COPD
NCQA HEDIS Compliance Audit™ .....	trademark of NCQA	SSD .....	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications
NCS .....	Non-Recommended Cervical Cancer Screening in Adolescent Females	Strep .....	Streptococcus
NR .....	Not Reported	Td; Tdap .....	Tetanus, Diphtheria Toxoids Vaccine; Td and Acellular Pertussis Vaccine
NQ .....	Not Required	TCS .....	Volunteer State Health Plan, Inc. d.b.a. TennCareSelect statewide
OB-GYN .....	Obstetrician-Gynecologist	UHC .....	UnitedHealthcare Plan of the River Valley, Inc. d.b.a. UnitedHealthcare
PBH .....	Persistence of Beta-Blocker Treatment After a Heart Attack	UHCE/UHCM/UHCW .....	UHC in the Tennessee East, Middle and West Grand Regions
PCE .....	Pharmacotherapy Management of COPD Exacerbation	UN .....	Un-Audited
PCP .....	Primary Care Practitioner	URI .....	Upper Respiratory Infection, and the measure: Appropriate Treatment for Children With URI
PCV .....	Pneumococcal Conjugate Vaccination	VZV .....	Chicken Pox/Varicella Zoster Vaccination
PMPY .....	Per Member Per Year	W15 .....	Well-Child Visits in the First 15 Months of Life
PPC .....	Prenatal and Postpartum Care	W34 .....	Well-Child Visits in the Third, Fourth, Fifth, and Sixth Years of Life
Qsource® .....	a registered trademark	WCC .....	Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
Quality Compass® .....	a registered trademark of NCQA, the comprehensive national database of health plans' HEDIS and CAHPS results		
R .....	Reportable		
RA .....	Rheumatoid Arthritis		
RV .....	Rotavirus Vaccination		
SAA .....	Adherence to Antipsychotic Medications for Individuals With Schizophrenia		

## Executive Summary

Medicaid managed care organizations (MCOs) are required to report a full Healthcare Effectiveness Data and Information Set (HEDIS) as a part of the accreditation mandates in Tennessee. The HEDIS requirement is an integral part of the accreditation process of the National Committee for Quality Assurance (NCQA). In 2006, Tennessee became the first state in the nation requiring all MCOs to become accredited by NCQA, an independent, not-for-profit organization that assesses and scores MCO performance on important dimensions of care and service in a broad range of health issues.

By 2016, more than 90% of health plans in America were using the HEDIS tool because its standardized measures of MCO performance allow comparisons to national averages and benchmarks as well as between a state's MCOs, and over time. The Consumer Assessment of Healthcare Providers and Systems (CAHPS) set of standardized surveys is included in HEDIS to measure members' satisfaction with their care. This *2016 HEDIS/CAHPS Report* summarizes the results for the MCOs contracting with TennCare, the Medicaid program of the Tennessee Division of Health Care Finance and Administration.

For an overview of the performance of Tennessee's MCOs, a calculated weighted average of the scores of all those reporting is provided alongside national averages in the [Statewide](#)

[Performance](#) section. MCO-specific measures are presented in the [Individual Plan Performance](#) section for cross-comparison with color-coding for national and state benchmark comparison where available/applicable. Weighted average performances of Tennessee's MCOs on certain measures are presented in the [HEDIS Trending Since 2006](#) section. Beginning in January 2015, there were 400,000 TennCare enrollees transitioning to new MCOs. The transition occurred over several months and may have influenced measure results, resulting in downward trend for some measures. Subsequently, trending should be made with caution.

[Appendix A](#) contains a comprehensive table of plan-specific results for HEDIS 2016 Utilization Measures and HEDIS 2015 national benchmarks. The table in [Appendix B](#) contains the HEDIS 2015 National Medicaid Means and Percentiles for reference to these benchmarks, and the table in [Appendix C](#) reveals populations reported by MCOs in member months by age and sex for HEDIS 2016. [Appendix D](#) presents the reporting options for each measure, whether administrative, hybrid or both.

## Background

### HEDIS Measures—Domains of Care

HEDIS is an important tool designed to ensure the public has the information needed to reliably compare the performance of managed healthcare plans. Standardized methodologies incorporating statistically valid samples of members ensure the integrity of measure reporting and help purchasers make more reliable, relevant comparisons between health plans. HEDIS measures are subject to a NCQA HEDIS Compliance Audit that must be conducted by an NCQA-certified HEDIS Compliance Auditor under the auspices of an NCQA-licensed organization. This ensures the integrity of the HEDIS collection and calculation process at each MCO through an overall information systems capabilities assessment, followed by an evaluation of the ability to comply with HEDIS specifications.

The HEDIS rates presented in this report refer to data collected during the review period of the previous calendar year (CY), from January 1 to December 31. For HEDIS 2016 results, CY2015 was the review period. Similarly, comparative data presented in this report from the HEDIS 2015 Medicaid Means and Percentiles reflect data procured during CY2014.

HEDIS 2016 assesses care across body systems, access to and satisfaction with healthcare services and specific utilization

through a total of 88 measures (Commercial, Medicare and Medicaid) across seven domains of care:

- ◆ Effectiveness of Care
- ◆ Access/Availability of Care
- ◆ Utilization and Risk-Adjusted Utilization
- ◆ Relative Resource Use
- ◆ Experience of Care (CAHPS Survey Results)
- ◆ Health Plan Descriptive Information
- ◆ Measures Collected Using Electronic Clinical Data Systems

The following brief descriptions of selected HEDIS measures were extracted from NCQA's *HEDIS 2016 Volume 2: Technical Specifications*, which includes additional information related to each measure. The measures presented in this report reflect data submitted from the following domains of care: Effectiveness of Care, Access/Availability of Care, Utilization, and Risk-Adjusted Utilization, and Experience of Care.

### Effectiveness of Care Measures

The measures in the Effectiveness of Care domain assess the quality of clinical care delivered within an MCO. Measures in this domain address how well the MCO delivers widely accepted preventive services and recommended screening for common diseases. The domain also includes some measures for

overuse and patient safety and addresses four major aspects of clinical care:

1. How well the MCO delivers preventive services and keeps members healthy
2. Whether members are offered the most up-to-date treatments for acute episodes of illness and get better
3. How well the MCO delivers care and assistance with coping to members with chronic diseases
4. Whether members can get appropriate tests

Starting with HEDIS 2008 reporting, Effectiveness of Care measures were grouped into more specific clinical categories, which have slightly changed:

- ◆ Prevention and Screening
- ◆ Respiratory Conditions
- ◆ Cardiovascular Conditions
- ◆ Diabetes
- ◆ Musculoskeletal Conditions
- ◆ Behavioral Health
- ◆ Medication Management
- ◆ Overuse/Appropriateness
- ◆ Measures collected by the CAHPS Health Plan Survey

Only certain measures from these categories are presented in this report, which does not include the additional category in this domain specific to Medicare. For some measures, eligible members cannot have more than one gap in continuous enrollment of up to 45 days during the measurement year (MY). Select Utilization Measures are included in [Appendix A](#).

## Prevention and Screening

Immunization measures follow guidelines for immunizations from the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices. HEDIS implements changes (e.g., new recommendations) after three years, to account for the measures' look-back period and to allow the industry time to adapt to new guidelines.

### Adult BMI Assessment (ABA)

ABA measures the percentage of members 18 to 74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the MY or the year prior to the MY.

*NOTE: For HEDIS 2016, the age criteria for BMI and BMI percentile numerator was revised from 21 years in references to 20 years.*

### Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents (WCC)

WCC measures the percentage of members 3 to 17 years of age who had an outpatient visit with a primary care practitioner (PCP) or obstetrician-gynecologist (OB-GYN) and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the MY.

*Note: Because BMI norms for youth vary with age and gender, this measure evaluated whether BMI percentile is assessed rather than an absolute BMI value. For HEDIS 2016, the physical activity requirement was revised to add that notation of safety guidance without specific mention of physical activity recommendations does not meet criteria.*

Childhood Immunization Status (CIS)

CIS assesses the percentage of children who became two years of age and who, on or before two years of age, had four diphtheria, tetanus, acellular pertussis (DTaP); three polio (IPV); one measles, mumps, and rubella (MMR); three *Haemophilus influenzae* type B (HiB); three hepatitis B (HepB); one chicken pox/varicella zoster (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (Flu) vaccines. The measure calculates a rate for each vaccine and nine separate combination rates numbered 2 to 10 as shown in **Table CIS**.

**Table CIS. Combination Vaccinations for Childhood Immunization Status (CIS)**

#	DTaP	IPV	MMR	HiB	HepB	VZV	PCV	HepA	RV	Flu
2	✓	✓	✓	✓	✓	✓				
3	✓	✓	✓	✓	✓	✓	✓			
4	✓	✓	✓	✓	✓	✓	✓	✓		
5	✓	✓	✓	✓	✓	✓	✓		✓	
6	✓	✓	✓	✓	✓	✓	✓			✓
7	✓	✓	✓	✓	✓	✓	✓	✓	✓	
8	✓	✓	✓	✓	✓	✓	✓	✓		✓
9	✓	✓	✓	✓	✓	✓	✓		✓	✓
10	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓

Immunizations for Adolescents (IMA)

IMA measures the percentage of adolescents 13 years of age who had one dose of meningococcal vaccine and one tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap) or one tetanus, diphtheria toxoids vaccine (Td) by the 13th birthday, calculating a rate for each vaccine and one combination (Meningococcal, Tdap/Td).

Human Papillomavirus Vaccine for Female Adolescents (HPV)

This measure assesses the percentage of female adolescents 13 years of age who received three doses of human papillomavirus vaccine (HPV) by the 13th birthday.

Lead Screening in Children (LSC)

LSC assesses the percentage of children two years of age who had one or more capillary or venous lead blood tests for lead poisoning on or before the second birthday.

Breast Cancer Screening (BCS)

BCS looks at whether female members are being screened for breast cancer, measuring the percentage of women 50 to 74 years of age who had a mammogram to screen for breast cancer between October 1 two years prior to the MY, and through December 31 of the MY.

*NOTE: This measure does not include biopsies, breast ultrasounds or MRIs because they are not appropriate methods for primary breast cancer screening. HEDIS 2016 added new value sets to identify bilateral mastectomy.*

### Cervical Cancer Screening (CCS)

CCS measures the percentage of women 21 to 64 years of age who were appropriately screened for cervical cancer using either of the following criteria:

- ◆ Women age 21–64 who had cervical cytology performed every three years
- ◆ Women age 30–64 who had cervical cytology/HPV co-testing performed every five years

### Chlamydia Screening in Women (CHL)

CHL assesses the percentage of women 16 to 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the MY. This measure calculates a total rate as well as two age stratifications:

- ◆ Women age 16–20
- ◆ Women age 21–24

## **Respiratory Conditions**

### Appropriate Testing for Children With Pharyngitis (CWP)

CWP measures the percentage of children 3 to 18 years of age who were diagnosed with pharyngitis, prescribed an antibiotic at an outpatient visit, and received a group A streptococcus (strep) test for the episode. A higher rate represents better performance (i.e., appropriate testing).

*Note: For HEDIS 2016, the description and ages were changed from “2–18 years of age” to “3–18 years of age”.*

### Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)

SPR reports the percentage of members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) who received appropriate spirometry testing to confirm the diagnosis.

### Pharmacotherapy Management of COPD Exacerbation (PCE)

PCE assesses the percentage of COPD exacerbation for members 40 years of age and older who had an acute inpatient (IP) discharge or emergency department (ED) visit on or between January 1 and November 30 of the MY and who were dispensed appropriate medications. Two rates are reported:

- ◆ Dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event
- ◆ Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event

*Note: The eligible population for this measure is based on acute IP discharges and ED visits, not on members. The denominator may include multiple events for the same individual.*

### Medication Management for People With Asthma (MMA)

MMA records the percentage of members 5 to 64 years of age during the MY who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period.

Two rates are reported for the percentage of members who remained on an asthma controller medication:

- ◆ For at least 50% of their treatment period
- ◆ For at least 75% of their treatment period

For MMA, a total rate and four age stratifications are reported:

- ◆ 5–11 years
- ◆ 12–18 years
- ◆ 19–50 years
- ◆ 51–64 years

*NOTE: The previous measure Use of Appropriate Medications for People With Asthma (ASM) was omitted, age stratifications added to MMA and explanatory tables for ASM replaced as MMA for HEDIS 2016. Also, clarifications were added defining oral medication dispensing events.*

### Asthma Medication Ratio (AMR)

AMR assesses the percentage of members 5 to 64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the MY. This measure calculates a total rate as well as four age stratifications:

- ◆ 5–11 years
- ◆ 12–18 years
- ◆ 19–50 years
- ◆ 51–64 years

### **Cardiovascular Conditions**

#### Controlling High Blood Pressure (CBP)

CBP reports the percentage of members 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled during the MY, a single rate based on a sum of the following criteria groups by age:

- ◆ Members 18–59 years whose BP was <140/90 mm Hg

- ◆ Members 60–85 years with a diagnosis of diabetes whose BP was <140/90 mm Hg
- ◆ Members 60–85 years without a diagnosis of diabetes whose BP was <150/90 mm Hg

#### Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)

PBH examines the use of beta-blockers as a way to prevent a second heart attack by measuring the percentage of members 18 years of age and older during the MY who were hospitalized and discharged from July 1 of the year prior to the MY to June 30 of the MY with a diagnosis of acute myocardial infarction (AMI) and who received persistent beta-blocker treatment for six months after discharge.

#### Statin Therapy for Patients With Cardiovascular Disease (SPC)

SPC reports the percentage of members identified as having clinical atherosclerotic CVD and who met the following criteria:

- ◆ *Received Statin Therapy*—Members who were dispensed at least one high or moderate-intensity statin medication during the MY
- ◆ *Statin Adherence 80%*—Members who remained on a high or moderate-intensity statin medication for at least 80% of the treatment period

For SPC, a total rate and two gender and age (during the MY) stratifications are reported:

- ◆ Males 21–75 years
- ◆ Females 40–75 years

## Diabetes

### Comprehensive Diabetes Care (CDC)

The CDC composite of seven rates measures an MCO's performance on clinical management in aspects of diabetic care through the percentage of a single sample of diabetic members (type 1 and type 2) 18 to 75 years of age who met the criteria by having the following during the MY:

- ◆ Hemoglobin A1c (HbA1c) blood test
- ◆ Poorly controlled diabetes (HbA1c >9.0%)  
*Note: a lower rate indicates better performance (i.e., low rates of poor control indicate better care)*
- ◆ Controlled diabetes (most recent HbA1c <8.0%)
- ◆ Controlled diabetes (most recent HbA1c <7.0%) for a selected population
- ◆ Eye exam (retinal)
- ◆ Medical attention for nephropathy
- ◆ Controlled blood pressure (<140/90 mm Hg)

### Statin Therapy for Patients With Diabetes (SPD)

SPD reports the percentage of members 40 to 75 years of age who do not have atherosclerotic CVD and met the following criteria reported as two rates:

- ◆ *Received Statin Therapy*—Members who were dispensed at least one statin medication of any intensity during the MY
- ◆ *Statin Adherence 80%*—Members who remained on a statin medication of any intensity for at least 80% of the treatment period

## Musculoskeletal Conditions

### Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

ART assesses whether members who were diagnosed with rheumatoid arthritis (RA) were prescribed a disease-modifying anti-rheumatic drug (DMARD) to attenuate the damaging progression, reduce inflammation and improve functional status. The rate is the percentage of members diagnosed with RA, and not HIV or pregnancy, who were dispensed at least one ambulatory prescription for a DMARD during the MY.

## Behavioral Health

### Antidepressant Medication Management (AMM)

AMM measures the percentage of members 18 years of age and older who had a diagnosis of major depression, who were initiated and remained on an antidepressant medication treatment. Two rates are reported:

- ◆ *Effective Acute Phase Treatment*—The percentage who remained on medication for a three-month adequate acute phase trial (at least 84 days/12 weeks)
- ◆ *Effective Continuation Phase Treatment*—The percentage who completed continuous medication treatment (remained on medication for at least 180 days/6 months)

### Follow-Up Care for Children Prescribed ADHD Medication (ADD)

ADD assesses the percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of these visits must have been within 30 days of the earliest ambulatory prescription dispensed for ADHD medication, at which time the member must have been 6 to 12 years of age. Two rates are reported:

- ◆ *Initiation Phase*—The percentage who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase
- ◆ *Continuation and Maintenance Phase*—The percentage who remained on the medication for at least 210 days and who, in addition to the Initiation Phase follow-up, had at least two follow-up visits with a practitioner within 270 days (nine months) of the end of the Initiation Phase

### Follow-Up After Hospitalization for Mental Illness (FUH)

FUH examines continuity of care for mental illness through the percentage of discharges for members six years of age and older who were hospitalized for selected mental illness diagnoses and who had an outpatient visit, an intensive outpatient encounter or partial hospitalization with a mental health practitioner.

Two rates are reported as the percentage of discharges for which the member received follow-up within the following:

- ◆ 7 days of discharge
- ◆ 30 days of discharge

### Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)

SSD measures the percentage of members 18 to 64 years of age with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the MY.

### Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)

SMD is the percentage of members 18 to 64 years of age with schizophrenia and diabetes who had both an low-density lipoprotein cholesterol (LDL-C) test and an HbA1c test during the MY.

### Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)

SMC reports the percentage of members 18 to 64 years of age with schizophrenia and CVD who had an LDL-C test during the MY.

### Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

SAA assesses the percentage of members with schizophrenia who were 19 to 64 years of age during the MY who were

dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

#### Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

APM measures the percentage of children and adolescents 1 to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. It calculates a total rate as well as three age stratifications:

- ◆ 1–5 years
- ◆ 6–11 years
- ◆ 12–17 years

### **Medication Management**

#### Annual Monitoring for Patients on Persistent Medications (MPM)

MPM reports the percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the MY and at least one therapeutic monitoring event for the therapeutic agent in the MY. Three rates are reported separately and as a sum total rate:

- ◆ Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB)
- ◆ Annual monitoring for members on digoxin
- ◆ Annual monitoring for members on diuretics

### **Overuse/Appropriateness**

*Not new measures for HEDIS 2016, but grouped under this new category.*

#### Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)

NCS records the percentage of adolescent females 16 to 20 years of age who were screened unnecessarily for cervical cancer.

*Note: A lower rate indicates better performance.*

#### Appropriate Treatment for Children With Upper Respiratory Infection (URI)

This measures the percentage of children 3 months to 18 years of age who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription. This measure is reported as an inverted rate  $[1 - (\text{numerator}/\text{eligible population})]$ , with a higher rate indicating appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed).

#### Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)

AAB reports the percentage of adults 18 to 64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription. This measure is reported as an inverted rate  $[1 - (\text{numerator}/\text{eligible population})]$ , with a higher rate indicating appropriate treatment of adults with acute bronchitis (i.e., the proportion for whom antibiotics were not prescribed).

### Use of Imaging Studies for Low Back Pain (LBP)

LBP assesses the percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis. This measure is reported as an inverted rate [ $1 - (\text{numerator}/\text{eligible population})$ ], with a higher rate indicating an appropriate treatment of low back pain (i.e., the proportion for whom imaging studies did not occur).

### Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)

APC measures the percentage of children and adolescents 1 to 17 years of age who were on two or more concurrent antipsychotic medications. This measure calculates a total rate as well as three age stratifications:

- ◆ 1–5 years
- ◆ 6–11 years
- ◆ 12–17 years

*Note: For this measure, a lower rate indicates better performance (i.e., low rates of concurrent antipsychotics indicate better care).*

## Measures Collected Through CAHPS Health Plan Survey

### Flu vaccinations for adults ages 18 to 64 (FVA)

FVA reports the percentage of members 18 to 64 years of age who received a flu vaccination between July 1 of the MY and the date when the CAHPS 5.0H Adult Survey was completed.

### Medical Assistance With Smoking and Tobacco Use Cessation (MSC)

This measure is collected using the survey methodology to arrive at a rolling average that represents the percentage of members 18 years of age and older who were current smokers or tobacco users seen during the MY.

MSC assesses the following facets of providing medical assistance with smoking and tobacco use cessation:

- ◆ *Advising Smokers and Tobacco Users to Quit*—Those who received advice to quit
- ◆ *Discussing Cessation Medications*—Those for whom cessation medications were recommended or discussed
- ◆ *Discussing Cessation Strategies*—Those for whom cessation methods or strategies were provided or discussed

**Percentage of Current Smokers** is not a HEDIS performance measure, but provides additional information to support analysis of other MSC data. The MCOs started reporting this data in 2015 in CAHPS results; subsequently, the rates have been added to this report.

## Access/Availability of Care Measures

The measures in the Access/Availability of Care domain evaluate how members access important and basic services of their MCO. Included are measures of overall access, how many

members are actually using basic MCO services, and the use and availability of specific services.

#### Adults' Access to Preventive/Ambulatory Health Services (AAP)

This measures the percentage of members 20 years and older who had an ambulatory or preventive care visit during the MY to assess whether adult members have access to/receive such services. MCOs report a total rate and three age stratifications:

- ◆ 20–44 years
- ◆ 45–64 years
- ◆ ≥ 65 years

*Note: Rates for adults 65 years of age and older are not included in this report as those services would be provided by Medicare. Because the total rate would include this age group, it has been excluded from this report as well.*

#### Children and Adolescents' Access to Primary Care Practitioners (CAP)

CAP assesses general access to care for children and adolescents through the percentage of members 12 months to 6 years of age who had a visit with a PCP (e.g., pediatrician, family physician) during the MY, and members 7 to 19 years of age who had a visit with a PCP during the MY or the year prior. MCOs report four separate percentages:

- ◆ 12–24 months
- ◆ 25 months – 6 years
- ◆ 7–11 years
- ◆ 12–19 years

#### Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET)

IET assesses adolescent and adult members age 13 and older who demonstrated a new episode of alcohol or other drug (AOD) dependence and received the following:

- ◆ *Initiation of AOD Treatment*—initial treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or patient hospitalization within 14 days of diagnosis
- ◆ *Engagement of AOD Treatment*—two or more services with an AOD diagnosis within 30 days of the initiation visit in addition to initiating treatment

MCOs report a total rate and two age stratifications for each:

- ◆ 13–17 years
- ◆ ≥ 18 years

#### Prenatal and Postpartum Care (PPC)

PPC measures the percentage of live birth deliveries between November 6 of the year prior to the MY and November 5 of the MY. For these women, the composite assesses the percentage of deliveries where members received the following PPC facets:

- ◆ *Timeliness of Prenatal Care*—received a prenatal care visit as a member of the MCO in the first trimester *or* within 42 days of MCO enrollment
- ◆ *Postpartum Care*—had a postpartum visit on or between 21 and 56 days after delivery

#### Call Answer Timeliness (CAT)

CAT reports the percentage of calls received by the MCO's Member Services call centers (during operating hours) during the MY that were answered by a live voice within 30 seconds. This measure complements member feedback on customer service obtained through the CAHPS 5.0H health plan survey.

### Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)

APP measures the percentage of children and adolescents 1 to 17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as first-line treatment. MCOs report a total rate and three age stratifications:

- ◆ 1–5 years
- ◆ 6–11 years
- ◆ 12–17 years

## Utilization and Risk-Adjusted Utilization

This domain name was adjusted for HEDIS 2016, but still consists of utilization measures designed to capture the frequency of certain services provided to measure how MCOs use and manage resources and provision of member care. Three kinds of measures are included, i.e., those that express rates of service in per 1,000 member years/months (see [Appendix A](#)) or percentages of members receiving certain services (as in the Effectiveness of Care Domain and included in this section), and risk-adjusted measures. Medicaid categories are reported separately and as a total rate:

- ◆ Disabled
- ◆ Low Income

*Note: The total rate includes the category of Medicaid/Medicare dual eligibles, but those members are part of a special needs plan and for TennCare report separately via the Annual HEDIS D-SNPs Report.*

### Frequency of Ongoing Prenatal Care (FPC)

FPC is the percentage of members who delivered a child between November 6 of the year prior to the MY and November 5 of the MY, and received the expected number of prenatal care visits. This measure uses the same denominator, structure and calculation guidelines as [PPC](#). Rates are reported by the percentage of expected visits:

- ◆ < 21%
- ◆ 21– 40%
- ◆ 41– 60%
- ◆ 61– 80%
- ◆ ≥ 81%

### Well-Child Visits in the First 15 Months of Life (W15)

W15 assesses the percentage of members who turned 15 months old during the MY and who had the following number of well-child visits with a PCP during their first 15 months of life: zero, one, two, three, four, five, or six or more. This measure uses the same structure and calculation guidelines as those in the Effectiveness of Care domain.

### Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)

W34 reports the percentage of members who were 3 to 6 years of age who had one or more well-child visits with a PCP during the MY. This measure uses the same structure and calculation guidelines as those in the Effectiveness of Care domain.

### Adolescent Well-Care Visits (AWC)

AWC assesses the percentage of enrolled members 12 to 21 years of age who had at least one comprehensive well-care visit

with a PCP or an OB-GYN practitioner during the MY. This measure uses the same structure and calculation guidelines as those in the Effectiveness of Care domain.

## Relative Resource Use

These measures summarize resource use during the MY by members with specific acute or chronic conditions, are presented as a ratio to provide better understanding of efficiency or value of services delivered, and are detailed in the separate annual *Relative Resource Use Report* for TennCare.

## Experience of Care

For a plan's results in this domain to be considered reliable, the Medicaid MCO must follow one of the standard CAHPS protocols or an enhanced protocol approved by NCQA. Details regarding this calculation methodology and the questions used in each composite are included in *HEDIS 2016, Volume 3: Specifications for Survey Measures*.

### CAHPS Health Plan Survey 5.0H Adult Version (CPA) and 5.0H Child Version (CPC)

The CAHPS Health Plan Survey 5.0H Adult Version (CPA) and 5.0H Child Version (CPC) are tools for measuring consumer healthcare satisfaction with the quality of care and customer service provided by their MCOs.

The CAHPS Health Plan Surveys include five composites asked of members (CPA) or parents of child members (CPC):

- ◆ Getting Needed Care
- ◆ Getting Care Quickly
- ◆ How Well Doctors Communicate
- ◆ Customer Service
- ◆ Shared Decision Making

Each composite category represents an overall aspect of plan quality, how well the MCO meets members' expectations. There are four global rating questions that use a 0–10 scale to assess overall experience:

- ◆ Rating of All Health Care
- ◆ Rating of Personal Doctor
- ◆ Rating of Specialist Seen Most Often
- ◆ Rating of Health Plan

For these scaled responses, a 0 represents the 'worst possible' and 10 represents the 'best possible' healthcare received in the last six months. Summary rates represent the percentage of members who responded with a 9 or 10. Additional Health Promotion and Education as well as Coordination of Care questions use the same calculations.

For any given CPA and CPC question used in a composite, the percentage of respondents answering in a certain way is calculated for each MCO. Summary rates represent the percentage of members who responded in the most positive

way, as defined by NCQA. The following descriptions provide a brief explanation of the five composite categories.

#### Getting Needed Care

The Getting Needed Care Composite measures the ease with which members were able to access care, tests, or treatments needed in the last 6 months. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

#### Getting Care Quickly

The Getting Care Quickly Composite measures the ease with which members were able to access care quickly, including getting appointments as soon as needed, in the last 6 months. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

#### How Well Doctors Communicate

The How Well Doctors Communicate Composite evaluates provider-patient communications for the last 6 months by asking members how often their personal doctor listens carefully, explains things in a way to easily understand, shows respect for what they have to say and spends enough time with them. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

#### Customer Service

The Customer Service Composite measures how often members were able to get information and help from an MCO and how well they were treated by the MCO's customer service in the last 6 months. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

#### Shared Decision Making

The Shared Decision Making Composite measures how often doctors offered choices regarding healthcare, mentioned the good and bad things associated with each treatment option, the extent to which doctors requested input regarding healthcare preferences, and how often doctors involved members in the decision-making process, according to their preference. The summary rate represents the percentage of members who responded 'Yes' to specified questions. Means and variances are not calculated for this composite.

#### **Children With Chronic Conditions (CCC)**

The CAHPS Consortium decided in 2002 to integrate a new set of items in the 3.0H version of the CAHPS Health Plan Survey child questionnaires (now 5.0H) to better address the needs of children with chronic conditions, commonly referred to as children with special healthcare needs. CCC is designed for children with a chronic physical, developmental, behavioral or emotional condition and who also require health and related

services of a type or amount beyond that generally required by children. Three composites summarize parents' satisfaction with their MCO's basic components of care essential for successful treatment, management and support of children with chronic conditions:

- ◆ Access to Specialized Services
- ◆ Family Centered Care: Personal Doctor Who Knows Child
- ◆ Coordination of Care for CCC

Summary rates are reported for each composite and are reported individually for two concepts:

- ◆ Access to Prescription Medicines
- ◆ Family Centered Care: Getting Needed Information

## Health Plan Descriptive Information Measures

These measures help describe an MCO's structure, staffing and enrollment—factors that contribute to its ability to provide effective healthcare to Medicaid members.

### Enrollment by Product Line (ENP)

ENP reports the total number of members enrolled in the product line, stratified by age and gender (for the MCOs, reported as ENPA: Total Medicaid). These results are included in [Appendix C](#) as population in member months by MCO and Tennessee Grand Region served.

## Measures Collected Using Electronic Clinical Data Systems (ECDS)

This domain requires automated and accessible data by the healthcare team at the point of care. The measure in this domain is not reported by the MCOs, hence, not included in this report.

# Results

## Statewide Performance

In conjunction with NCQA accreditation, MCOs are required to submit a full set of audited HEDIS measures to NCQA and TennCare each year. For HEDIS 2016, this included the statewide MCO Volunteer State Health Plan, Inc., doing business as TennCareSelect (TCS), and three statewide MCOs doing business in each respective Grand Region (East, Middle and West): Amerigroup Community Care, Inc., as Amerigroup (AG—AGE, AGM and AGW); Volunteer State Health Plan, Inc., as BlueCare Tennessee (BC—BCE, BCM and BCW); and UnitedHealthcare Plan of the River Valley, Inc., as UnitedHealthcare (UHC—UHCE, UHCM and UHCW). Beginning in January 2015, there were 400,000 TennCare enrollees transitioning to new MCOs. The transition occurred over several months and may have influenced measure results, resulting in downward trend for some measures. Subsequently, trending should be made with caution.

Tables 1 (a and b), 2 and 3 summarize the weighted average TennCare score for each of the selected HEDIS 2015 and HEDIS 2016 measures as well as the HEDIS 2015 Medicaid National

Average. The Medicaid National Average represents the sum of the reported rates divided by the total number of health plans reporting the rate. Weighted state rates are determined by applying the size of the eligible population within each plan to their overall results. Using this methodology, plan-specific findings contribute to the TennCare statewide estimate, proportionate to eligible population size.

Where possible in Tables 1 (a and b), 2 and 3, the statewide changes for each measure reported during both HEDIS 2015 and HEDIS 2016 are presented. The column titled ‘Change 2015 to 2016’ indicates whether there was an improvement (▲) or a decline (▼) in statewide performance for the measure from HEDIS 2015 to HEDIS 2016. Cells are shaded gray for those measures that were not calculated or for which data were not reported. Each year some measures’ technical specifications change. Based on whether the changes are significant or minor, the measures may need to be trended with caution or may not be able to be trended. At the time this report was finalized, NCQA did not determine the ability for 2016 measures to be trended.

Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<b>Prevention and Screening</b>				
<b>Adult BMI Assessment (ABA)</b>	79.91%	82.84%	82.46%	↓
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC):</b>				
BMI Percentile: 3–11 years	63.61%	65.98%	71.33%	↑
12–17 years	64.71%	67.14%	65.74%	↓
<b>Total</b>	<b>64.05%</b>	<b>66.30%</b>	<b>69.55%</b>	↑
Counseling for Nutrition: 3–11 years	62.15%	64.42%	62.76%	↓
12–17 years	57.55%	56.91%	54.98%	↓
<b>Total</b>	<b>60.52%</b>	<b>62.03%</b>	<b>60.29%</b>	↓
Counseling for Physical Activity: 3–11 years	52.62%	55.64%	53.08%	↓
12–17 years	55.25%	56.09%	54.47%	↓
<b>Total</b>	<b>53.54%</b>	<b>55.77%</b>	<b>53.59%</b>	↓
<b>Childhood Immunization Status (CIS):</b>				
DTaP	77.98%	78.23%	76.91%	↓
IPV	88.96%	92.36%	91.23%	↓
MMR	89.98%	90.18%	88.46%	↓
HiB	89.30%	91.04%	88.77%	↓
HepB	89.31%	92.95%	92.14%	↓
VZV	89.72%	90.56%	88.52%	↓
PCV	78.32%	81.16%	79.20%	↓
HepA	83.39%	89.52%	87.18%	↓
RV	68.08%	68.74%	69.62%	↑
Influenza	51.10%	44.23%	42.86%	↓
Combination 2	73.79%	74.24%	74.27%	↑
Combination 3	70.42%	72.13%	71.08%	↓
Combination 4	66.17%	71.28%	70.27%	↓

Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
Combination 5	57.21%	57.31%	57.87%	↑
Combination 6	43.56%	38.15%	37.28%	↓
Combination 7	54.73%	56.69%	57.32%	↑
Combination 8	42.10%	37.92%	37.02%	↓
Combination 9	37.13%	32.56%	31.78%	↓
Combination 10	36.10%	32.37%	31.64%	↓
<b>Immunizations for Adolescents (IMA):</b>				
Meningococcal	73.43%	67.74%	67.84%	↑
Tdap/Td	83.75%	84.27%	81.80%	↓
Combination 1	71.39%	66.75%	67.13%	↑
<b>Human Papillomavirus Vaccine for Female Adolescents (HPV)</b>	22.19%	17.43%	15.89%	↓
<b>Lead Screening in Children (LSC)</b>	66.78%	73.70%	70.29%	↓
<b>Breast Cancer Screening (BCS)</b>	58.76%	54.08%	54.47%	↑
<b>Cervical Cancer Screening (CCS)</b>	60.22%	64.83%	55.60%	↓
<b>Chlamydia Screening in Women (CHL):</b>				
16–20 years	51.27%	48.88%	48.17%	↓
21–24 years	60.16%	55.93%	54.61%	↓
<b>Total</b>	<b>54.63%</b>	<b>52.03%</b>	<b>51.19%</b>	<b>↓</b>
<b>Respiratory Conditions</b>				
<b>Appropriate Testing for Children With Pharyngitis (CWP)</b>	69.54%	79.06%	79.45%	↑
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)</b>	30.95%	33.68%	31.36%	↓
<b>Pharmacotherapy Management of COPD Exacerbation (PCE):</b>				
Systemic corticosteroid	65.30%	51.32%	52.23%	↑
Bronchodilator	78.90%	76.43%	75.41%	↓

Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures				
Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<b>Medication Management for People With Asthma (MMA):</b>				
Medication Compliance 50%*: 5-11 years		50.05%	54.71%	↑
12–18 years		46.80%	51.61%	↑
19–50 years		49.68%	60.00%	↑
51–64 years		67.38%	66.13%	↓
<b>Total</b>		<b>49.31%</b>	<b>55.05%</b>	<b>↑</b>
Medication Compliance 75%: 5-11 years	26.62%	23.64%	26.87%	↑
12–18 years	24.34%	23.57%	26.63%	↑
19–50 years	35.46%	28.01%	38.38%	↑
51–64 years	48.10%	41.94%	42.90%	↑
<b>Total</b>	<b>30.34%</b>	<b>24.61%</b>	<b>29.35%</b>	<b>↑</b>
<b>Asthma Medical Ratio (AMR):</b>				
5–11 years	69.47%	75.38%	77.09%	↑
12–18 years	57.68%	62.32%	64.97%	↑
19–50 years	47.11%	40.18%	48.93%	↑
51–64 years	49.01%	38.48%	45.36%	↑
<b>Total</b>	<b>59.33%</b>	<b>63.70%</b>	<b>66.25%</b>	<b>↑</b>
<b>Cardiovascular Conditions</b>				
<b>Controlling High Blood Pressure (CBP)</b>	57.08%	54.99%	55.10%	↑
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)</b>	83.22%	79.32%	75.75%	↓
<b>Statin Therapy for Patients with Cardiovascular Disease (SPC)**:</b>				
Received Statin Therapy: Males 21-75 years			66.61%	
Females 40 -75 years			66.05%	
<b>Total</b>			<b>66.34%</b>	

Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
Statin Adherence 80%: Males 21-75 years			56.17%	
Females 40 -75 years			50.77%	
<b>Total</b>			<b>53.56%</b>	
<b>Diabetes</b>				
<b>Comprehensive Diabetes Care (CDC):</b>				
HbA1c Testing	86.30%	81.88%	82.59%	↑
HbA1c Control (<7.0%)	34.10%	37.05%	34.64%	↓
HbA1c Control (<8.0%)	46.47%	49.06%	47.62%	↓
Retinal Eye Exam Performed	54.30%	41.45%	42.87%	↑
Medical Attention for Nephropathy	80.93%	78.18%	90.89%	↑
Blood Pressure Control (<140/90 mm Hg)	61.92%	59.91%	58.22%	↓
<b>Statin Therapy for Patients with Diabetes (SPD)**:</b>				
Received Statin Therapy: 40–75 years			53.06%	
Statin Adherence 80%: 40–75 years			48.03%	
<b>Musculoskeletal Conditions</b>				
<b>Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)</b>	69.44%	63.31%	62.66%	↓
<b>Behavioral Health</b>				
<b>Antidepressant Medication Management (AMM):</b>				
Effective Acute Phase Treatment	52.25%	48.62%	47.75%	↓
Effective Continuation Phase Treatment	36.99%	31.39%	32.19%	↑
<b>Follow-Up Care for Children Prescribed ADHD Medication (ADD):</b>				
Initiation Phase	40.06%	47.78%	49.26%	↑
Continuation and Maintenance Phase	47.52%	59.69%	63.14%	↑

Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<b>Follow-Up After Hospitalization for Mental Illness (FUH):</b>				
7-day follow-up	43.95%	61.94%	55.95%	↓
30-day follow-up	63.09%	75.91%	70.63%	↓
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</b>	79.84%	81.65%	81.20%	↓
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</b>	69.34%	71.20%	69.70%	↓
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)</b>	76.58%	86.08%	82.89%	↓
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)</b>	59.99%	59.70%	58.62%	↓
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)***:</b>				
1–5 Years		19.55%	13.59%	↓
6–11 Years		31.67%	28.71%	↓
12–17 Years		39.03%	37.69%	↓
<b>Total</b>		<b>35.98%</b>	<b>34.10%</b>	<b>↓</b>
<b>Medication Management</b>				
<b>Annual Monitoring for Patients on Persistent Medications (MPM):</b>				
ACE Inhibitors or ARBs	87.23%	90.61%	90.46%	↓
Digoxin	53.83%	57.14%	54.95%	↓
Diuretics	86.85%	90.88%	90.92%	↑
<b>Total</b>	<b>86.75%</b>	<b>90.33%</b>	<b>90.31%</b>	<b>↓</b>
<b>Overuse/Appropriateness</b>				
<b>Appropriate Treatment for Children With Upper Respiratory Infection (URI)</b>	87.00%	77.02%	79.25%	↑
<b>Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)</b>	28.54%	27.89%	30.49%	↑
<b>Use of Imaging Studies for Low Back Pain (LBP)</b>	75.10%	67.71%	65.56%	↓

**Table 1a. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures**

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<i>Measures Collected Through CAHPS Health Plan Survey</i>				
<b>Flu vaccinations for adults ages 18 to 64 (FVA)</b>	39.49%	42.30%	37.23%	↓
<b>Medical Assistance With Smoking and Tobacco Use Cessation (MSC):</b>				
Advising Smokers and Tobacco Users to Quit	75.79%	78.21%	77.05%	†
Discussing Cessation Medications	46.75%	42.67%	43.01%	†
Discussing Cessation Strategies	42.46%	37.39%	38.28%	†
Supplemental Data: % Current Smokers	32.84%	35.37%	37.28%	†

\*Benchmarks are not currently reported by Quality Compass for this rate.

\*\*First-year measure

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures.

† In 2015, the averages were not weighted for CAHPS measures, therefore comparisons cannot be made with 2016.

For the Effectiveness of Care Measures presented in **Table 1b**, a lower rate (particularly one below the national average) is an indication of better performance (↑). A decrease in rates from the prior year also indicates improvement.

**Table 1b. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance**

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<i>Diabetes</i>				
<b>Comprehensive Diabetes Care (CDC): HbA1c Poor Control (&gt;9.0%)</b>	43.55%	41.80%	43.23%	↓
<i>Overuse/Appropriateness</i>				
<b>Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)</b>	3.84%	8.75%	5.25%	↑

**Table 1b. Comparative Weighted State and National HEDIS Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance**

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<b>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC) ***:</b>				
1–5 Years		1.44%	1.49%	↓
6–11 Years		1.29%	1.71%	↓
12–17 Years		1.25%	3.41%	↓
<b>Total</b>		<b>1.27%</b>	<b>2.78%</b>	<b>↓</b>

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures.

Table 2 summarizes results for the Access/Availability Domain of Care.

**Table 2. Comparative Weighted State and National HEDIS Rates: Access/Availability of Care Measures**

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<b>Adults' Access to Preventive/Ambulatory Health Services (AAP):</b>				
20–44 years	79.36%	77.03%	73.00%	↓
45–64 years	86.60%	87.95%	84.97%	↓
<b>Children and Adolescents' Access to Primary Care Practitioners (CAP):</b>				
12–24 months	95.50%	94.22%	91.77%	↓
25 months–6 years	87.78%	88.06%	85.15%	↓
7–11 years	90.95%	93.55%	91.15%	↓
12–19 years	89.32%	89.96%	87.78%	↓
<b>Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET):</b>				
Initiation of AOD Treatment: 13–17 years	41.35%	48.96%	49.11%	↑
≥18 years	38.01%	37.22%	33.36%	↓
<b>Total</b>	<b>38.25%</b>	<b>37.90%</b>	<b>34.22%</b>	<b>↓</b>

**Table 2. Comparative Weighted State and National HEDIS Rates: Access/Availability of Care Measures**

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
Engagement of AOD Treatment: 13–17 years	15.74%	26.42%	25.96%	↓
≥18 years	10.75%	9.83%	8.70%	↓
<b>Total</b>	<b>11.24%</b>	<b>10.78%</b>	<b>9.64%</b>	<b>↓</b>
<b>Prenatal and Postpartum Care (PPC):</b>				
Timeliness of Prenatal Care	82.43%	80.23%	76.34%	↓
Postpartum Care	61.79%	58.74%	55.57%	↓
<b>Call Answer Timeliness (CAT)</b>	80.85%	86.11%	85.38%	↓
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)**:</b>				
1–5 Years		38.38%	30.51%	↓
6–11 Years		54.31%	53.91%	↓
12–17 Years		55.10%	53.50%	↓
<b>Total</b>		<b>53.92%</b>	<b>52.80%</b>	<b>↓</b>

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures.

**Table 3** summarizes results for the Utilization measures included in the Utilization and Risk-Adjusted Utilization Domain of Care.

**Table 3. Comparative Weighted State and National HEDIS Rates: Utilization Measures**

Measure	HEDIS 2015 Medicaid National Avg.	Weighted State Rate		Change 2015 to 2016
		2015	2016	
<b>Frequency of Ongoing Prenatal Care (FPC): ≥ 81%</b>	55.24%	58.30%	55.51%	↓
<b>Well-Child Visits in the First 15 Months of Life (W15): 6 or More Visits</b>	58.86%	60.69%	57.63%	↓
<b>Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)</b>	71.89%	69.70%	68.01%	↓
<b>Adolescent Well-Care Visits (AWC)</b>	50.02%	47.18%	42.34%	↓

## Individual Plan Performance

This section is intended to provide an overview of individual plan performance using appropriate and available comparison data. The results highlight those areas where each MCO is performing in relation to the HEDIS 2015 National Medicaid Means and Percentiles for select MCO-reported HEDIS measures. Qsource uses these data to determine overall TennCare plan performance in a distribution of statistical values that represent the lowest to highest percentiles achieved. For example, the 50th percentile represents the point at which half of the reported rates are below and half of the reported rates are above that value.

**Tables 5 (a and b), 6 and 7** display the plan-specific performance rates for each measure selected from the Effectiveness of Care, Access/Availability of Care, and Utilization and Risk-Adjusted Utilization domains. **Table 4** details the potential color-coding and measure designations used in **Tables 5a** through **7** to indicate the rating of the MCO percentile achieved, and provides additional related comments. While Medical Assistance With Smoking and Tobacco Use Cessation is an Effectiveness of Care measure, results are reported through the CPA as noted in **Tables 1a** and **5a**.

**Table 4. HEDIS 2016 Rating Color and Measure Designations**

Color Designation	Percentile MCO Achieved	Additional Comments
	Greater than 75th	No additional comments
	25th to 75th	No additional comments
	Less than 25th	No additional comments
	No Rating Available	Benchmarking data not available
Measure Designation	Definition	
R	Reportable, a reportable rate was submitted for the measure.	
NA	Not Applicable, there was a small denominator, i.e., the MCO followed the specifications, but the denominator was too small (<30) to report a valid rate, hence results are not presented.	
NB	No Benefit, the MCO did not offer the health benefit required by the measure (e.g., mental health, chemical dependency).	
NR	Not Reported, the MCO chose not to report the measure.	
NO	Not Required, the MCO was not required to report the measure.	

Table 4. HEDIS 2016 Rating Color and Measure Designations

BR	Biased Rate, the calculated rate was materially biased.
UN	Un-Audited, the MCO chose to report a measure that is not required to be audited. This result applies to only a limited set of measures.

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<i>Prevention and Screening</i>											
Adult BMI Assessment (ABA)	70.33%	80.47%	66.28%	80.98%	77.86%	81.64%	60.30%	88.41%	81.22%	84.69%	83.45%
<i>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC):</i>											
BMI Percentile: 3-11 years	68.65%	74.84%	72.37%	66.67%	72.76%	68.77%	64.32%	73.02%	72.20%	76.21%	66.86%
12-17 years	50.39%	62.30%	71.88%	65.89%	69.70%	66.67%	59.60%	66.18%	73.60%	65.55%	67.47%
<b>Total</b>	<b>63.19%</b>	<b>71.30%</b>	<b>72.22%</b>	<b>66.42%</b>	<b>71.78%</b>	<b>68.13%</b>	<b>62.04%</b>	<b>70.62%</b>	<b>72.66%</b>	<b>72.94%</b>	<b>67.23%</b>
Counseling for Nutrition: 3-11 years	60.73%	66.77%	60.53%	60.64%	59.14%	57.19%	52.11%	67.06%	66.80%	70.26%	63.00%
12-17 years	51.16%	50.82%	57.81%	49.61%	53.79%	54.76%	47.98%	57.35%	66.40%	59.66%	58.33%
<b>Total</b>	<b>57.87%</b>	<b>62.27%</b>	<b>59.72%</b>	<b>57.18%</b>	<b>57.42%</b>	<b>56.45%</b>	<b>50.12%</b>	<b>63.66%</b>	<b>66.67%</b>	<b>67.01%</b>	<b>61.44%</b>
Counseling for Physical Activity: 3-11 years	51.82%	58.71%	50.00%	49.29%	53.05%	46.32%	40.38%	55.95%	61.00%	55.76%	53.36%
12-17 years	46.51%	48.36%	56.25%	48.84%	58.33%	53.97%	47.47%	59.56%	64.80%	57.98%	56.34%
<b>Total</b>	<b>50.23%</b>	<b>55.79%</b>	<b>51.85%</b>	<b>49.15%</b>	<b>54.74%</b>	<b>48.66%</b>	<b>43.80%</b>	<b>57.22%</b>	<b>62.24%</b>	<b>56.44%</b>	<b>53.89%</b>
<i>Childhood Immunization Status (CIS):</i>											
DTaP	68.29%	77.55%	64.50%	78.83%	70.56%	79.56%	76.40%	74.94%	80.05%	72.02%	79.52%
IPV	87.04%	90.74%	83.29%	91.48%	86.13%	93.19%	91.73%	91.24%	92.46%	89.78%	91.22%

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
MMR	84.72%	88.43%	83.99%	88.56%	87.59%	91.48%	86.37%	85.64%	90.27%	87.59%	90.93%
HIB	85.19%	89.35%	80.51%	86.62%	84.18%	90.75%	88.08%	89.54%	90.27%	88.08%	91.00%
HepB	89.12%	91.20%	86.08%	91.97%	85.89%	92.46%	92.46%	91.24%	95.13%	92.21%	91.48%
VZV	83.56%	89.81%	82.60%	88.32%	86.37%	91.24%	86.86%	85.89%	90.75%	86.13%	91.17%
PCV	71.30%	82.87%	64.04%	79.32%	73.97%	80.78%	78.59%	77.86%	82.73%	72.51%	79.88%
HepA	82.87%	86.81%	82.83%	86.13%	87.59%	89.78%	85.40%	86.13%	89.78%	85.40%	84.43%
RV	63.89%	75.23%	49.42%	69.59%	62.29%	70.07%	52.07%	66.42%	75.67%	66.42%	69.91%
Flu	31.48%	52.55%	16.01%	44.53%	33.33%	32.60%	50.36%	43.07%	51.58%	29.44%	51.34%
Combination 2	65.51%	75.23%	62.18%	76.40%	66.91%	75.91%	72.75%	72.99%	77.13%	69.83%	75.47%
Combination 3	62.50%	73.38%	57.54%	73.24%	64.72%	72.75%	70.80%	69.59%	73.97%	64.48%	71.53%
Combination 4	61.57%	72.69%	57.08%	72.02%	64.48%	71.78%	69.34%	68.86%	73.48%	63.75%	67.64%
Combination 5	50.46%	64.81%	38.28%	59.37%	50.12%	57.91%	41.85%	54.50%	63.02%	52.31%	58.36%
Combination 6	25.46%	45.37%	13.46%	39.90%	29.20%	28.95%	41.36%	37.47%	45.01%	24.57%	43.65%
Combination 7	49.77%	64.12%	37.82%	58.15%	50.12%	57.42%	41.12%	54.01%	62.77%	52.31%	55.52%
Combination 8	25.46%	45.14%	13.46%	39.90%	29.20%	28.47%	40.15%	37.47%	44.77%	24.09%	42.23%
Combination 9	22.22%	40.74%	9.05%	32.85%	23.84%	24.82%	25.55%	31.87%	40.88%	19.71%	36.68%
Combination 10	22.22%	40.51%	9.05%	32.85%	23.84%	24.57%	24.82%	31.87%	40.63%	19.71%	35.88%
<b>Immunization for Adolescents (IMA):</b>											
Meningococcal	60.82%	76.61%	66.43%	67.21%	69.10%	68.85%	64.58%	67.12%	66.08%	63.52%	75.69%
Tdap/Td	75.77%	85.48%	77.94%	83.06%	80.78%	83.33%	75.52%	82.21%	80.99%	81.14%	86.26%
Combination 1	60.05%	75.54%	64.99%	66.67%	68.13%	68.85%	64.06%	66.85%	64.91%	62.28%	73.15%
<b>Human Papillomavirus Vaccine for Female</b>											
Adolescents (HPV)	15.50%	15.97%	10.78%	17.52%	17.59%	13.63%	15.82%	17.52%	16.79%	13.87%	21.90%

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
Lead Screening in Children (LSC)	50.93%	67.82%	52.20%	70.80%	54.50%	72.99%	71.29%	72.26%	74.70%	68.13%	71.93%
Breast Cancer Screening (BCS)	17.78%	51.47%	23.53%	63.31%	48.70%	60.94%	49.63%	56.11%	49.25%	46.80%	58.34%
Cervical Cancer Screening (CCS)	30.52%	61.74%	38.46%	69.95%	46.47%	66.94%	38.20%	50.61%	62.43%	59.69%	61.05%
<b>Chlamydia Screening in Women (CHL):</b>											
16-20 years	47.80%	48.17%	52.78%	44.28%	54.31%	49.35%	49.82%	42.01%	48.51%	47.11%	50.17%
21-24 years	49.86%	55.52%	59.78%	50.31%	57.68%	57.60%	45.54%	50.36%	53.87%	56.33%	61.21%
<b>Total</b>	<b>48.87%</b>	<b>51.65%</b>	<b>56.46%</b>	<b>47.05%</b>	<b>56.10%</b>	<b>53.13%</b>	<b>49.43%</b>	<b>45.70%</b>	<b>50.94%</b>	<b>51.87%</b>	<b>54.40%</b>
<b>Respiratory Conditions</b>											
<b>Appropriate Testing for Children with Pharyngitis (CWP)</b>											
	74.43%	80.72%	56.24%	77.32%	85.28%	80.37%	78.15%	75.83%	86.35%	77.91%	71.48%
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)</b>											
	24.32%	27.11%	NA	34.45%	19.51%	38.89%	NA	30.08%	27.43%	36.21%	30.77%
<b>Pharmacotherapy Management of COPD Exacerbation (PCE):</b>											
Systemic corticosteroid	51.19%	50.95%	55.56%	46.74%	45.01%	43.85%	NA	61.72%	51.43%	53.80%	69.01%
Bronchodilator	66.01%	75.32%	68.40%	77.64%	68.78%	73.55%	NA	80.33%	77.05%	76.37%	83.43%
<b>Medication Management for People With Asthma (MMA):</b>											
Medication Compliance 50%*: 5-11 years	NA	52.46%	NA	61.39%	65.63%	42.31%	56.61%	59.12%	55.78%	51.09%	
12-18 years	NA	50.24%	NA	52.97%	NA	43.21%	57.84%	54.56%	54.38%	45.48%	
19-50 years	NA	62.75%	NA	63.68%	NA	50.75%	66.30%	67.64%	62.43%	46.26%	
51-64 years	NA	71.43%	NA	70.73%	NA	54.72%	NA	69.44%	65.45%	65.00%	
<b>Total</b>	<b>NA</b>	<b>54.66%</b>	<b>NA</b>	<b>59.30%</b>	<b>58.57%</b>	<b>44.51%</b>	<b>57.94%</b>	<b>60.04%</b>	<b>57.12%</b>	<b>48.95%</b>	

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
Medication Compliance 75%: 5-11 years	NA	23.47%	NA	31.28%	37.50%	17.53%	34.08%	31.87%	25.88%	22.83%	24.86%
12-18 years	NA	25.83%	NA	28.36%	NA	20.38%	32.84%	25.36%	30.41%	20.34%	23.30%
19-50 years	NA	44.82%	NA	43.22%	NA	33.73%	46.74%	43.07%	34.62%	23.81%	35.28%
51-64 years	NA	53.06%	NA	39.02%	NA	30.19%	NA	48.61%	43.64%	40.00%	48.51%
<b>Total</b>	<b>NA</b>	<b>29.52%</b>	<b>NA</b>	<b>32.45%</b>	<b>35.71%</b>	<b>21.75%</b>	<b>34.51%</b>	<b>33.05%</b>	<b>29.51%</b>	<b>22.90%</b>	<b>29.60%</b>
<b>Asthma Medical Ratio (AMR):</b>											
5-11 years	NA	76.31%	NA	81.68%	76.47%	67.60%	76.19%	82.70%	78.61%	72.97%	70.41%
12-18 years	NA	63.91%	NA	65.81%	NA	56.24%	72.41%	68.81%	62.70%	63.47%	58.44%
19-50 years	NA	51.92%	NA	50.68%	NA	44.74%	55.17%	53.20%	48.46%	40.00%	48.28%
51-64 years	NA	50.63%	NA	41.43%	NA	41.18%	NA	43.93%	51.22%	42.11%	50.19%
<b>Total</b>	<b>NA</b>	<b>65.94%</b>	<b>NA</b>	<b>69.74%</b>	<b>63.75%</b>	<b>58.40%</b>	<b>72.53%</b>	<b>69.50%</b>	<b>65.88%</b>	<b>61.02%</b>	<b>60.76%</b>
<b>Cardiovascular Conditions</b>											
<b>Controlling High Blood Pressure (CBP)</b>	45.69%	51.17%	47.20%	60.85%	53.53%	58.88%	64.91%	61.77%	53.83%	47.93%	57.53%
<b>Persistence of Beta-Blocker Treatment after a</b>											
<b>Heart Attack (PBH)</b>	65.79%	81.67%	NA	93.33%	48.48%	58.70%	NA	86.26%	68.57%	83.64%	84.15%
<b>Statin Therapy for Patients with Cardiovascular disease (SPC) **</b>											
Received Statin Therapy: Males 21-75 years	NA	67.11%	NA	64.33%	47.22%	67.75%	NA	68.46%	66.03%	67.15%	
Females 40 -75 years	NA	67.25%	NA	61.22%	NA	57.58%	NA	69.58%	69.72%	68.11%	
<b>Total</b>	<b>NA</b>	<b>67.17%</b>	<b>NA</b>	<b>62.75%</b>	<b>53.33%</b>	<b>62.07%</b>	<b>53.33%</b>	<b>68.99%</b>	<b>67.86%</b>	<b>67.62%</b>	

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
Statin Adherence 80%: Males 21-75 years	NA	77.31%	NA	49.48%	NA	37.98%	NA	59.14%	57.26%	45.26%	
Females 40 -75 years	NA	74.72%	NA	45.81%	NA	26.34%	NA	57.10%	46.97%	45.86%	
<b>Total</b>	<b>NA</b>	<b>76.20%</b>	<b>NA</b>	<b>47.66%</b>	<b>46.88%</b>	<b>31.94%</b>	<b>NA</b>	<b>58.17%</b>	<b>52.00%</b>	<b>45.55%</b>	
<b>Diabetes</b>											
<b>Comprehensive Diabetes Care (CDC):</b>											
HbA1c Testing	80.50%	83.87%	79.93%	84.67%	84.49%	79.56%	66.96%	84.00%	83.31%	80.67%	86.20%
HbA1c Control (<7.0%)	24.59%	34.34%	25.76%	38.31%	35.46%	29.89%	31.44%	36.84%	37.23%	34.43%	36.47%
HbA1c Control (<8.0%)	35.17%	40.91%	32.38%	53.28%	47.63%	44.34%	37.83%	54.00%	51.21%	48.80%	47.91%
Retinal Eye Exam Performed	20.33%	42.52%	25.30%	50.18%	30.84%	47.81%	52.17%	49.60%	41.65%	43.73%	54.74%
Medical Attention for Nephropathy	90.83%	90.03%	91.91%	89.78%	93.80%	90.69%	75.87%	90.80%	90.44%	92.93%	81.75%
Blood Pressure Control (<140/90 mm Hg)	51.33%	54.25%	47.72%	62.23%	59.12%	55.66%	61.52%	64.40%	61.34%	53.07%	62.23%
<b>Statin Therapy for Patients with Diabetes (SPD) **</b>											
Received Statin Therapy: 40 -75 years	43.21%	53.67%	42.86%	50.42%	43.97%	52.50%	50.43%	56.41%	51.69%	53.82%	
Statin Adherence 80%: 40 -75 years	51.43%	52.74%	50.00%	43.57%	35.48%	35.23%	74.14%	55.16%	50.34%	45.15%	
<b>Musculoskeletal Conditions</b>											
<b>Disease-Modifying Anti-Rheumatic Drug Therapy for</b>											
<b>Rheumatoid Arthritis (ART)</b>	61.22%	59.93%	53.00%	65.47%	47.52%	62.82%	NA	74.25%	59.07%	56.82%	69.68%

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<b>Behavioral Health</b>											
<b>Antidepressant Medication Management (AMM):</b>											
Effective Acute Phase Treatment	60.00%	52.90%	50.43%	45.45%	50.21%	38.51%	41.64%	52.46%	46.19%	43.15%	50.51%
Effective Continuation Phase Treatment	37.05%	37.89%	38.36%	28.68%	33.79%	24.30%	24.16%	36.53%	31.27%	29.50%	34.02%
<b>Follow-Up Care for Children Prescribed ADHD Medication (ADD):</b>											
Initiation Phase	NA	58.02%	NA	49.16%	NA	38.42%	43.50%	55.98%	54.94%	43.55%	40.79%
Continuation and Maintenance Phase	NA	65.31%	NA	64.10%	NA	54.59%	56.34%	66.76%	70.99%	63.80%	50.61%
<b>Follow-Up After Hospitalization for Mental Illness (FUH):</b>											
7-day follow-up	45.33%	55.50%	55.68%	55.14%	47.96%	68.14%	56.36%	55.17%	58.07%	61.51%	46.22%
30-day follow-up	63.69%	75.21%	67.59%	73.13%	60.60%	77.01%	70.69%	70.41%	73.29%	72.56%	66.64%
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD):</b>											
	78.45%	84.08%	70.77%	85.33%	81.79%	77.97%	78.27%	83.56%	85.50%	76.13%	80.10%
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</b>											
	60.66%	79.45%	62.39%	76.15%	75.47%	65.54%	68.00%	66.03%	77.74%	61.22%	69.61%
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)</b>											
	NA	83.87%	NA	84.00%	NA	91.11%	NA	78.00%	83.08%	78.72%	79.07%
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)</b>											
	55.89%	63.67%	42.86%	65.46%	46.68%	55.67%	66.26%	62.95%	66.07%	55.35%	60.68%
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)***</b>											
1-5 Years	NA	NA	NA	20.00%	NA	NA	18.75%	14.71%	NA	NA	
6-11 Years	22.15%	30.95%	21.10%	31.20%	24.78%	25.11%	30.35%	30.50%	29.65%	25.00%	
12-17 Years	35.89%	34.17%	22.65%	38.89%	34.00%	25.15%	42.86%	34.77%	34.65%	31.42%	
<b>Total</b>	<b>30.51%</b>	<b>32.53%</b>	<b>21.69%</b>	<b>35.65%</b>	<b>29.52%</b>	<b>24.69%</b>	<b>38.72%</b>	<b>32.35%</b>	<b>31.75%</b>	<b>28.83%</b>	

Table 5a. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<b>Medication Management</b>											
<b>Annual Monitoring for Patients on Persistent Medications (MPM):</b>											
ACE Inhibitors or ARBs	87.23%	88.98%	88.90%	91.59%	87.56%	90.00%	84.34%	92.11%	90.30%	92.38%	87.72%
Digoxin	NA	37.63%	62.86%	51.35%	55.56%	59.72%	NA	54.27%	48.51%	75.24%	53.85%
Diuretics	88.16%	90.38%	88.09%	91.71%	88.00%	89.97%	88.59%	92.91%	91.26%	92.17%	87.04%
<b>Total</b>	<b>87.38%</b>	<b>89.01%</b>	<b>88.30%</b>	<b>91.36%</b>	<b>87.53%</b>	<b>89.70%</b>	<b>84.86%</b>	<b>92.01%</b>	<b>90.27%</b>	<b>92.09%</b>	<b>87.05%</b>
<b>Overuse/Appropriateness</b>											
<b>Appropriate Treatment for Children with Upper</b>											
<b>Respiratory Infection (URI)</b>	71.76%	83.64%	72.53%	76.86%	84.16%	73.44%	76.23%	75.02%	85.74%	76.09%	88.09%
<b>Avoidance of Antibiotic Treatment in Adults with</b>											
<b>Acute Bronchitis (AAB)</b>	31.98%	28.38%	41.42%	27.34%	32.21%	34.64%	38.26%	27.53%	33.35%	32.33%	26.30%
<b>Use of Imaging Studies for Low Back Pain (LBP)</b>	65.68%	66.92%	67.92%	68.00%	64.91%	67.58%	58.06%	62.46%	61.47%	67.00%	74.95%
<b>Measures Collected Through CAHPS Health Plan Survey</b>											
<b>Flu vaccinations for adults ages 18 to 64 (FVA)</b>	27.61%	40.24%	24.33%	40.21%	32.02%	40.31%	NA	41.87%	44.26%	35.73%	39.04%
<b>Medical Assistance with Smoking and Tobacco Use Cessation (MSC):</b>											
Advising Smokers and Tobacco Users to Quit	66.27%	75.88%	74.76%	80.85%	NA	80.56%	NA	79.15%	78.38%	78.51%	76.74%
Discussing Cessation Medications	36.53%	40.85%	37.25%	45.16%	NA	46.96%	NA	46.57%	41.58%	46.69%	46.70%
Discussing Cessation Strategies	29.34%	33.77%	34.00%	42.35%	NA	46.63%	NA	38.86%	38.42%	42.68%	42.50%
Supplemental Data - % Current Smokers	48.33%	36.23%	33.23%	40.98%	40.00%	31.73%	17.48%	42.07%	38.32%	29.40%	34.19%

\*Benchmarks are not currently reported by Quality Compass for this rate.

\*\*First-year measure

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures.

For the Effectiveness of Care Measures presented in **Table 5b**, a lower rate (particularly one below the national 50th percentile) is an indication of better performance. For example, a rate in the 10th percentile is better than a rate in the 90th percentile.

Table 5b. HEDIS 2016 Plan-Specific Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance											
Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<b>Diabetes</b>											
<b>Comprehensive Diabetes Care (CDC):</b>											
HbA1c Poor Control (>9.0%)	56.67%	51.47%	60.20%	36.31%	41.61%	47.63%	58.91%	36.53%	37.66%	43.20%	42.22%
<b>Overuse/Appropriateness</b>											
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	5.42%	4.46%	6.99%	5.35%	4.34%	5.48%	4.03%	5.62%	5.38%	5.55%	3.63%
<b>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)***</b>											
1-5 Years	NA	NA	NA	NA	NA	NA	0.00%	NA	NA	NA	
6-11 Years	0.00%	0.98%	1.45%	2.48%	2.98%	0.00%	2.28%	1.94%	0.00%	0.86%	
12-17 Years	0.55%	2.78%	2.86%	3.33%	1.42%	2.53%	4.38%	2.80%	3.72%	0.89%	
<b>Total</b>	<b>0.33%</b>	<b>1.99%</b>	<b>2.26%</b>	<b>3.05%</b>	<b>2.06%</b>	<b>1.52%</b>	<b>3.70%</b>	<b>2.36%</b>	<b>2.45%</b>	<b>0.87%</b>	

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures.

Table 6. HEDIS 2016 Plan-Specific Rates: Access/Availability of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<b>Adults' Access to Preventive/Ambulatory Health Services (AAP):</b>											
20-44 years	63.22%	73.86%	67.58%	78.24%	74.91%	75.58%	49.32%	74.63%	77.92%	71.29%	81.37%
45-64 years	73.36%	85.00%	77.64%	89.82%	85.90%	87.24%	49.24%	87.50%	87.47%	83.20%	87.84%
<b>Children and Adolescents' Access to Primary Care Practitioners (CAP):</b>											
12-24 months	89.17%	92.84%	88.14%	96.02%	93.07%	94.01%	88.70%	90.27%	91.41%	88.15%	96.28%
25 months-6 years	79.81%	85.50%	81.99%	88.36%	87.39%	84.61%	82.31%	84.45%	87.84%	83.74%	88.46%
7-11 years	81.36%	90.08%	NA	93.24%	92.75%	92.24%	92.19%	88.72%	92.07%	89.35%	91.42%
12-19 years	67.16%	86.15%	NA	90.44%	90.38%	89.07%	88.12%	85.67%	89.37%	84.83%	90.06%
<b>Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET):</b>											
Initiation of AOD Treatment: 13-17 years	42.86%	48.97%	51.81%	43.12%	42.75%	47.64%	54.25%	50.68%	49.18%	51.45%	41.91%
≥ 18 years	39.57%	34.77%	40.78%	31.43%	35.29%	29.72%	42.16%	34.93%	27.55%	30.65%	37.61%
<b>Total</b>	<b>39.70%</b>	<b>35.46%</b>	<b>41.20%</b>	<b>31.96%</b>	<b>35.52%</b>	<b>30.72%</b>	<b>47.65%</b>	<b>35.50%</b>	<b>28.51%</b>	<b>31.69%</b>	<b>38.03%</b>
Engagement of AOD Treatment: 13-17 years	30.25%	31.44%	21.69%	22.83%	25.19%	11.52%	29.76%	26.70%	32.79%	19.08%	14.99%
≥ 18 years	10.93%	11.33%	10.04%	6.60%	11.10%	7.03%	13.32%	7.07%	8.41%	7.56%	9.83%
<b>Total</b>	<b>11.66%</b>	<b>12.31%</b>	<b>10.48%</b>	<b>7.33%</b>	<b>11.53%</b>	<b>7.28%</b>	<b>20.79%</b>	<b>7.79%</b>	<b>9.50%</b>	<b>8.14%</b>	<b>10.07%</b>
<b>Prenatal and Postpartum Care (PPC):</b>											
Timeliness of Prenatal Care	68.00%	75.94%	63.00%	85.96%	73.24%	72.86%	70.32%	83.95%	76.64%	70.07%	85.19%
Postpartum Care	48.94%	58.96%	42.15%	70.76%	50.36%	54.28%	46.47%	60.74%	49.64%	43.07%	62.77%
<b>Call Answer Timeliness (CAT)</b>	<b>92.22%</b>	<b>92.22%</b>	<b>92.22%</b>	<b>74.57%</b>	<b>73.72%</b>	<b>74.56%</b>	<b>83.34%</b>	<b>91.30%</b>	<b>91.30%</b>	<b>91.30%</b>	<b>85.37%</b>

Table 6. HEDIS 2016 Plan-Specific Rates: Access/Availability of Care Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) ***</b>											
1-5 Years	NA										
6-11 Years	75.00%	71.00%	66.67%	50.00%	67.57%	54.46%	48.34%	42.50%	61.04%	39.81%	
12-17 Years	76.00%	70.14%	62.16%	56.51%	66.25%	53.18%	46.06%	51.06%	57.14%	43.13%	
<b>Total</b>	<b>73.81%</b>	<b>69.29%</b>	<b>61.87%</b>	<b>52.82%</b>	<b>65.00%</b>	<b>52.74%</b>	<b>46.58%</b>	<b>46.63%</b>	<b>57.14%</b>	<b>41.18%</b>	

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures.

Table 7. HEDIS 2016 Plan-Specific Rates: Use of Services Measures

Measure	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	HEDIS 2015 National Medicaid 50th Percentile
<b>Frequency of Ongoing Prenatal Care (FPC):</b>											
≥ 81 percent	57.65%	55.42%	37.94%	73.39%	49.88%	49.39%	46.47%	65.43%	45.26%	48.91%	59.49%
<b>Well-Child Visits in the First 15 Months of Life (W15):</b>											
6 or More Visits	16.00%	58.80%	14.29%	70.45%	47.13%	45.26%	45.26%	64.91%	58.35%	47.07%	59.76%
<b>Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)</b>	68.29%	73.61%	64.27%	68.90%	69.83%	63.66%	67.29%	64.10%	70.69%	66.85%	72.02%
<b>Adolescent Well-Care Visits (AWC)</b>	40.05%	46.76%	46.99%	43.55%	41.36%	40.63%	45.01%	35.04%	42.58%	42.34%	49.15%

**Table 8** details the color-coding and the MCO rating scale, as well as any additional comments, used in **Tables 9** through **11** to indicate the rating achieved. **Tables 9** through **11** display the plan-specific performance rates for the CAHPS survey results. CAHPS measure results with an 'NA' indicate that there were

fewer than 100 valid responses and, hence, results are not presented. For all CAHPS survey results, performance is measured against the calculated statewide average. The 2015 National Medicaid CAHPS Benchmarking data were obtained from Quality Compass.

Table 8. 2016 CAHPS Rating Color and Measure Designations		
Color Designation	Rating Scale	Additional Comments
	Greater than one standard deviation above the statewide average	No additional comments
	Within one standard deviation above or below the statewide average	No additional comments
	Greater than one standard deviation below the statewide average	No additional comments
	No Rating Available	Benchmarking data were not available
Measure Designation	Definition	
NA	Not Applicable, there were fewer than 100 valid responses, hence results are not presented.	

Table 9. 2016 CAHPS 5.0H Adult Medicaid Survey Results											
AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2015 National Medicaid CAHPS Benchmarking
<b>1. Getting Needed Care (Always + Usually)</b>											
73.32%	83.36%	79.20%	86.63%	86.14%	86.01%	NA	84.20%	82.57%	80.65%	82.45%	80.82%
<b>2. Getting Care Quickly (Always + Usually)</b>											
75.35%	82.69%	82.17%	82.74%	85.69%	84.53%	NA	84.40%	81.53%	80.18%	82.14%	80.73%

Table 9. 2016 CAHPS 5.0H Adult Medicaid Survey Results

AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2015 National Medicaid CAHPS Benchmarking
<b>3. How Well Doctors Communicate (Always + Usually)</b>											
86.57%	90.04%	90.21%	89.75%	93.50%	90.29%	NA	92.22%	89.74%	88.82%	90.13%	90.66%
<b>4. Customer Service (Always + Usually)</b>											
84.98%	88.32%	NA	NA	NA	NA	NA	93.08%	90.94%	87.06%	88.88%	87.11%
<b>5. Shared Decision Making (Yes)</b>											
79.34%	80.65%	NA	77.26%	NA	78.21%	NA	75.68%	78.43%	69.88%	77.06%	78.71%
<b>6. Rating of All Health Care (9+10)</b>											
43.22%	58.31%	47.22%	57.85%	56.08%	54.84%	NA	55.11%	48.36%	53.33%	52.70%	52.56%
<b>7. Rating of Personal Doctor (9+10)</b>											
56.41%	63.50%	63.89%	64.43%	65.97%	60.78%	NA	73.59%	63.50%	66.13%	64.24%	64.66%
<b>8. Rating of Specialist Seen Most Often (9+10)</b>											
62.69%	64.90%	NA	71.76%	NA	68.91%	NA	73.64%	63.91%	64.94%	67.25%	65.06%
<b>9. Rating of Health Plan (9+10)</b>											
45.02%	57.85%	50.49%	63.58%	57.08%	67.42%	61.76%	61.91%	59.67%	62.32%	58.71%	57.93%

Table 10. 2016 CAHPS 5.0H Child Medicaid Survey Results (General Population)

AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2015 National Medicaid CAHPS Benchmarking
<b>1. Getting Needed Care (Always + Usually)</b>											
82.62%	85.11%	78.59%	92.39%	92.83%	86.26%	87.79%	86.31%	83.32%	85.42%	86.06%	84.39%
<b>2. Getting Care Quickly (Always + Usually)</b>											
89.45%	90.89%	87.04%	95.67%	95.74%	92.37%	94.06%	92.85%	89.80%	87.93%	91.58%	88.60%
<b>3. How Well Doctors Communicate (Always + Usually)</b>											
92.64%	93.52%	92.23%	95.49%	95.75%	94.88%	94.03%	94.75%	93.12%	91.49%	93.79%	93.14%

Table 10. 2016 CAHPS 5.0H Child Medicaid Survey Results (General Population)

AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2015 National Medicaid CAHPS Benchmarking
<b>4. Customer Service (Always + Usually)</b>											
87.71%	86.38%	93.23%	92.17%	NA	NA	88.50%	88.52%	88.91%	88.43%	89.23%	87.52%
<b>5. Shared Decision Making (Yes)</b>											
79.95%	78.71%	NA	84.78%	NA	NA	85.90%	77.27%	80.24%	76.61%	80.49%	78.00%
<b>6. Rating of All Health Care (9+10)</b>											
65.05%	73.60%	70.24%	77.34%	74.01%	68.70%	67.98%	72.60%	71.33%	68.59%	70.94%	66.41%
<b>7. Rating of Personal Doctor (9+10)</b>											
71.69%	80.57%	76.07%	79.15%	79.05%	77.90%	74.41%	79.55%	76.49%	74.04%	76.89%	74.58%
<b>8. Rating of Specialist Seen Most Often (9+10)</b>											
NA	73.04%	NA	82.40%	NA	NA	73.94%	79.09%	71.31%	NA	75.96%	70.75%
<b>9. Rating of Health Plan (9+10)</b>											
55.67%	76.65%	71.43%	79.45%	75.89%	79.15%	72.07%	73.87%	76.09%	75.94%	73.62%	68.71%

Table 11. 2016 CAHPS 5.0H Child Medicaid Survey Results (Children with Chronic Conditions)

AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2015 National Medicaid CAHPS Benchmarking
<b>1. Getting Needed Care (Always + Usually)</b>											
86.10%	87.06%	79.65%	90.83%	89.72%	87.46%	90.18%	91.66%	88.98%	87.70%	87.93%	85.90%
<b>2. Getting Care Quickly (Always + Usually)</b>											
92.29%	94.77%	92.01%	94.38%	93.26%	95.31%	95.37%	94.21%	92.78%	91.31%	93.57%	91.31%
<b>3. How Well Doctors Communicate (Always + Usually)</b>											
93.89%	93.80%	90.92%	95.05%	94.27%	96.18%	94.80%	95.00%	94.97%	93.34%	94.22%	93.69%

Table 11. 2016 CAHPS 5.0H Child Medicaid Survey Results (Children with Chronic Conditions)

AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2015 National Medicaid CAHPS Benchmarking
<b>4. Customer Service (Always + Usually)</b>											
85.38%	90.02%	93.64%	93.10%	NA	NA	90.44%	89.18%	88.89%	87.67%	89.79%	88.47%
<b>5. Shared Decision Making (Yes)</b>											
86.60%	85.23%	83.10%	87.16%	84.35%	88.69%	86.83%	85.22%	85.25%	85.91%	85.83%	84.33%
<b>6. Rating of All Health Care (9+10)</b>											
62.87%	68.99%	65.84%	71.24%	73.54%	74.12%	71.20%	70.51%	68.29%	68.60%	69.52%	63.84%
<b>7. Rating of Personal Doctor (9+10)</b>											
71.39%	73.84%	72.66%	77.26%	78.75%	75.20%	75.72%	78.33%	76.47%	74.85%	75.45%	73.52%
<b>8. Rating of Specialist Seen Most Often (9+10)</b>											
79.63%	71.60%	63.33%	75.12%	NA	73.27%	78.20%	75.34%	66.67%	72.66%	72.87%	70.26%
<b>9. Rating of Health Plan (9+10)</b>											
51.80%	69.85%	61.90%	74.24%	69.32%	79.69%	76.21%	69.43%	68.34%	70.98%	69.18%	64.28%
<b>10. Access to Specialized Services (Always + Usually)</b>											
NA	NA	NA	NA	NA	NA	82.39%	NA	78.00%	NA	80.20%	77.55%
<b>11. Family-Centered Care: Personal Doctor or Nurse Who Knows Child (Yes)</b>											
90.49%	90.83%	87.23%	91.17%	91.90%	91.08%	91.91%	90.80%	90.80%	93.25%	90.95%	89.70%
<b>12. Coordination of Care for Children With Chronic Conditions (Yes)</b>											
72.89%	76.42%	NA	80.87%	NA	NA	78.25%	77.81%	79.24%	NA	77.58%	77.56%
<b>13. Family-Centered Care: Getting Needed Information (Always + Usually)</b>											
92.16%	90.70%	90.46%	91.19%	88.39%	93.39%	90.85%	91.51%	92.07%	90.33%	91.11%	91.15%
<b>14. Access to Prescription Medicines (Always + Usually)</b>											
91.39%	92.35%	92.54%	95.08%	91.77%	94.40%	91.20%	93.58%	90.05%	93.92%	92.63%	89.97%

## HEDIS Trending—Statewide Weighted Rates


Each year of HEDIS reporting, Qsource has calculated statewide weighted averages for each measure by applying the size of the eligible population for each measure within a health plan to its reported rate. Using this methodology, plan-specific findings can be estimated from an overall TennCare statewide level, with each reporting health plan contributing to the statewide estimate proportionate to its eligible population size.

Trending for first-time measures—those reported for the first time in this year’s HEDIS/CAHPS report—is not possible and, therefore, not presented in this section. Remaining measures are plotted to reflect the statewide performance of TennCare MCOs since reporting began in 2006, except where measures were not reported for a particular year as stated in footnotes.

In 2008 new health plans were implemented in the Middle Grand Region that were not required to be NCQA accredited until December 2009. Similarly, new health plans were implemented in 2009 in the West Grand Region that were not required to be accredited until December 2010. The data would not have been reported by these MCOs for 2008 or 2009, respectively; hence, no 2008 or 2009 statewide weighted rates are presented. Beginning in January 2015, there were 400,000 TennCare enrollees transitioning to new MCOs. The transition occurred over several months and may have influenced measure results, resulting in downward trend for some measures. Subsequently, trending should be made with caution.


### Effectiveness of Care Measures—Prevention and Screening

**Fig. 1. Adult BMI Assessment (ABA)**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). Measure specifications were revised in 2012; trending between 2012 and prior years should be considered with caution.

**Fig. 2. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)—BMI Percentile: 3–11 years**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 3. WCC—BMI Percentile: 12–17 years**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 4. WCC—BMI Percentile: Total**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 5. WCC—Counseling for Nutrition: 3–11 years**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 6. WCC—Counseling for Nutrition: 12–17 years**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 7. WCC—Counseling for Nutrition: Total**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 8. WCC—Counseling for Physical Activity: 3–11 years**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 9. WCC—Counseling for Physical Activity: 12–17 years**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 10. WCC—Counseling for Physical Activity: Total**




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

**Fig. 11. Childhood Immunization Status (CIS): DTap**



Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


**Fig. 12. CIS: IPV**



Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Results—Effectiveness of Care Measures—Prevention and Screening

**Fig. 13. CIS: MMR**




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 14. CIS: HiB**




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 15. CIS: HepB**



Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


**Fig. 16. CIS: VZV**



Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Results—Effectiveness of Care Measures—Prevention and Screening

**Fig. 17. CIS: PCV**




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 18. CIS: HepA**




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 19. CIS: RV**



Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


**Fig. 20. CIS: Flu**



Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Results—Effectiveness of Care Measures—Prevention and Screening

**Fig. 21. CIS: Combination 2**




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 22. CIS: Combination 3**




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 23. CIS: Combination 4**



Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


**Fig. 24. CIS: Combination 5**



Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Results—Effectiveness of Care Measures—Prevention and Screening

**Fig. 25. CIS: Combination 6**




Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 27. CIS: Combination 8**




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 26. CIS: Combination 7**



Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


**Fig. 28. CIS: Combination 9**



Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Results—Effectiveness of Care Measures—Prevention and Screening

**Fig. 29. CIS: Combination 10**




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 30. Immunizations for Adolescents (IMA): Meningococcal**




Footnote: Data reporting began in 2010.

**Fig. 31. IMA: Tdap/Td**




Footnote: Data reporting began in 2010.

**Fig. 32. IMA: Combination 1**




Footnote: Data reporting began in 2010.

**Fig. 33. Human Papillomavirus Vaccine for Female Adolescents (HPV)**




Footnote: Data reporting began in 2012. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 35. Breast Cancer Screening (BCS)**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

**Fig. 34. Lead Screening in Children (LSC)**



Footnote: Data reporting began in 2008 (2008 and 2009 data are not reported in these graphs). Measure specifications changed in 2011; trending between 2011 and prior years should be considered with caution.


**Fig. 36. Cervical Cancer Screening (CCS)**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

Results—Effectiveness of Care Measures—Prevention and Screening

**Fig. 37. Chlamydia Screening in Women (CHL): 16–20 years**




**Fig. 38. CHL: 21–24 years**



Footnote: Age stratification changed in 2009 (2008 and 2009 data are not reported in these graphs); as such, no comparative data are available from previous years.


**Fig. 39. CHL: Total**




Footnote: Age stratification changed in 2009 (2008 and 2009 data are not reported in these graphs); as such, no comparative data are available from previous years.

### Effectiveness of Care Measures—Respiratory Conditions

**Fig. 40. Appropriate Testing for Children With Pharyngitis (CWP)**




**Fig. 41. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)**




Footnote: Measure specifications changed in 2011; trending between 2011 and prior years should be considered with caution.

**Fig. 42. Pharmacotherapy Management of COPD Exacerbation (PCE): Systemic Corticosteroid**



Footnote: Data reporting began in 2008 (2008 and 2009 data are not reported in these graphs).


**Fig. 43. PCE: Bronchodilator**



Footnote: Data reporting began in 2008 (2008 and 2009 data are not reported in these graphs).


Results—Effectiveness of Care Measures—Respiratory Conditions

**Fig. 44. Medication Management for People With Asthma (MMA)—Medication Compliance 50%: 5–11 years**




Footnote: Data reporting began in 2012.

**Fig. 45. MMA—Medication Compliance 50%: 12–18 years**




Footnote: Data reporting began in 2012.

**Fig. 46. MMA—Medication Compliance 50%: 19-50 years**



Footnote: Data reporting began in 2012.


**Fig. 47. MMA—Medication Compliance 50%: 51–64 years**



Footnote: Data reporting began in 2012.


Results—Effectiveness of Care Measures—Respiratory Conditions

**Fig. 48. MMA—Medication Compliance 50%: Total**




Footnote: Data reporting began in 2012.

**Fig. 49. MMA—Medication Compliance 75%: 5–11 years**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

**Fig. 50. MMA—Medication Compliance 75%: 12–18 years**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

**Fig. 51. MMA—Medication Compliance 75%: 19–50 years**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

**Fig. 52. MMA—Medication Compliance 75%: 51–64 years**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

**Fig. 53. MMA—Medication Compliance 75%: Total**




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

**Fig. 54. Asthma Medical Ratio (AMR): 5–11 years**



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.


**Fig. 55. AMR: 12–18 years**



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.


Results—Effectiveness of Care Measures—Respiratory Conditions

**Fig. 56. AMR: 19–50 years**




Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.

**Fig. 57. AMR: 50–64 years**



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.


**Fig. 58. AMR: Total**



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.


### Effectiveness of Care Measures—Cardiovascular Conditions

**Fig. 59. Controlling High Blood Pressure (CBP)**




Footnote: In 2015, due to notable changes to the measure specification, results should be considered with caution.

**Fig. 60. Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)**




### Effectiveness of Care Measures—Diabetes

**Fig. 61. Comprehensive Diabetes Care (CDC): HbA1c Testing**




Footnote: In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. In addition, changes were made to General Guideline 41: Measures That Require Results from the Most Recent Test that affect the HbA1c indicators. Trending between 2015 and prior years' should be considered with caution.

**Fig. 62. CDC: HbA1c Control (<7.0%)**




Footnote: Data reporting began in 2007. In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. In addition, changes were made to General Guideline 41: Measures That Require Results from the Most Recent Test that affect the HbA1c indicators. Trending between 2015 and prior years' should be considered with caution.

**Fig. 63. CDC: HbA1c Control (<8.0%)**




Footnote: Data reporting began in 2010. In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. In addition, changes were made to General Guideline 41: Measures That Require Results from the Most Recent Test that affect the HbA1c indicators. Trending between 2015 and prior years' should be considered with caution.

**Fig. 64. CDC: Retinal Eye Exam Performed**




Footnote: In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. Trending between 2015 and prior years' should be considered with caution.

**Fig. 65. CDC: Medical Attention for Nephropathy**




Footnote: In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. Trending between 2015 and prior years' should be considered with caution.

**Fig. 66. CDC: Blood Pressure Control (<140/90 mm Hg)**



Footnote: Data reporting began in 2007. In 2012, specification was clarified; trending between 2012 and prior years should be considered with caution. In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. Trending between 2015 and prior years' should be considered with caution.


**Fig. 67. CDC: HbA1c Poor Control (>9.0%)\***



\*Lower rates for this measure indicate better performance. In 2015, the ED visit requirement was revised when identifying the event/diagnosis of the eligible population. In addition, changes were made to General Guideline 41: Measures That Require Results from the Most Recent Test that affect the HbA1c indicators. Trending between 2015 and prior years' should be considered with caution.


### Effectiveness of Care Measures—Musculoskeletal Conditions

**Fig. 68. Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)**




### Effectiveness of Care Measures—Behavioral Health

**Fig. 69. Antidepressant Medication Management (AMM): Effective Acute Phase Treatment**



Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.


**Fig. 70. AMM: Effective Continuation Phase Treatment**



Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.


Results— Effectiveness of Care Measures—Behavioral Health

**Fig. 71. Follow-Up Care for Children Prescribed ADHD Medication (ADD): Initiation Phase**




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

**Fig. 72. ADD: Continuation and Maintenance Phase**




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

**Fig. 73. Follow-Up After Hospitalization for Mental Illness (FUH): 7-Day Follow-Up**



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.


**Fig. 74. FUH: 30-Day Follow-Up**



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.


Results— Effectiveness of Care Measures—Behavioral Health

**Fig. 75. Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)**




Footnote: Data reporting began in 2013.

**Fig. 76. Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)**




Footnote: Data reporting began in 2013. In 2015, due to notable changes in the measure specification, trending between 2015 and prior years' should be considered with caution.

**Fig. 77. Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)**




Footnote: Data reporting began in 2013.

**Fig. 78. Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)**




Footnote: Data reporting began in 2013.


**Fig. 79. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM): 1-5 Years**




**Fig. 80. APM: 6-11 Years**



**Fig. 81. APM: 12-17 Years**




**Fig. 82. APM: Total**




### Effectiveness of Care Measures—Medication Management

**Fig. 83. Annual Monitoring for Patients on Persistent Medications (MPM): ACE Inhibitors or ARBs**




Footnote: In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.

**Fig. 85. MPM: Diuretics**




Footnote: In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.

**Fig. 84. MPM: Digoxin**



Footnote: In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.


**Fig. 86. MPM: Total**



Footnote: The anticonvulsants rate was retired in 2015 and is no longer part of the total rate. In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.


**Effectiveness of Care Measures—Overuse/Appropriateness**

**Fig. 87. Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS) \***




\*Lower rates for this measure indicate better performance.  
Footnote: Data reporting began in 2014.

**Fig. 88. Appropriate Treatment for Children With Upper Respiratory Infection (URI)**




**Fig. 89. Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)**



Footnote: The measure rate was inverted in 2008 (2008 and 2009 data are not reported in these graphs); as such, no comparative data are available from previous years.


**Fig. 90. Use of Imaging Studies for Low Back Pain (LBP)**



Footnote: Because United American Healthcare Corporation did not report this measure in 2007, it was excluded from the statewide weighted average calculation for that report year.


Results—Effectiveness of Care Measures—Overuse/Appropriateness

**Fig. 91. Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC): 1-5 Years\***




\*Lower rates for this measure indicate better performance.  
Footnote: Data reporting began in 2014.

**Fig. 92. APC: 6-11 Years\***




\*Lower rates for this measure indicate better performance.  
Footnote: Data reporting began in 2014.

**Fig. 93. APC: 12-17 Years\***



\*Lower rates for this measure indicate better performance.  
Footnote: Data reporting began in 2014.


**Fig. 94. APC: Total\***




\*Lower rates for this measure indicate better performance.  
Footnote: Data reporting began in 2014.

**Access/Availability of Care Measures**


**Fig. 95. Adults' Access to Preventive/Ambulatory Health Services (AAP): 20–44 years**




**Fig. 96. AAP: 45–64 years**




**Fig. 97. Children and Adolescents' Access to Primary Care Practitioners (CAP): 12–24 months**




**Fig. 98. CAP: 25 months–6 years**




**Fig. 99. CAP: 7–11 years**




**Fig. 100. CAP: 12–19 years**



**Fig. 101. Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET)—Initiation of AOD Treatment: 13–17 years**




**Fig. 102. IET—Initiation of AOD Treatment: ≥18 years**



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.


Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

**Fig. 103. IET—Initiation of AOD Treatment: Total**




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

**Fig. 105. IET—Engagement of AOD Treatment: ≥18 years**




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

**Fig. 104. IET—Engagement of AOD Treatment: 13–17 years**




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

**Fig. 106. IET—Engagement of AOD Treatment: Total**




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.


**Fig. 107. Prenatal and Postpartum Care (PPC): Timeliness of Prenatal Care**




**Fig. 108. PPC: Postpartum Care**



**Fig. 109. Call Answer Timeliness (CAT)**




**Fig. 110. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP): 1-5 Years**




Footnote: Because United American Healthcare Corporation, Unison and Windsor did not report this measure in 2006, these health plans were excluded from statewide weighted average calculation. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with


**Fig. 111. APP: 6-11 Years**



**Fig. 112. APP: 12-17 Years**




**Fig. 113. APP: Total**




### Utilization and Risk-Adjusted Utilization Measures


**Fig. 114. Frequency of Ongoing Prenatal Care (FPC):  $\geq$  81%**



**Fig. 116. Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)**




**Fig. 115. Well-Child Visits in the First 15 Months of Life (W15): 6 or More Visits**



Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

**Fig. 117. Adolescent Well-Care Visits (AWC)**



## APPENDIX A | Utilization Measure Results and Benchmarks

### Utilization Additional Measure Descriptions

#### Frequency of Selected Procedure (FSP)

FSP summarizes the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization.

#### Ambulatory Care (AMB)

AMB summarizes utilization of ambulatory care in the following categories:

- ◆ Outpatient Visits
- ◆ ED Visits

#### Inpatient Utilization – General Hospital/Acute Care (IPU)

IPU summarizes utilization of acute IP care and services in the following categories:

- ◆ Total IP
- ◆ Medicine
- ◆ Surgery
- ◆ Maternity

#### Identification of Alcohol and Other Drug Services (IAD)

IAD summarizes the number and percentage of members with an AOD claim who received the following chemical dependency services during the measurement year:

- ◆ Any services
- ◆ IP
- ◆ Outpatient or ED
- ◆ Intensive outpatient or partial hospitalization

#### Mental Health Utilization (MPT)

MPT summarizes the number and percentage of members receiving the following mental health services during the measurement year:

- ◆ Any services
- ◆ IP
- ◆ Outpatient or ED
- ◆ Intensive outpatient or partial hospitalization

#### Antibiotic Utilization (ABX)

ABX summarizes the following data on outpatient utilization of antibiotic prescriptions during the MY, stratified by age and gender:

- ◆ Total number of and average (Avg.) number of antibiotic prescription per member per year (PMPY)
- ◆ Total and avg. days supplied for all antibiotic prescriptions
- ◆ Total number of prescriptions and avg. number of prescriptions PMPY for antibiotic of concern
- ◆ Percentage of antibiotic of concern for all antibiotic prescriptions
- ◆ Avg. number of antibiotics PMPY reported by drug class:
  - For selected 'antibiotics of concern'
  - For all other antibiotics

## Utilization Measures: Plan-Specific Rates/National Benchmarks

In Table A, cells are shaded gray for those measures that were not calculated or for which data were not reported.

Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures																		
Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles						
												Mean	P10	P25	P50	P75	P90	
<b>Frequency of Ongoing Prenatal Care (FPC):</b>																		
<21%	NA	16.00%	11.56%	17.80%	4.39%	13.87%	7.82%	12.90%	4.94%	13.38%	9.25%	14.24%	2.66%	5.60%	8.63%	15.09%	32.44%	
21–40%	NA	7.76%	9.43%	15.69%	4.09%	8.52%	8.80%	8.52%	7.16%	11.92%	9.98%	7.64%	2.54%	3.77%	5.62%	10.46%	14.36%	
41–60%	NA	9.65%	9.91%	11.94%	4.68%	11.44%	14.18%	13.87%	7.90%	10.95%	12.90%	8.43%	4.38%	5.93%	7.82%	10.22%	13.38%	
61–80%	NA	8.94%	13.68%	16.63%	13.45%	16.30%	19.80%	18.25%	14.57%	18.49%	18.98%	14.46%	7.73%	11.70%	14.19%	17.61%	20.68%	
≥81%	NA	57.65%	55.42%	37.94%	73.39%	49.88%	49.39%	46.47%	65.43%	45.26%	48.91%	55.24%	27.48%	46.72%	59.49%	69.78%	75.35%	
<b>Well-Child Visits in the First 15 Months of Life (W15):</b>																		
0 Visits	NA	32.00%	2.78%	20.00%	0.90%	7.38%	2.19%	7.79%	3.80%	2.74%	4.63%	2.17%	0.46%	0.96%	1.65%	2.94%	4.27%	
1 Visits	NA	6.00%	4.40%	22.86%	1.49%	7.79%	1.46%	3.16%	3.22%	4.74%	4.15%	2.11%	0.57%	1.10%	1.86%	2.91%	3.89%	
2 Visits	NA	16.00%	3.47%	11.43%	4.18%	9.43%	6.57%	6.81%	2.63%	4.74%	6.10%	3.29%	0.97%	2.03%	3.10%	4.38%	5.53%	
3 Visits	NA	14.00%	6.25%	14.29%	3.58%	7.38%	10.22%	7.06%	3.80%	6.98%	6.59%	5.53%	2.63%	3.94%	5.09%	6.81%	8.26%	
4 Visits	NA	2.00%	7.18%	11.43%	6.57%	7.79%	16.06%	12.17%	8.77%	7.73%	13.66%	10.39%	6.23%	7.89%	9.58%	11.81%	15.01%	
5 Visits	NA	14.00%	17.13%	5.71%	12.84%	13.11%	18.25%	17.76%	12.87%	14.71%	17.80%	17.65%	11.11%	14.66%	17.82%	20.44%	24.31%	
6 or More Visits	NA	16.00%	58.80%	14.29%	70.45%	47.13%	45.26%	45.26%	64.91%	58.35%	47.07%	58.86%	44.15%	51.76%	59.76%	66.24%	74.47%	
<b>Frequency of Selected Procedures (FSP)</b>																		
<b>Bariatric weight loss surgery: Procedures /1,000 Member Years</b>																		
0–19	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
20–44		0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.02	0.00	0.00	0.01	0.03	0.05
45–64		0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.02	0.00	0.00	0.00	0.02	0.05
0–19	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
20–44		0.01	0.01	0.00	0.05	0.01	0.01	0.00	0.04	0.05	0.01	0.07	0.00	0.03	0.06	0.10	0.17	
45–64		0.03	0.02	0.00	0.01	0.00	0.01	0.00	0.04	0.02	0.02	0.08	0.00	0.02	0.06	0.11	0.19	
<b>Tonsillectomy: Procedures /1,000 Member Years</b>																		
0–9	M&F	0.82	0.76	0.39	1.05	0.64	0.44	0.95	1.07	0.81	0.45	0.63	0.25	0.47	0.66	0.80	0.97	
10–19		0.34	0.37	0.24	0.48	0.36	0.25	0.24	0.57	0.37	0.27	0.28	0.10	0.18	0.26	0.35	0.41	
<b>Hysterectomy—Abdominal (A) and Vaginal (V): Procedures /1,000 Member Years</b>																		
A 15–44	F	0.10	0.14	0.09	0.10	0.13	0.17	0.02	0.13	0.18	0.19	0.15	0.06	0.11	0.15	0.18	0.24	
A 45–64		0.10	0.16	0.23	0.15	0.27	0.32	0.00	0.17	0.15	0.32	0.35	0.18	0.25	0.31	0.42	0.50	

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
V 15-44	F	0.20	0.22	0.07	0.26	0.16	0.10	0.03	0.30	0.17	0.10	0.16	0.04	0.07	0.13	0.23	0.31
V 45-64		0.20	0.10	0.12	0.28	0.17	0.14	0.00	0.29	0.26	0.12	0.25	0.07	0.13	0.19	0.31	0.46
<b>Cholecystectomy—Open (O) and Closed (C)/Laparoscopic: Procedures /1,000 Member Years</b>																	
O 30-64	M	0.03	0.02	0.04	0.04	0.03	0.06	0.12	0.04	0.02	0.06	0.03	0.00	0.01	0.03	0.05	0.08
O 15-44	F	0.00	0.01	0.02	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.01	0.00	0.00	0.01	0.02	0.02
O 45-64		0.03	0.03	0.06	0.02	0.04	0.05	0.00	0.01	0.04	0.13	0.04	0.00	0.01	0.03	0.06	0.08
C 30-64	M	0.39	0.34	0.19	0.40	0.33	0.37	0.18	0.56	0.40	0.33	0.32	0.13	0.19	0.31	0.39	0.54
C 15-44	F	0.85	0.80	0.49	0.88	0.73	0.49	0.43	0.90	0.75	0.49	0.71	0.35	0.55	0.69	0.88	1.04
C 45-64		0.70	0.70	0.36	0.68	0.81	0.59	0.36	0.95	0.68	0.77	0.66	0.33	0.50	0.66	0.83	0.96
<b>Back Surgery: Procedures /1,000 Member Years</b>																	
20-44	M	0.20	0.27	0.17	0.37	0.25	0.10	0.00	0.33	0.40	0.26	0.28	0.06	0.13	0.23	0.37	0.49
	F	0.10	0.21	0.07	0.21	0.16	0.13	0.00	0.27	0.36	0.11	0.25	0.06	0.11	0.18	0.24	0.33
45-64	M	0.50	0.71	0.40	0.86	0.70	0.49	0.16	0.77	1.20	0.38	0.63	0.18	0.37	0.58	0.77	0.98
	F	0.34	0.54	0.23	0.70	0.67	0.32	0.00	1.00	1.34	0.39	0.55	0.17	0.31	0.51	0.69	0.84
<b>Mastectomy: Procedures /1,000 Member Years</b>																	
15-44	F	0.03	0.02	0.03	0.05	0.02	0.01	0.00	0.05	0.03	0.03	0.03	0.00	0.01	0.03	0.04	0.05
45-64		0.13	0.15	0.06	0.58	0.19	0.47	0.00	0.31	0.45	0.14	0.17	0.04	0.09	0.15	0.21	0.31
<b>Lumpectomy: Procedures /1,000 Member Years</b>																	
15-44	F	0.09	0.13	0.09	0.12	0.12	0.12	0.04	0.11	0.12	0.08	0.13	0.07	0.10	0.13	0.16	0.18
45-64		0.10	0.52	0.23	0.55	0.25	0.89	0.00	0.34	0.46	0.31	0.40	0.22	0.30	0.37	0.46	0.61
<b>Ambulatory Care: Total (AMB)</b>																	
<b>Outpatient Visits: Visits/1,000 Member Months</b>																	
<1	NA	736.13	755.64	564.87	809.86	718.43	653.71	898.72	720.33	698.66	571.69						
1-9	NA	242.67	301.53	208.53	321.04	271.76	273.49	360.28	291.22	310.54	262.65						
10-19	NA	189.90	230.87	164.09	262.59	207.80	214.81	246.42	242.79	249.04	204.92						
20-44	NA	217.15	325.73	222.07	349.37	299.75	330.48	117.75	341.40	382.65	310.98						
45-64	NA	390.28	650.34	363.79	723.69	579.85	664.71	252.88	693.98	763.98	605.84						
65-74	NA	257.31	639.03	296.17	96.86	169.95	287.67	519.53	737.28	656.69	530.99						
75-84	NA	207.50	554.20	210.43	20.71	120.96	115.42	90.91	490.52	298.51	278.61						
≥85	NA	76.15	419.58	96.77	17.96	111.11	118.06		238.70	121.20	114.07						
<b>Total</b>	<b>NA</b>	<b>247.34</b>	<b>345.65</b>	<b>225.44</b>	<b>378.14</b>	<b>303.78</b>	<b>324.30</b>	<b>279.53</b>	<b>370.20</b>	<b>380.31</b>	<b>310.45</b>	<b>355.41</b>	<b>257.36</b>	<b>304.73</b>	<b>348.18</b>	<b>391.39</b>	<b>460.08</b>

Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
<b>ED Visits: Visits/1,000 Member Months</b>																	
<1	NA	130.95	86.28	128.34	101.46	94.36	112.70	96.18	113.47	83.94	109.19						
1-9	NA	71.07	43.47	54.77	59.93	50.24	52.03	51.97	59.08	44.53	49.31						
10-19	NA	63.72	42.13	44.62	57.48	43.31	39.25	48.82	54.50	45.36	38.03						
20-44	NA	140.50	96.61	113.40	111.85	117.15	88.96	41.18	115.88	109.28	93.17						
45-64	NA	109.63	87.17	96.06	102.24	100.97	89.48	41.89	110.50	109.41	93.63						
65-74	NA	42.40	54.90	57.02	13.17	15.03	34.68	31.25	84.14	68.85	67.55						
75-84	NA	23.45	57.12	49.41	1.45	5.50	6.03	0.00	52.25	34.23	29.69						
≥85	NA	12.48	41.42	12.90	4.14	14.12	3.47		23.84	15.86	14.99						
<b>Total</b>	<b>NA</b>	<b>96.74</b>	<b>64.06</b>	<b>76.21</b>	<b>80.60</b>	<b>74.42</b>	<b>65.13</b>	<b>49.58</b>	<b>82.13</b>	<b>70.62</b>	<b>65.18</b>	<b>62.11</b>	<b>39.64</b>	<b>50.67</b>	<b>61.89</b>	<b>72.42</b>	<b>83.68</b>
<b>Inpatient Utilization—General Hospital/Acute Care: Total (IPU)</b>																	
<b>Total Inpatient</b>																	
<b>Discharges: Discharges/1,000 Member Months</b>																	
<1	NA	12.77	7.59	10.80	9.79	7.28	7.94	32.67	10.49	7.15	8.73						
1-9	NA	1.25	0.95	1.25	1.17	0.91	0.96	7.02	1.00	0.86	0.90						
10-19	NA	2.06	2.22	2.39	2.62	2.07	2.16	4.42	2.06	2.11	1.97						
20-44	NA	11.15	12.25	12.55	13.43	11.57	12.84	5.68	10.90	12.25	10.57						
45-64	NA	23.19	19.66	22.00	18.86	22.95	19.37	9.73	22.24	19.21	17.76						
65-74	NA	16.08	23.54	15.04	3.88	7.51	17.13	19.53	30.27	22.78	23.07						
75-84	NA	10.55	27.96	18.30	1.09	9.62	6.03	0.00	25.09	13.22	12.38						
≥85	NA	3.75	19.37	14.52	2.76	10.36	0.00		13.70	7.69	6.80						
<b>Total</b>	<b>NA</b>	<b>7.02</b>	<b>6.66</b>	<b>7.12</b>	<b>7.37</b>	<b>6.49</b>	<b>6.63</b>	<b>6.09</b>	<b>8.03</b>	<b>6.77</b>	<b>6.24</b>	<b>7.84</b>	<b>5.18</b>	<b>5.95</b>	<b>7.03</b>	<b>8.39</b>	<b>10.21</b>
<b>Days: Days/1,000 Member Months</b>																	
<1	NA	116.31	50.60	96.35	64.40	38.32	44.06	380.75	101.01	47.95	97.11						
1-9	NA	3.58	3.42	4.72	3.31	2.62	2.95	37.59	3.49	2.63	3.22						
10-19	NA	6.90	7.22	8.30	7.78	5.88	6.34	23.09	6.69	7.27	7.16						
20-44	NA	43.65	39.76	45.73	43.89	38.54	42.74	26.42	42.32	43.15	40.91						
45-64	NA	151.57	106.41	141.09	98.92	111.79	118.62	64.49	121.70	101.49	107.41						
65-74	NA	83.33	141.36	110.64	21.75	40.43	94.95	89.84	179.82	129.11	153.20						
75-84	NA	116.06	165.01	86.92	6.90	62.54	33.59	0.00	138.61	78.98	84.61						
≥85	NA	18.73	123.72	104.84	26.24	51.79	0.00		76.80	40.61	44.71						
<b>Total</b>	<b>NA</b>	<b>34.19</b>	<b>27.41</b>	<b>32.77</b>	<b>29.16</b>	<b>24.62</b>	<b>27.22</b>	<b>35.76</b>	<b>39.28</b>	<b>28.99</b>	<b>31.71</b>	<b>33.30</b>	<b>16.59</b>	<b>22.01</b>	<b>27.98</b>	<b>33.69</b>	<b>45.97</b>

Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles						
												Mean	P10	P25	P50	P75	P90	
<b>Average Length of Stay: Average # of Days</b>																		
<1	NA	9.11	6.67	8.92	6.58	5.26	5.55	11.66	9.63	6.71	11.13							
1-9	NA	2.86	3.59	3.77	2.83	2.87	3.08	5.36	3.51	3.05	3.58							
10-19	NA	3.35	3.26	3.48	2.96	2.85	2.94	5.23	3.25	3.45	3.63							
20-44	NA	3.92	3.25	3.64	3.27	3.33	3.33	4.65	3.88	3.52	3.87							
45-64	NA	6.54	5.41	6.41	5.25	4.87	6.12	6.63	5.47	5.28	6.05							
65-74	NA	5.18	6.01	7.36	5.61	5.38	5.54	4.60	5.94	5.67	6.64							
75-84	NA	11.00	5.90	4.75	6.33	6.50	5.57		5.53	5.97	6.83							
≥85	NA	5.00	6.39	7.22	9.50	5.00			5.61	5.28	6.58							
Unknown	NA							2.50										
<b>Total</b>	<b>NA</b>	<b>4.87</b>	<b>4.11</b>	<b>4.61</b>	<b>3.96</b>	<b>3.79</b>	<b>4.11</b>	<b>5.87</b>	<b>4.89</b>	<b>4.28</b>	<b>5.08</b>	<b>3.99</b>	<b>3.05</b>	<b>3.42</b>	<b>3.99</b>	<b>4.35</b>	<b>4.79</b>	
<b>Medicine</b>																		
<b>Discharges: Discharges/1,000 Member Months</b>																		
<1	NA	11.33	6.44	7.77	8.82	6.34	6.90	25.05	8.82	6.10	6.23							
1-9	NA	1.01	0.71	0.92	1.00	0.72	0.79	5.57	0.79	0.62	0.65							
10-19	NA	0.63	0.57	0.67	0.80	0.64	0.49	2.98	0.64	0.51	0.50							
20-44	NA	3.61	2.61	2.99	3.20	3.24	3.32	3.10	3.24	2.45	2.25							
45-64	NA	15.37	13.30	14.53	14.22	17.68	14.79	8.04	15.27	12.58	11.75							
65-74	NA	13.16	18.43	12.48	3.17	6.44	13.22	15.63	22.12	15.11	15.17							
75-84	NA	7.03	22.47	14.64	1.09	7.56	6.03	0.00	19.76	9.84	9.45							
≥85	NA	0.00	17.21	12.90	2.76	6.59	0.00		10.94	6.50	5.14							
<b>Total</b>	<b>NA</b>	<b>3.36</b>	<b>2.79</b>	<b>2.87</b>	<b>3.34</b>	<b>3.05</b>	<b>2.93</b>	<b>4.37</b>	<b>4.32</b>	<b>2.80</b>	<b>2.68</b>	<b>3.75</b>	<b>1.43</b>	<b>2.30</b>	<b>3.05</b>	<b>4.04</b>	<b>5.88</b>	
<b>Days: Days/1,000 Member Months</b>																		
<1	NA	94.11	34.70	31.27	55.04	29.76	25.76	183.83	78.97	35.24	30.56							
1-9	NA	2.42	1.97	2.65	2.62	1.84	2.27	24.76	2.03	1.42	1.81							
10-19	NA	1.57	1.95	2.19	2.37	1.87	1.46	14.80	1.79	1.73	1.61							
20-44	NA	13.47	9.13	10.91	13.93	12.99	13.82	16.27	12.74	9.41	8.89							
45-64	NA	69.95	59.35	66.10	67.46	76.42	78.37	51.71	68.22	56.20	53.63							
65-74	NA	55.56	106.27	74.89	18.93	35.06	62.65	74.22	106.94	70.28	76.72							
75-84	NA	56.27	113.04	64.96	6.90	46.74	33.59	0.00	95.73	55.19	51.93							
≥85	NA	0.00	100.05	85.48	26.24	16.01	0.00		54.56	31.17	29.02							
<b>Total</b>	<b>NA</b>	<b>14.54</b>	<b>11.73</b>	<b>11.45</b>	<b>15.13</b>	<b>12.32</b>	<b>13.04</b>	<b>22.13</b>	<b>19.73</b>	<b>12.05</b>	<b>11.65</b>	<b>15.23</b>	<b>4.77</b>	<b>8.32</b>	<b>11.64</b>	<b>15.18</b>	<b>24.59</b>	

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles						
												Mean	P10	P25	P50	P75	P90	
<b>Average Length of Stay: Average # of Days</b>																		
<1	NA	8.31	5.39	4.03	6.24	4.69	3.73	7.34	8.96	5.78	4.90							
1-9	NA	2.40	2.77	2.86	2.63	2.55	2.87	4.44	2.56	2.30	2.79							
10-19	NA	2.49	3.39	3.26	2.95	2.93	2.98	4.97	2.81	3.40	3.24							
20-44	NA	3.73	3.50	3.65	4.35	4.01	4.17	5.25	3.93	3.85	3.96							
45-64	NA	4.55	4.46	4.55	4.74	4.32	5.30	6.43	4.47	4.47	4.56							
65-74	NA	4.22	5.77	6.00	5.96	5.44	4.74	4.75	4.83	4.65	5.06							
75-84	NA	8.00	5.03	4.44	6.33	6.18	5.57		4.85	5.61	5.49							
≥85	NA		5.81	6.63	9.50	2.43			4.99	4.79	5.64							
Unknown	NA							2.50										
<b>Total</b>	<b>NA</b>	<b>4.33</b>	<b>4.21</b>	<b>3.98</b>	<b>4.53</b>	<b>4.05</b>	<b>4.45</b>	<b>5.06</b>	<b>4.57</b>	<b>4.31</b>	<b>4.35</b>	<b>3.81</b>	<b>3.02</b>	<b>3.46</b>	<b>3.79</b>	<b>4.14</b>	<b>4.54</b>	
<b>Surgery</b>																		
<b>Discharges: Discharges/1,000 Member Months</b>																		
<1	NA	1.44	1.15	3.03	0.97	0.94	1.04	7.61	1.68	1.04	2.49							
1-9	NA	0.25	0.24	0.33	0.17	0.19	0.17	1.44	0.20	0.25	0.25							
10-19	NA	0.35	0.34	0.38	0.26	0.25	0.23	0.80	0.32	0.33	0.32							
20-44	NA	1.84	1.45	1.66	1.15	1.08	1.15	0.80	1.87	1.40	1.46							
45-64	NA	7.78	6.34	7.45	4.63	5.28	4.58	1.69	6.89	6.58	5.98							
65-74	NA	2.92	5.11	2.55	0.71	1.07	3.90	3.91	8.06	7.67	7.90							
75-84	NA	3.52	5.49	3.66	0.00	2.06	0.00	0.00	5.29	3.32	2.93							
≥85	NA	3.75	2.15	1.61	0.00	3.77	0.00		2.64	1.19	1.66							
<b>Total</b>	<b>NA</b>	<b>1.52</b>	<b>1.23</b>	<b>1.43</b>	<b>0.98</b>	<b>0.92</b>	<b>0.89</b>	<b>1.16</b>	<b>1.84</b>	<b>1.35</b>	<b>1.39</b>	<b>1.61</b>	<b>0.69</b>	<b>0.98</b>	<b>1.37</b>	<b>1.76</b>	<b>2.49</b>	
<b>Days: Days/1,000 Member Months</b>																		
<1	NA	22.20	15.90	65.08	9.35	8.56	18.30	196.92	22.03	12.47	66.55							
1-9	NA	1.17	1.45	2.07	0.69	0.77	0.68	12.84	1.46	1.22	1.41							
10-19	NA	2.15	1.77	2.85	1.32	0.95	1.16	6.65	1.66	1.78	1.76							
20-44	NA	15.52	8.65	14.49	6.72	6.01	7.87	5.71	12.41	7.70	9.92							
45-64	NA	81.45	46.99	74.93	31.44	35.37	40.25	12.78	53.17	45.15	53.62							
65-74	NA	27.78	35.09	35.74	2.82	5.37	32.30	15.63	72.38	58.83	76.48							
75-84	NA	59.79	51.97	21.96	0.00	15.81	0.00	0.00	42.72	23.49	32.69							
≥85	NA	18.73	23.67	19.35	0.00	35.78	0.00		21.87	9.44	15.69							
<b>Total</b>	<b>NA</b>	<b>14.03</b>	<b>8.58</b>	<b>14.13</b>	<b>6.21</b>	<b>5.51</b>	<b>7.09</b>	<b>12.22</b>	<b>13.97</b>	<b>8.82</b>	<b>13.04</b>	<b>11.56</b>	<b>4.00</b>	<b>5.80</b>	<b>9.00</b>	<b>12.34</b>	<b>18.67</b>	

Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
<b>Average Length of Stay: Average # of Days</b>																	
<1	NA	15.45	13.81	21.46	9.68	9.10	17.61	25.86	13.14	12.00	26.69						
1-9	NA	4.72	5.98	6.30	3.99	4.06	4.10	8.89	7.35	4.91	5.62						
10-19	NA	6.06	5.15	7.43	5.08	3.82	5.13	8.26	5.14	5.43	5.46						
20-44	NA	8.43	5.94	8.73	5.86	5.56	6.86	7.14	6.63	5.52	6.80						
45-64	NA	10.47	7.41	10.06	6.79	6.71	8.79	7.55	7.72	6.86	8.97						
65-74	NA	9.50	6.86	14.00	4.00	5.00	8.28	4.00	8.98	7.67	9.68						
75-84	NA	17.00	9.47	6.00		7.67			8.08	7.07	11.16						
≥85	NA	5.00	11.00	12.00		9.50			8.28	7.93	9.47						
<b>Total</b>	<b>NA</b>	<b>9.25</b>	<b>6.96</b>	<b>9.87</b>	<b>6.33</b>	<b>6.01</b>	<b>8.00</b>	<b>10.52</b>	<b>7.60</b>	<b>6.54</b>	<b>9.37</b>	<b>6.72</b>	<b>4.77</b>	<b>5.85</b>	<b>6.71</b>	<b>7.59</b>	<b>8.54</b>
<b>Maternity (calculated using member months for members 10-64 years)</b>																	
<b>Discharges: Discharges/1,000 Member Months</b>																	
10-19	NA	1.08	1.30	1.33	1.56	1.18	1.44	0.63	1.10	1.27	1.15						
20-44	NA	5.70	8.18	7.91	9.08	7.25	8.37	1.78	5.79	8.41	6.86						
45-64	NA	0.04	0.03	0.02	0.00	0.00	0.00	0.00	0.09	0.05	0.03						
<b>Total</b>	<b>NA</b>	<b>3.15</b>	<b>4.34</b>	<b>4.37</b>	<b>4.75</b>	<b>3.90</b>	<b>4.40</b>	<b>0.86</b>	<b>2.94</b>	<b>4.36</b>	<b>3.56</b>	<b>4.08</b>	<b>0.95</b>	<b>2.58</b>	<b>3.66</b>	<b>5.56</b>	<b>7.35</b>
<b>Days: Days/1,000 Member Months</b>																	
10-19	NA	3.18	3.50	3.27	4.08	3.06	3.72	1.63	3.24	3.76	3.79						
20-44	NA	14.66	21.98	20.33	23.24	19.54	21.06	4.44	17.17	26.04	22.10						
45-64	NA	0.17	0.08	0.06	0.01	0.00	0.00	0.00	0.31	0.13	0.16						
<b>Total</b>	<b>NA</b>	<b>8.28</b>	<b>11.66</b>	<b>11.17</b>	<b>12.18</b>	<b>10.46</b>	<b>11.09</b>	<b>2.20</b>	<b>8.73</b>	<b>13.44</b>	<b>11.49</b>	<b>10.62</b>	<b>2.90</b>	<b>6.67</b>	<b>9.52</b>	<b>13.74</b>	<b>19.01</b>
<b>Average Length of Stay: Average # of Days</b>																	
10-19	NA	2.95	2.69	2.46	2.62	2.59	2.58	2.59	2.95	2.96	3.29						
20-44	NA	2.57	2.69	2.57	2.56	2.70	2.51	2.49	2.97	3.10	3.22						
45-64	NA	4.20	3.00	3.00	3.00				3.52	2.56	4.80						
Unknown	NA																
<b>Total</b>	<b>NA</b>	<b>2.63</b>	<b>2.69</b>	<b>2.56</b>	<b>2.57</b>	<b>2.68</b>	<b>2.52</b>	<b>2.55</b>	<b>2.97</b>	<b>3.08</b>	<b>3.23</b>	<b>2.65</b>	<b>2.29</b>	<b>2.45</b>	<b>2.61</b>	<b>2.77</b>	<b>2.97</b>
<b>Identification of Alcohol and Other Drug Services: Total (IAD)</b>																	
<b>Any Services</b>																	
0-12	M	0.06%	0.04%	0.05%	0.06%	0.04%	0.05%	0.11%	0.06%	0.05%	0.05%						
	F	0.05%	0.04%	0.04%	0.05%	0.03%	0.05%	0.16%	0.06%	0.03%	0.04%						
	M&F	0.06%	0.04%	0.04%	0.06%	0.03%	0.05%	0.13%	0.06%	0.04%	0.05%						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
13-17	M	2.16%	1.98%	2.13%	2.24%	1.88%	1.91%	6.08%	2.06%	2.27%	2.07%						
	F	1.62%	1.45%	0.90%	1.49%	0.87%	1.09%	6.39%	1.56%	1.55%	0.94%						
	M&F	1.89%	1.72%	1.52%	1.87%	1.38%	1.49%	6.19%	1.81%	1.91%	1.49%						
18-24	M	5.12%	4.31%	4.01%	3.73%	4.41%	2.19%	3.66%	4.73%	4.60%	3.60%						
	F	7.38%	4.50%	3.81%	5.13%	5.07%	2.60%	3.80%	5.59%	4.47%	2.81%						
	M&F	6.52%	4.44%	3.88%	4.68%	4.84%	2.46%	3.71%	5.28%	4.51%	3.08%						
25-34	M	11.32%	9.05%	9.38%	10.71%	11.57%	8.91%	2.17%	10.55%	12.58%	8.45%						
	F	12.03%	8.43%	5.73%	11.44%	10.55%	6.03%	1.65%	10.56%	10.08%	6.27%						
	M&F	11.85%	8.56%	6.29%	11.30%	10.77%	6.47%	1.82%	10.56%	10.57%	6.63%						
35-64	M	15.53%	13.36%	15.20%	15.72%	18.62%	14.86%	2.23%	16.90%	16.55%	14.94%						
	F	10.73%	9.23%	7.60%	13.33%	13.76%	9.17%	1.19%	12.12%	14.01%	8.64%						
	M&F	12.61%	10.73%	10.17%	14.13%	15.38%	10.71%	1.66%	13.95%	14.90%	10.76%						
≥65	M	3.81%	10.53%	7.97%	1.39%	0.67%	2.11%	0.00%	7.80%	7.47%	7.26%						
	F	0.49%	3.78%	2.01%	0.84%	0.00%	2.20%	0.00%	3.71%	3.78%	2.86%						
	M&F	1.62%	6.17%	3.89%	1.00%	0.23%	2.18%	0.00%	4.93%	4.86%	4.12%						
Unknown	M																
	F																
	M&F																
Total	M	<b>4.38%</b>	<b>3.38%</b>	<b>3.25%</b>	<b>3.90%</b>	<b>3.96%</b>	<b>2.77%</b>	<b>2.52%</b>	<b>5.10%</b>	<b>4.22%</b>	<b>3.50%</b>						
	F	<b>5.67%</b>	<b>4.02%</b>	<b>3.16%</b>	<b>5.83%</b>	<b>5.28%</b>	<b>3.49%</b>	<b>2.34%</b>	<b>5.54%</b>	<b>5.41%</b>	<b>3.34%</b>						
	M&F	<b>5.11%</b>	<b>3.75%</b>	<b>3.20%</b>	<b>5.04%</b>	<b>4.73%</b>	<b>3.20%</b>	<b>2.45%</b>	<b>5.35%</b>	<b>4.91%</b>	<b>3.41%</b>	<b>5.48%</b>	<b>1.71%</b>	<b>2.74%</b>	<b>4.07%</b>	<b>6.28%</b>	<b>10.41%</b>
<b>Inpatient</b>																	
0-12	M	0.00%	0.01%	0.01%	0.01%	0.00%	0.00%	0.01%	0.02%	0.00%	0.00%						
	F	0.00%	0.00%	0.00%	0.01%	0.00%	0.01%	0.05%	0.00%	0.01%	0.01%						
	M&F	0.00%	0.00%	0.01%	0.01%	0.00%	0.01%	0.03%	0.01%	0.00%	0.01%						
13-17	M	0.40%	0.44%	0.66%	0.43%	0.35%	0.58%	1.04%	0.37%	0.37%	0.73%						
	F	0.44%	0.50%	0.36%	0.39%	0.22%	0.45%	1.23%	0.47%	0.39%	0.33%						
	M&F	0.42%	0.47%	0.51%	0.41%	0.29%	0.51%	1.11%	0.42%	0.38%	0.52%						
18-24	M	1.91%	1.21%	1.32%	0.89%	1.45%	0.67%	1.35%	1.51%	1.45%	1.38%						
	F	3.43%	1.76%	1.23%	2.24%	1.81%	0.86%	1.46%	2.45%	1.63%	0.84%						
	M&F	2.86%	1.57%	1.26%	1.81%	1.68%	0.79%	1.39%	2.11%	1.57%	1.02%						
25-34	M	3.75%	3.10%	4.22%	2.61%	3.90%	2.57%	0.72%	3.44%	4.14%	2.98%						
	F	5.06%	3.06%	1.54%	4.22%	3.41%	1.54%	0.96%	3.85%	3.11%	1.60%						
	M&F	4.73%	3.07%	1.95%	3.92%	3.52%	1.69%	0.89%	3.75%	3.31%	1.82%						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles				
												Mean	P10	P25	P50	P75
35-64	M	6.06%	4.72%	6.39%	3.88%	7.31%	4.99%	0.87%	5.30%	4.94%	4.72%					
	F	3.27%	2.47%	2.36%	2.79%	3.54%	2.01%	0.56%	2.74%	2.81%	1.65%					
	M&F	4.36%	3.29%	3.73%	3.16%	4.80%	2.81%	0.70%	3.72%	3.56%	2.69%					
≥65	M	1.90%	3.32%	1.45%	1.39%	0.67%	0.70%	0.00%	3.30%	2.91%	2.58%					
	F	0.49%	1.10%	0.34%	0.14%	0.00%	0.00%	0.00%	0.92%	1.01%	0.58%					
	M&F	0.97%	1.89%	0.69%	0.50%	0.23%	0.20%	0.00%	1.63%	1.57%	1.16%					
Unknown	M															
	F															
	M&F															
Total	M	1.57%	1.12%	1.29%	0.94%	1.42%	0.89%	0.59%	1.59%	1.25%	1.15%					
	F	2.18%	1.29%	0.94%	1.70%	1.56%	0.86%	0.64%	1.61%	1.36%	0.76%					
	M&F	1.92%	1.22%	1.08%	1.39%	1.50%	0.87%	0.61%	1.61%	1.32%	0.92%	1.47%	0.44%	0.74%	0.97%	1.73%
<b>Intensive Outpatient/Partial Hospitalization</b>																
0-12	M	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%					
	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.00%	0.00%	0.00%					
	M&F	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%					
13-17	M	0.76%	0.54%	0.42%	0.75%	0.65%	0.41%	2.11%	0.71%	0.86%	0.41%					
	F	0.22%	0.26%	0.00%	0.40%	0.16%	0.16%	2.40%	0.28%	0.33%	0.19%					
	M&F	0.49%	0.40%	0.21%	0.58%	0.41%	0.28%	2.22%	0.49%	0.60%	0.30%					
18-24	M	0.57%	0.51%	0.33%	0.71%	1.06%	0.31%	0.66%	0.63%	0.80%	0.40%					
	F	1.24%	0.54%	0.40%	0.96%	1.28%	0.25%	0.77%	0.53%	0.71%	0.36%					
	M&F	0.98%	0.53%	0.37%	0.88%	1.20%	0.27%	0.70%	0.57%	0.74%	0.37%					
25-34	M	1.30%	1.17%	0.94%	1.63%	2.58%	1.10%	0.29%	0.70%	2.12%	0.88%					
	F	1.73%	1.32%	0.65%	2.28%	2.33%	0.90%	0.21%	1.47%	1.42%	0.99%					
	M&F	1.62%	1.29%	0.69%	2.15%	2.38%	0.93%	0.23%	1.30%	1.56%	0.97%					
35-64	M	0.61%	1.06%	0.94%	1.14%	2.56%	0.98%	0.00%	0.55%	1.07%	0.89%					
	F	0.69%	0.75%	0.45%	1.20%	1.81%	0.61%	0.00%	0.53%	0.74%	0.54%					
	M&F	0.66%	0.86%	0.62%	1.18%	2.06%	0.71%	0.00%	0.54%	0.85%	0.66%					
≥65	M	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%	0.07%	0.00%					
	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%					
	M&F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.02%	0.00%					
Unknown	M															
	F															
	M&F															

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
Total	M	0.38%	0.36%	0.27%	0.46%	0.72%	0.27%	0.71%	0.32%	0.48%	0.27%						
	F	0.68%	0.46%	0.28%	0.83%	0.97%	0.34%	0.70%	0.44%	0.51%	0.33%						
	M&F	0.55%	0.42%	0.27%	0.68%	0.86%	0.31%	0.70%	0.39%	0.50%	0.31%	0.34%	0.00%	0.02%	0.11%	0.38%	1.03%
<b>Outpatient/ED*</b>																	
0-12	M	0.06%	0.03%	0.03%	0.05%	0.03%	0.05%	0.10%	0.04%	0.04%	0.05%						
	F	0.05%	0.04%	0.03%	0.04%	0.03%	0.05%	0.10%	0.06%	0.03%	0.03%						
	M&F	0.05%	0.04%	0.03%	0.05%	0.03%	0.05%	0.10%	0.05%	0.04%	0.04%						
13-17	M	1.66%	1.47%	1.61%	1.67%	1.21%	1.45%	4.44%	1.63%	1.59%	1.56%						
	F	1.26%	1.05%	0.66%	1.05%	0.66%	0.90%	5.07%	1.12%	1.10%	0.62%						
	M&F	1.47%	1.26%	1.14%	1.36%	0.94%	1.16%	4.67%	1.37%	1.34%	1.08%						
18-24	M	4.16%	3.48%	3.13%	2.98%	2.96%	1.76%	3.10%	3.75%	3.54%	2.46%						
	F	5.13%	3.48%	3.07%	3.24%	3.64%	2.04%	2.81%	3.88%	3.26%	2.08%						
	M&F	4.76%	3.48%	3.10%	3.16%	3.40%	1.94%	2.99%	3.83%	3.35%	2.21%						
25-34	M	9.15%	7.67%	7.31%	8.82%	8.43%	7.52%	2.21%	8.59%	10.18%	6.48%						
	F	9.32%	7.04%	4.81%	8.65%	8.13%	5.12%	1.01%	8.31%	8.45%	5.07%						
	M&F	9.27%	7.17%	5.20%	8.68%	8.19%	5.48%	1.34%	8.37%	8.79%	5.30%						
35-64	M	12.38%	11.03%	11.96%	13.55%	14.43%	12.13%	2.47%	14.19%	14.20%	12.16%						
	F	8.80%	8.04%	6.36%	11.46%	11.34%	8.11%	0.93%	10.59%	12.53%	7.49%						
	M&F	10.20%	9.13%	8.26%	12.16%	12.38%	9.20%	1.53%	11.97%	13.12%	9.06%						
≥65	M	1.90%	8.66%	7.24%	0.35%	0.00%	1.41%	0.00%	5.31%	5.53%	5.57%						
	F	0.00%	3.15%	2.01%	0.70%	0.00%	2.20%	0.00%	3.02%	3.26%	2.37%						
	M&F	0.65%	5.10%	3.67%	0.60%	0.00%	1.98%	0.00%	3.70%	3.92%	3.29%						
Unknown	M																
	F																
	M&F																
Total	M	3.51%	2.77%	2.54%	3.27%	2.95%	2.25%	1.95%	4.19%	3.48%	2.77%						
	F	4.39%	3.38%	2.62%	4.63%	4.16%	3.01%	1.80%	4.56%	4.62%	2.77%						
	M&F	4.01%	3.12%	2.59%	4.07%	3.65%	2.71%	1.89%	4.40%	4.15%	2.77%	4.96%	1.41%	2.46%	3.54%	5.88%	9.31%
<b>Mental Health Utilization: Total (MPT)</b>																	
<b>Any Services</b>																	
0-12	M	9.47%	7.39%	5.30%	8.96%	7.04%	4.60%	25.52%	8.79%	7.21%	4.63%						
	F	5.71%	4.61%	2.79%	5.64%	4.09%	2.78%	17.45%	5.03%	4.36%	2.54%						
	M&F	7.64%	6.02%	4.05%	7.33%	5.57%	3.69%	22.20%	6.95%	5.81%	3.59%						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
13-17	M	14.79%	11.89%	9.10%	14.49%	9.93%	8.37%	36.95%	12.90%	12.97%	8.07%						
	F	13.82%	14.62%	7.51%	15.17%	10.79%	7.45%	36.80%	14.18%	13.78%	7.68%						
	M&F	14.32%	13.25%	8.31%	14.83%	10.35%	7.90%	36.89%	13.55%	13.37%	7.87%						
18-64	M	9.80%	14.26%	10.53%	11.36%	8.30%	8.39%	13.17%	14.35%	12.88%	12.32%						
	F	12.50%	16.22%	8.69%	14.60%	10.89%	8.41%	9.20%	16.84%	14.78%	9.74%						
	M&F	11.57%	15.61%	9.21%	13.66%	10.10%	8.40%	11.40%	15.99%	14.21%	10.50%						
≥65	M	24.74%	9.38%	13.04%	3.48%	9.43%	6.32%	14.72%	9.09%	8.96%	7.83%						
	F	27.48%	12.06%	15.41%	4.64%	14.61%	6.89%	0.00%	12.83%	11.59%	7.99%						
	M&F	26.55%	11.12%	14.66%	4.31%	12.88%	6.73%	7.72%	11.71%	10.82%	7.94%						
Unknown	M																
	F																
	M&F																
Total	M	<b>10.31%</b>	<b>10.13%</b>	<b>7.46%</b>	<b>10.54%</b>	<b>7.83%</b>	<b>6.26%</b>	<b>25.61%</b>	<b>11.36%</b>	<b>9.77%</b>	<b>7.48%</b>						
	F	<b>10.21%</b>	<b>11.47%</b>	<b>6.43%</b>	<b>11.39%</b>	<b>8.28%</b>	<b>6.24%</b>	<b>19.51%</b>	<b>12.40%</b>	<b>10.68%</b>	<b>6.85%</b>						
	M&F	<b>10.25%</b>	<b>10.90%</b>	<b>6.85%</b>	<b>11.04%</b>	<b>8.09%</b>	<b>6.25%</b>	<b>23.11%</b>	<b>11.96%</b>	<b>10.30%</b>	<b>7.11%</b>	<b>12.35%</b>	<b>4.31%</b>	<b>7.17%</b>	<b>11.39%</b>	<b>15.15%</b>	<b>20.65%</b>
<b>Inpatient</b>																	
0-12	M	0.10%	0.06%	0.15%	0.10%	0.10%	0.11%	0.96%	0.09%	0.07%	0.08%						
	F	0.07%	0.05%	0.10%	0.07%	0.06%	0.08%	0.48%	0.07%	0.05%	0.06%						
	M&F	0.09%	0.05%	0.13%	0.08%	0.08%	0.10%	0.76%	0.08%	0.06%	0.07%						
13-17	M	0.87%	0.78%	1.02%	0.97%	0.66%	0.95%	3.20%	0.97%	0.84%	0.81%						
	F	1.35%	1.44%	1.05%	1.37%	0.88%	1.34%	4.29%	1.10%	1.28%	1.18%						
	M&F	1.10%	1.11%	1.03%	1.17%	0.77%	1.15%	3.60%	1.03%	1.06%	1.00%						
18-64	M	2.03%	1.97%	2.35%	1.49%	1.80%	1.73%	1.76%	2.17%	2.11%	2.61%						
	F	1.63%	1.47%	1.22%	1.35%	1.42%	1.16%	1.60%	1.67%	1.53%	1.40%						
	M&F	1.77%	1.63%	1.54%	1.39%	1.54%	1.31%	1.69%	1.84%	1.70%	1.75%						
≥65	M	21.89%	2.45%	7.24%	2.09%	8.76%	4.22%	0.00%	4.93%	5.45%	4.68%						
	F	26.01%	3.94%	8.04%	3.51%	13.59%	2.20%	0.00%	6.55%	6.33%	4.58%						
	M&F	24.61%	3.42%	7.79%	3.10%	11.97%	2.77%	0.00%	6.06%	6.08%	4.61%						
Unknown	M																
	F																
	M&F																
Total	M	<b>0.96%</b>	<b>0.76%</b>	<b>0.98%</b>	<b>0.67%</b>	<b>0.74%</b>	<b>0.70%</b>	<b>1.76%</b>	<b>1.10%</b>	<b>0.90%</b>	<b>1.04%</b>						
	F	<b>1.11%</b>	<b>0.95%</b>	<b>0.82%</b>	<b>0.91%</b>	<b>0.89%</b>	<b>0.79%</b>	<b>1.66%</b>	<b>1.33%</b>	<b>1.13%</b>	<b>1.02%</b>						
	M&F	<b>1.05%</b>	<b>0.87%</b>	<b>0.88%</b>	<b>0.81%</b>	<b>0.83%</b>	<b>0.76%</b>	<b>1.72%</b>	<b>1.23%</b>	<b>1.03%</b>	<b>1.03%</b>	<b>1.44%</b>	<b>0.41%</b>	<b>0.52%</b>	<b>0.86%</b>	<b>1.25%</b>	<b>2.38%</b>

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles						
												Mean	P10	P25	P50	P75	P90	
<b>Intensive Outpatient/Partial Hospitalization</b>																		
0-12	M	0.01%	0.00%	0.07%	0.02%	0.00%	0.06%	0.16%	0.02%	0.00%	0.03%							
	F	0.01%	0.00%	0.02%	0.01%	0.00%	0.06%	0.12%	0.02%	0.00%	0.02%							
	M&F	0.01%	0.00%	0.05%	0.02%	0.00%	0.06%	0.14%	0.02%	0.00%	0.03%							
13-17	M	0.15%	0.20%	0.54%	0.22%	0.06%	0.39%	0.61%	0.16%	0.03%	0.29%							
	F	0.12%	0.17%	0.33%	0.09%	0.07%	0.51%	1.64%	0.19%	0.07%	0.49%							
	M&F	0.13%	0.18%	0.44%	0.16%	0.06%	0.45%	0.99%	0.18%	0.05%	0.39%							
18-64	M	0.10%	0.13%	0.23%	0.07%	0.53%	0.20%	0.32%	0.09%	0.13%	0.27%							
	F	0.21%	0.22%	0.21%	0.16%	0.56%	0.22%	0.26%	0.17%	0.15%	0.27%							
	M&F	0.17%	0.19%	0.22%	0.14%	0.55%	0.21%	0.29%	0.15%	0.15%	0.27%							
≥65	M	0.00%	0.00%	0.00%	0.00%	0.67%	0.00%	0.00%	0.00%	0.07%	0.08%							
	F	0.00%	0.00%	0.00%	0.00%	0.34%	0.00%	0.00%	0.00%	0.06%	0.00%							
	M&F	0.00%	0.00%	0.00%	0.00%	0.45%	0.00%	0.00%	0.00%	0.07%	0.02%							
Unknown	M																	
	F																	
	M&F																	
<b>Total</b>	<b>M</b>	<b>0.06%</b>	<b>0.07%</b>	<b>0.19%</b>	<b>0.07%</b>	<b>0.18%</b>	<b>0.15%</b>	<b>0.32%</b>	<b>0.06%</b>	<b>0.05%</b>	<b>0.14%</b>							
	<b>F</b>	<b>0.13%</b>	<b>0.12%</b>	<b>0.15%</b>	<b>0.10%</b>	<b>0.30%</b>	<b>0.19%</b>	<b>0.50%</b>	<b>0.11%</b>	<b>0.08%</b>	<b>0.20%</b>							
	<b>M&amp;F</b>	<b>0.10%</b>	<b>0.10%</b>	<b>0.16%</b>	<b>0.09%</b>	<b>0.25%</b>	<b>0.18%</b>	<b>0.39%</b>	<b>0.09%</b>	<b>0.07%</b>	<b>0.17%</b>	<b>0.50%</b>	<b>0.00%</b>	<b>0.02%</b>	<b>0.14%</b>	<b>0.41%</b>	<b>1.92%</b>	
<b>Outpatient/ED</b>																		
0-12	M	9.47%	7.38%	5.25%	8.94%	7.02%	4.56%	25.27%	8.78%	7.20%	4.62%							
	F	5.67%	4.60%	2.76%	5.62%	4.07%	2.76%	17.30%	5.02%	4.36%	2.53%							
	M&F	7.62%	6.01%	4.01%	7.31%	5.56%	3.67%	21.99%	6.94%	5.80%	3.59%							
13-17	M	14.53%	11.78%	8.83%	14.36%	9.69%	8.05%	36.17%	12.78%	12.79%	7.84%							
	F	13.64%	14.49%	7.29%	14.99%	10.61%	7.13%	35.97%	13.98%	13.64%	7.40%							
	M&F	14.10%	13.13%	8.07%	14.67%	10.14%	7.58%	36.10%	13.39%	13.21%	7.62%							
18-64	M	9.07%	13.69%	9.84%	10.85%	7.38%	7.91%	14.49%	13.90%	12.44%	11.56%							
	F	11.90%	15.93%	8.33%	14.17%	10.21%	8.08%	9.44%	16.45%	14.42%	9.32%							
	M&F	10.92%	15.23%	8.76%	13.21%	9.35%	8.04%	12.17%	15.58%	13.82%	9.98%							
≥65	M	4.76%	7.07%	5.79%	1.39%	0.67%	2.81%	15.69%	4.54%	3.88%	3.31%							
	F	1.96%	8.83%	7.71%	1.12%	1.02%	4.96%	0.00%	6.73%	5.90%	3.67%							
	M&F	2.91%	8.21%	7.10%	1.20%	0.90%	4.35%	8.11%	6.08%	5.31%	3.57%							
Unknown	M																	
	F																	
	M&F																	

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
Total	M	9.95%	9.92%	7.16%	10.34%	7.48%	6.04%	25.94%	11.04%	9.51%	7.12%						
	F	9.77%	11.26%	6.17%	11.11%	7.86%	6.02%	19.53%	11.86%	10.28%	6.44%						
	M&F	9.85%	10.69%	6.57%	10.79%	7.70%	6.03%	23.30%	11.51%	9.96%	6.72%	11.69%	3.72%	6.80%	10.81%	14.22%	20.16%
<b>Antibiotic Utilization: Total (ABX)</b>																	
<b>Antibiotic Utilization</b>																	
<b>Average Scripts PMPY for Antibiotics</b>																	
0-9	M	1.34	1.08	0.92	1.36	1.01	1.01	1.30	1.24	1.12	0.89						
	F	1.42	1.10	0.92	1.40	1.04	1.04	1.40	1.25	1.15	0.89						
	M&F	1.38	1.09	0.92	1.38	1.02	1.02	1.34	1.25	1.13	0.89						
10-17	M	0.83	0.63	0.57	0.82	0.54	0.57	0.72	0.75	0.63	0.53						
	F	1.11	0.88	0.77	1.11	0.73	0.78	1.09	1.04	0.90	0.69						
	M&F	0.97	0.75	0.67	0.97	0.63	0.68	0.86	0.90	0.76	0.61						
18-34	M	0.78	0.67	0.67	0.69	0.56	0.56	0.56	0.71	0.69	0.60						
	F	1.89	1.51	1.88	1.53	1.47	1.52	1.00	1.51	1.46	1.43						
	M&F	1.54	1.28	1.57	1.32	1.21	1.28	0.75	1.27	1.27	1.22						
35-49	M	0.93	0.92	0.99	0.96	0.83	0.97	0.33	0.96	0.95	0.95						
	F	1.68	1.54	1.69	1.62	1.42	1.63	0.31	1.58	1.57	1.50						
	M&F	1.42	1.35	1.49	1.41	1.25	1.49	0.32	1.37	1.37	1.36						
50-64	M	0.94	1.13	0.86	1.01	0.90	0.96	0.73	1.15	1.19	1.04						
	F	1.40	1.62	1.32	1.57	1.32	1.56	0.69	1.80	1.81	1.60						
	M&F	1.19	1.39	1.12	1.36	1.15	1.34	0.71	1.51	1.55	1.34						
65-74	M	0.74	1.22	0.71	0.17	0.73	0.60	0.29	1.41	1.10	1.05						
	F	0.98	1.64	0.89	0.33	0.51	0.73	1.20	2.05	1.64	1.38						
	M&F	0.88	1.47	0.83	0.28	0.60	0.69	0.75	1.81	1.45	1.26						
75-84	M	0.80	1.19	0.79	0.00	0.34	0.25	0.00	1.09	0.61	0.56						
	F	0.78	1.70	0.96	0.14	0.49	0.12	0.00	1.37	0.87	0.69						
	M&F	0.79	1.55	0.91	0.10	0.45	0.16	0.00	1.29	0.79	0.65						
≥85	M	1.38	1.57	0.87	0.39	1.42	1.05		1.12	0.24	0.27						
	F	1.36	1.56	0.41	0.46	0.62	0.46		0.67	0.38	0.33						
	M&F	1.36	1.56	0.50	0.45	0.80	0.63		0.74	0.36	0.32						
Unknown	M																
	F																
	M&F																

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
Total	M	1.03	0.91	0.79	1.06	0.78	0.81	0.88	1.01	0.93	0.78	0.78	0.53	0.65	0.75	0.89	1.06
	F	1.56	1.28	1.36	1.43	1.19	1.26	1.15	1.40	1.29	1.14	1.13	0.82	0.94	1.10	1.26	1.52
	M&F	1.33	1.12	1.13	1.28	1.02	1.08	0.99	1.23	1.14	0.99	0.98	0.68	0.82	0.93	1.11	1.32
<b>Average Days Supplied per Antibiotic Script</b>																	
0-9	M	9.09	9.39	9.36	9.26	9.35	9.40	10.55	9.17	9.49	9.39						
	F	9.23	9.50	9.35	9.42	9.45	9.43	10.97	9.28	9.60	9.42						
	M&F	9.16	9.44	9.35	9.34	9.40	9.42	10.74	9.22	9.55	9.41						
10-17	M	9.45	9.93	9.18	10.23	9.25	9.78	11.33	10.31	9.97	10.10						
	F	9.23	9.46	8.90	9.69	9.24	9.14	10.75	9.82	9.40	9.34						
	M&F	9.32	9.66	9.02	9.92	9.24	9.40	11.06	10.03	9.64	9.66						
18-34	M	9.05	9.64	8.98	9.55	8.69	9.36	11.87	9.96	9.89	9.48						
	F	8.18	8.16	7.64	8.38	7.96	8.01	9.41	8.51	8.31	8.08						
	M&F	8.32	8.37	7.79	8.53	8.05	8.16	10.47	8.75	8.53	8.25						
35-49	M	9.13	9.56	9.92	9.36	9.21	9.96	9.53	9.59	9.69	10.25						
	F	8.54	8.63	8.57	8.74	8.62	8.74	10.48	8.77	8.70	8.76						
	M&F	8.67	8.83	8.81	8.87	8.73	8.91	10.08	8.97	8.92	9.03						
50-64	M	9.06	10.21	10.26	9.65	9.64	10.17	13.14	9.78	9.82	10.42						
	F	8.49	9.14	8.50	8.86	8.56	9.18	12.66	9.12	9.25	8.67						
	M&F	8.70	9.55	9.09	9.08	8.92	9.45	12.94	9.35	9.43	9.30						
65-74	M	7.73	9.70	9.82	7.84	12.26	10.16	12.67	9.73	9.14	9.95						
	F	6.96	8.62	10.40	9.09	7.89	9.91	13.23	8.96	9.02	8.80						
	M&F	7.22	8.97	10.23	8.85	10.01	9.98	13.13	9.18	9.05	9.16						
75-84	M	7.25	9.56	5.76		6.67	10.50		8.99	9.16	8.40						
	F	8.47	8.91	9.74	7.04	8.24	7.11		9.44	9.02	9.21						
	M&F	8.04	9.06	8.73	7.04	7.89	8.47		9.33	9.05	9.03						
≥85	M	7.80	6.67	5.22	5.67	8.18	3.43		7.58	7.98	8.69						
	F	9.21	8.72	8.88	7.92	5.47	5.75		9.05	11.02	8.03						
	M&F	8.98	8.33	7.62	7.67	6.54	4.67		8.69	10.70	8.10						
Unknown	M																
	F																
	M&F																
Total	M	9.16	9.59	9.37	9.51	9.25	9.56	11.01	9.57	9.65	9.71	9.82	9.39	9.54	9.74	10.12	10.57
	F	8.64	8.85	8.27	8.95	8.62	8.72	10.59	9.02	8.97	8.73	8.99	8.52	8.79	8.99	9.25	9.63
	M&F	8.82	9.10	8.58	9.14	8.82	8.98	10.81	9.21	9.20	9.04	9.29	8.87	9.06	9.24	9.56	9.91

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
<b>Average Scripts PMPY for Antibiotics of Concern</b>																	
0-9	M	0.67	0.49	0.41	0.70	0.46	0.49	0.62	0.64	0.50	0.41						
	F	0.66	0.47	0.40	0.68	0.44	0.47	0.62	0.61	0.50	0.39						
	M&F	0.67	0.48	0.40	0.69	0.45	0.48	0.62	0.62	0.50	0.40						
10-17	M	0.42	0.30	0.28	0.41	0.25	0.28	0.32	0.37	0.30	0.25						
	F	0.51	0.38	0.35	0.52	0.32	0.36	0.46	0.48	0.40	0.30						
	M&F	0.46	0.34	0.31	0.46	0.29	0.32	0.37	0.43	0.35	0.28						
18-34	M	0.37	0.33	0.32	0.34	0.27	0.27	0.24	0.35	0.32	0.28						
	F	0.80	0.64	0.75	0.67	0.61	0.64	0.41	0.67	0.63	0.60						
	M&F	0.66	0.56	0.64	0.58	0.51	0.55	0.32	0.58	0.55	0.52						
35-49	M	0.48	0.47	0.50	0.49	0.43	0.52	0.16	0.50	0.49	0.49						
	F	0.85	0.78	0.80	0.85	0.71	0.78	0.14	0.84	0.80	0.71						
	M&F	0.72	0.68	0.71	0.74	0.63	0.72	0.15	0.73	0.70	0.65						
50-64	M	0.55	0.61	0.44	0.56	0.50	0.50	0.23	0.64	0.61	0.54						
	F	0.80	0.87	0.70	0.91	0.74	0.84	0.29	1.04	1.00	0.87						
	M&F	0.68	0.75	0.59	0.78	0.64	0.71	0.25	0.86	0.84	0.72						
65-74	M	0.46	0.72	0.33	0.11	0.34	0.39	0.10	0.87	0.65	0.57						
	F	0.57	0.95	0.47	0.16	0.32	0.39	0.18	1.16	0.91	0.72						
	M&F	0.53	0.86	0.42	0.15	0.33	0.39	0.14	1.06	0.82	0.67						
75-84	M	0.68	0.71	0.41	0.00	0.25	0.13	0.00	0.64	0.33	0.31						
	F	0.46	0.89	0.53	0.06	0.21	0.11	0.00	0.80	0.49	0.36						
	M&F	0.53	0.84	0.49	0.05	0.22	0.11	0.00	0.76	0.44	0.35						
≥85	M	1.29	0.80	0.39	0.26	0.81	0.90		0.69	0.14	0.14						
	F	0.61	0.86	0.10	0.28	0.23	0.17		0.35	0.18	0.19						
	M&F	0.72	0.85	0.15	0.28	0.36	0.38		0.41	0.18	0.18						
Unknown	M																
	F																
	M&F																
<b>Total</b>	<b>M</b>	<b>0.52</b>	<b>0.43</b>	<b>0.37</b>	<b>0.54</b>	<b>0.37</b>	<b>0.40</b>	<b>0.41</b>	<b>0.52</b>	<b>0.44</b>	<b>0.37</b>	<b>0.33</b>	<b>0.21</b>	<b>0.25</b>	<b>0.31</b>	<b>0.39</b>	<b>0.50</b>
	<b>F</b>	<b>0.71</b>	<b>0.58</b>	<b>0.58</b>	<b>0.69</b>	<b>0.53</b>	<b>0.57</b>	<b>0.49</b>	<b>0.69</b>	<b>0.60</b>	<b>0.51</b>	<b>0.47</b>	<b>0.31</b>	<b>0.36</b>	<b>0.44</b>	<b>0.54</b>	<b>0.67</b>
	<b>M&amp;F</b>	<b>0.63</b>	<b>0.51</b>	<b>0.49</b>	<b>0.63</b>	<b>0.46</b>	<b>0.50</b>	<b>0.44</b>	<b>0.62</b>	<b>0.53</b>	<b>0.45</b>	<b>0.41</b>	<b>0.26</b>	<b>0.32</b>	<b>0.38</b>	<b>0.47</b>	<b>0.62</b>
<b>Percentage of Antibiotics of Concern of All Antibiotic Scripts</b>																	
0-9	M	50.19%	45.27%	44.50%	51.60%	45.98%	48.46%	47.68%	51.50%	45.05%	45.43%						
	F	46.74%	43.01%	42.87%	48.63%	42.44%	45.72%	43.98%	48.33%	43.89%	43.54%						
	M&F	48.46%	44.15%	43.69%	50.12%	44.20%	47.09%	46.03%	49.94%	44.47%	44.50%						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
10-17	M	50.32%	47.10%	49.36%	49.71%	47.03%	50.23%	44.81%	48.89%	47.20%	48.00%						
	F	45.79%	42.89%	45.06%	46.77%	44.42%	45.55%	42.20%	46.54%	44.81%	43.11%						
	M&F	47.78%	44.66%	46.88%	48.03%	45.54%	47.46%	43.59%	47.53%	45.81%	45.18%						
18-34	M	47.10%	48.91%	47.29%	48.88%	48.55%	47.96%	43.81%	49.08%	47.03%	46.81%						
	F	42.18%	42.62%	39.97%	43.65%	41.31%	41.92%	41.06%	44.52%	42.88%	41.97%						
	M&F	42.98%	43.51%	40.78%	44.33%	42.26%	42.58%	42.24%	45.26%	43.47%	42.58%						
35-49	M	51.73%	51.21%	50.27%	51.48%	51.87%	53.36%	48.65%	52.51%	51.25%	51.39%						
	F	50.92%	50.21%	47.19%	52.56%	50.29%	47.82%	43.79%	53.29%	50.62%	47.47%						
	M&F	51.10%	50.42%	47.75%	52.33%	50.60%	48.60%	45.83%	53.11%	50.76%	48.20%						
50-64	M	58.03%	53.57%	51.22%	55.92%	55.19%	51.78%	30.94%	55.80%	50.81%	51.87%						
	F	56.89%	53.71%	52.84%	57.83%	56.11%	53.45%	41.62%	57.43%	55.44%	54.40%						
	M&F	57.31%	53.66%	52.30%	57.29%	55.80%	52.99%	35.50%	56.86%	53.94%	53.50%						
65-74	M	62.75%	59.49%	45.83%	65.79%	47.06%	65.67%	33.33%	61.79%	58.56%	54.40%						
	F	58.00%	57.82%	52.91%	49.69%	62.50%	53.03%	15.38%	56.93%	55.66%	52.41%						
	M&F	59.60%	58.36%	50.82%	52.79%	55.00%	56.23%	18.75%	58.32%	56.44%	53.04%						
75-84	M	85.00%	59.88%	52.38%		75.00%	50.00%		58.28%	53.23%	55.93%						
	F	58.33%	52.24%	54.84%	45.83%	42.86%	88.89%		58.55%	56.01%	52.66%						
	M&F	67.86%	53.99%	54.22%	45.83%	50.00%	73.33%		58.49%	55.38%	53.37%						
≥85	M	93.33%	51.11%	44.44%	66.67%	57.14%	85.71%		61.54%	60.00%	54.29%						
	F	44.74%	55.33%	23.53%	62.50%	37.21%	37.50%		53.17%	47.49%	56.88%						
	M&F	52.75%	54.55%	30.77%	62.96%	45.07%	60.00%		55.23%	48.81%	56.58%						
Unknown	M																
	F																
	M&F																
Total	M	50.35%	47.37%	46.70%	51.24%	47.56%	49.37%	46.06%	51.76%	46.91%	47.44%	42.31%	35.70%	38.48%	42.30%	46.41%	49.61%
	F	45.78%	45.09%	42.68%	48.20%	44.17%	45.34%	42.79%	49.44%	46.22%	44.93%	40.88%	34.81%	37.97%	40.53%	44.10%	47.67%
	M&F	47.32%	45.88%	43.81%	49.24%	45.25%	46.55%	44.50%	50.25%	46.45%	45.74%	41.39%	35.22%	38.49%	41.26%	44.66%	48.72%

**Antibiotics of Concern Utilization**

**Average Scripts PMPY for Quinolones**

0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
10-17	M	0.01	0.01	0.00	0.01	0.00	0.00	0.01	0.01	0.01	0.01						
	F	0.02	0.02	0.01	0.02	0.01	0.02	0.04	0.02	0.02	0.01						
	M&F	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.02	0.01	0.01						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
18-34	M	0.06	0.06	0.05	0.05	0.04	0.05	0.04	0.06	0.06	0.05						
	F	0.17	0.14	0.16	0.13	0.13	0.13	0.09	0.14	0.14	0.13						
	M&F	0.13	0.12	0.14	0.11	0.11	0.11	0.06	0.12	0.12	0.11						
35-49	M	0.12	0.12	0.13	0.11	0.11	0.13	0.07	0.13	0.13	0.14						
	F	0.23	0.21	0.23	0.22	0.20	0.21	0.05	0.22	0.22	0.19						
	M&F	0.19	0.18	0.20	0.19	0.17	0.19	0.05	0.19	0.19	0.18						
50-64	M	0.20	0.22	0.17	0.20	0.19	0.18	0.11	0.23	0.22	0.19						
	F	0.29	0.33	0.25	0.30	0.27	0.29	0.10	0.36	0.36	0.32						
	M&F	0.25	0.28	0.21	0.26	0.24	0.24	0.11	0.30	0.30	0.26						
65-74	M	0.17	0.27	0.11	0.04	0.12	0.13	0.10	0.34	0.26	0.27						
	F	0.26	0.39	0.19	0.07	0.21	0.17	0.18	0.50	0.39	0.32						
	M&F	0.22	0.34	0.16	0.06	0.18	0.16	0.14	0.44	0.34	0.30						
75-84	M	0.28	0.30	0.34	0.00	0.11	0.08	0.00	0.26	0.15	0.15						
	F	0.24	0.42	0.33	0.04	0.11	0.03	0.00	0.35	0.21	0.17						
	M&F	0.25	0.38	0.33	0.03	0.11	0.04	0.00	0.33	0.19	0.16						
≥85	M	0.37	0.42	0.39	0.00	0.66	0.60		0.37	0.06	0.07						
	F	0.32	0.49	0.07	0.13	0.09	0.12		0.16	0.08	0.09						
	M&F	0.33	0.48	0.14	0.12	0.21	0.25		0.19	0.08	0.09						
Unknown	M																
	F																
	M&F																
Total	M	0.04	0.04	0.03	0.03	0.03	0.03	0.02	0.06	0.04	0.04	0.03	0.01	0.02	0.03	0.04	0.05
	F	0.11	0.10	0.10	0.10	0.09	0.09	0.04	0.13	0.11	0.10	0.08	0.05	0.06	0.07	0.09	0.12
	M&F	0.08	0.07	0.07	0.07	0.06	0.07	0.03	0.10	0.08	0.07	0.06	0.03	0.04	0.05	0.07	0.09
<b>Average Scripts PMPY for Cephalosporins 2nd-4th Generation</b>																	
0-9	M	0.22	0.21	0.13	0.26	0.19	0.17	0.23	0.23	0.22	0.13						
	F	0.24	0.21	0.14	0.28	0.19	0.18	0.25	0.23	0.23	0.13						
	M&F	0.23	0.21	0.13	0.27	0.19	0.17	0.24	0.23	0.22	0.13						
10-17	M	0.08	0.06	0.05	0.08	0.05	0.05	0.06	0.07	0.06	0.04						
	F	0.11	0.08	0.06	0.11	0.07	0.06	0.10	0.10	0.09	0.05						
	M&F	0.10	0.07	0.05	0.10	0.06	0.05	0.07	0.08	0.07	0.05						
18-34	M	0.02	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.03	0.02						
	F	0.05	0.05	0.03	0.05	0.05	0.03	0.03	0.05	0.05	0.03						
	M&F	0.04	0.05	0.03	0.04	0.04	0.03	0.03	0.04	0.04	0.03						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
35-49	M	0.03	0.03	0.03	0.03	0.03	0.03	0.01	0.04	0.04	0.02						
	F	0.06	0.06	0.03	0.06	0.05	0.03	0.01	0.07	0.06	0.03						
	M&F	0.05	0.05	0.03	0.06	0.04	0.03	0.01	0.06	0.06	0.03						
50-64	M	0.03	0.03	0.02	0.04	0.03	0.02	0.01	0.05	0.04	0.03						
	F	0.06	0.06	0.03	0.08	0.05	0.05	0.02	0.09	0.08	0.04						
	M&F	0.05	0.05	0.03	0.07	0.04	0.04	0.01	0.07	0.06	0.03						
65-74	M	0.04	0.05	0.01	0.01	0.11	0.04	0.00	0.09	0.08	0.03						
	F	0.09	0.07	0.02	0.02	0.01	0.03	0.00	0.12	0.09	0.04						
	M&F	0.07	0.06	0.02	0.02	0.05	0.03	0.00	0.11	0.08	0.04						
75-84	M	0.16	0.05	0.07	0.00	0.06	0.00	0.00	0.07	0.03	0.03						
	F	0.09	0.09	0.00	0.01	0.00	0.04	0.00	0.12	0.06	0.05						
	M&F	0.11	0.08	0.02	0.00	0.02	0.03	0.00	0.11	0.05	0.04						
≥85	M	0.28	0.17	0.00	0.00	0.05	0.30		0.12	0.01	0.02						
	F	0.13	0.13	0.00	0.13	0.06	0.06		0.06	0.02	0.03						
	M&F	0.15	0.14	0.00	0.12	0.06	0.13		0.07	0.02	0.03						
Unknown	M																
	F																
	M&F																
Total	M	0.11	0.12	0.07	0.15	0.10	0.10	0.11	0.12	0.12	0.07	0.06	0.01	0.02	0.05	0.07	0.11
	F	0.11	0.11	0.07	0.13	0.10	0.08	0.13	0.12	0.12	0.07	0.06	0.01	0.03	0.05	0.08	0.12
	M&F	0.11	0.11	0.07	0.14	0.10	0.09	0.12	0.12	0.12	0.07	0.06	0.01	0.03	0.05	0.08	0.11
<b>Average Scripts PMPY for Azithromycins and Clarithromycins</b>																	
0-9	M	0.27	0.15	0.12	0.26	0.14	0.16	0.19	0.25	0.14	0.13						
	F	0.25	0.14	0.12	0.24	0.13	0.15	0.17	0.23	0.14	0.12						
	M&F	0.26	0.14	0.12	0.25	0.13	0.15	0.18	0.24	0.14	0.13						
10-17	M	0.20	0.13	0.13	0.19	0.11	0.13	0.13	0.18	0.13	0.11						
	F	0.24	0.16	0.15	0.24	0.14	0.17	0.18	0.22	0.18	0.14						
	M&F	0.22	0.15	0.14	0.22	0.12	0.15	0.15	0.20	0.15	0.12						
18-34	M	0.13	0.13	0.12	0.12	0.11	0.11	0.10	0.13	0.13	0.11						
	F	0.30	0.26	0.31	0.26	0.24	0.26	0.17	0.26	0.25	0.24						
	M&F	0.25	0.22	0.26	0.22	0.20	0.22	0.13	0.22	0.22	0.21						
35-49	M	0.14	0.16	0.16	0.16	0.14	0.17	0.05	0.15	0.16	0.15						
	F	0.28	0.28	0.25	0.29	0.25	0.27	0.05	0.28	0.28	0.24						
	M&F	0.23	0.24	0.23	0.25	0.22	0.25	0.05	0.24	0.24	0.22						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
50-64	M	0.13	0.17	0.12	0.16	0.12	0.13	0.05	0.17	0.19	0.15						
	F	0.23	0.28	0.23	0.28	0.25	0.25	0.08	0.32	0.31	0.26						
	M&F	0.19	0.23	0.18	0.23	0.20	0.20	0.06	0.25	0.26	0.21						
65-74	M	0.13	0.23	0.08	0.03	0.06	0.12	0.00	0.22	0.14	0.11						
	F	0.13	0.30	0.09	0.04	0.06	0.08	0.00	0.30	0.28	0.21						
	M&F	0.13	0.27	0.09	0.04	0.06	0.09	0.00	0.27	0.23	0.18						
75-84	M	0.00	0.18	0.00	0.00	0.08	0.04	0.00	0.17	0.08	0.07						
	F	0.07	0.19	0.05	0.01	0.01	0.01	0.00	0.17	0.14	0.08						
	M&F	0.04	0.19	0.03	0.00	0.03	0.02	0.00	0.17	0.12	0.07						
≥85	M	0.28	0.17	0.00	0.26	0.00	0.00		0.10	0.05	0.03						
	F	0.05	0.14	0.02	0.00	0.04	0.00		0.07	0.05	0.03						
	M&F	0.09	0.15	0.02	0.03	0.03	0.00		0.07	0.05	0.03						
Unknown	M																
	F																
	M&F																
Total	M	<b>0.20</b>	<b>0.15</b>	<b>0.13</b>	<b>0.20</b>	<b>0.13</b>	<b>0.14</b>	<b>0.14</b>	<b>0.19</b>	<b>0.14</b>	<b>0.12</b>	<b>0.14</b>	<b>0.08</b>	<b>0.11</b>	<b>0.13</b>	<b>0.16</b>	<b>0.19</b>
	F	<b>0.27</b>	<b>0.21</b>	<b>0.22</b>	<b>0.25</b>	<b>0.19</b>	<b>0.21</b>	<b>0.17</b>	<b>0.25</b>	<b>0.21</b>	<b>0.18</b>	<b>0.19</b>	<b>0.12</b>	<b>0.15</b>	<b>0.19</b>	<b>0.22</b>	<b>0.27</b>
	M&F	<b>0.24</b>	<b>0.18</b>	<b>0.18</b>	<b>0.23</b>	<b>0.16</b>	<b>0.18</b>	<b>0.15</b>	<b>0.23</b>	<b>0.18</b>	<b>0.16</b>	<b>0.17</b>	<b>0.11</b>	<b>0.13</b>	<b>0.16</b>	<b>0.19</b>	<b>0.24</b>
<b>Average Scripts PMPY for Amoxicillin/Clavulanates</b>																	
0-9	M	0.16	0.11	0.11	0.16	0.11	0.13	0.16	0.15	0.13	0.11						
	F	0.15	0.11	0.09	0.15	0.10	0.12	0.15	0.13	0.12	0.10						
	M&F	0.15	0.11	0.10	0.15	0.11	0.12	0.16	0.14	0.12	0.11						
10-17	M	0.10	0.07	0.07	0.10	0.06	0.07	0.08	0.09	0.08	0.06						
	F	0.11	0.08	0.07	0.12	0.07	0.07	0.09	0.11	0.09	0.07						
	M&F	0.11	0.08	0.07	0.11	0.07	0.07	0.08	0.10	0.08	0.06						
18-34	M	0.07	0.07	0.07	0.07	0.06	0.06	0.05	0.08	0.07	0.07						
	F	0.14	0.12	0.13	0.13	0.10	0.12	0.07	0.13	0.11	0.12						
	M&F	0.12	0.11	0.12	0.11	0.09	0.10	0.06	0.11	0.10	0.10						
35-49	M	0.09	0.10	0.10	0.11	0.08	0.12	0.02	0.11	0.09	0.11						
	F	0.15	0.15	0.17	0.16	0.13	0.17	0.03	0.16	0.15	0.15						
	M&F	0.13	0.13	0.15	0.14	0.12	0.16	0.02	0.14	0.13	0.14						
50-64	M	0.10	0.11	0.08	0.10	0.09	0.10	0.03	0.12	0.09	0.11						
	F	0.13	0.12	0.12	0.15	0.11	0.17	0.03	0.16	0.15	0.16						
	M&F	0.11	0.12	0.10	0.13	0.10	0.14	0.03	0.14	0.13	0.13						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
65-74	M	0.07	0.10	0.09	0.03	0.04	0.09	0.00	0.13	0.11	0.09						
	F	0.10	0.12	0.08	0.02	0.03	0.07	0.00	0.16	0.10	0.10						
	M&F	0.09	0.11	0.09	0.02	0.03	0.07	0.00	0.15	0.11	0.09						
75-84	M	0.20	0.15	0.00	0.00	0.00	0.00	0.00	0.12	0.07	0.05						
	F	0.00	0.10	0.09	0.01	0.02	0.03	0.00	0.09	0.05	0.05						
	M&F	0.07	0.11	0.07	0.00	0.02	0.02	0.00	0.10	0.06	0.05						
≥85	M	0.37	0.00	0.00	0.00	0.10	0.00		0.04	0.02	0.02						
	F	0.11	0.06	0.00	0.02	0.04	0.00		0.04	0.02	0.02						
	M&F	0.15	0.05	0.00	0.02	0.06	0.00		0.04	0.02	0.02						
Unknown	M																
	F																
	M&F																
Total	M	<b>0.12</b>	<b>0.10</b>	<b>0.09</b>	<b>0.12</b>	<b>0.09</b>	<b>0.10</b>	<b>0.10</b>	<b>0.12</b>	<b>0.10</b>	<b>0.09</b>	<b>0.08</b>	<b>0.05</b>	<b>0.06</b>	<b>0.08</b>	<b>0.09</b>	<b>0.13</b>
	F	<b>0.14</b>	<b>0.11</b>	<b>0.11</b>	<b>0.14</b>	<b>0.10</b>	<b>0.12</b>	<b>0.11</b>	<b>0.13</b>	<b>0.12</b>	<b>0.11</b>	<b>0.09</b>	<b>0.05</b>	<b>0.07</b>	<b>0.09</b>	<b>0.11</b>	<b>0.13</b>
	M&F	<b>0.13</b>	<b>0.11</b>	<b>0.10</b>	<b>0.13</b>	<b>0.09</b>	<b>0.11</b>	<b>0.10</b>	<b>0.13</b>	<b>0.11</b>	<b>0.10</b>	<b>0.09</b>	<b>0.05</b>	<b>0.07</b>	<b>0.08</b>	<b>0.10</b>	<b>0.13</b>
<b>Average Scripts PMPY for Ketolides</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10-17	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18-34	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35-49	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50-64	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65-74	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
75-84	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
≥85	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
Unknown	M																
	F																
	M&F																
Total	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
<b>Average Scripts PMPY for Clindamycins</b>																	
0-9	M	0.02	0.02	0.05	0.02	0.02	0.04	0.03	0.01	0.02	0.03						
	F	0.02	0.02	0.05	0.02	0.02	0.03	0.03	0.01	0.02	0.03						
	M&F	0.02	0.02	0.05	0.02	0.02	0.03	0.03	0.01	0.02	0.03						
10-17	M	0.02	0.03	0.04	0.02	0.02	0.03	0.04	0.02	0.02	0.03						
	F	0.03	0.03	0.05	0.03	0.03	0.04	0.05	0.03	0.03	0.03						
	M&F	0.03	0.03	0.04	0.03	0.02	0.04	0.04	0.03	0.03	0.03						
18-34	M	0.08	0.04	0.05	0.06	0.04	0.04	0.04	0.06	0.04	0.04						
	F	0.14	0.07	0.11	0.10	0.09	0.09	0.05	0.09	0.08	0.08						
	M&F	0.12	0.07	0.10	0.09	0.07	0.08	0.04	0.08	0.07	0.07						
35-49	M	0.10	0.05	0.07	0.08	0.07	0.07	0.02	0.08	0.07	0.07						
	F	0.13	0.08	0.11	0.11	0.09	0.10	0.01	0.11	0.08	0.10						
	M&F	0.12	0.07	0.10	0.10	0.08	0.09	0.01	0.10	0.08	0.09						
50-64	M	0.07	0.06	0.05	0.06	0.06	0.07	0.02	0.07	0.06	0.05						
	F	0.09	0.07	0.07	0.08	0.05	0.08	0.05	0.09	0.08	0.09						
	M&F	0.08	0.07	0.06	0.08	0.06	0.07	0.03	0.08	0.07	0.07						
65-74	M	0.04	0.07	0.03	0.01	0.01	0.02	0.00	0.06	0.04	0.05						
	F	0.00	0.06	0.04	0.02	0.01	0.04	0.00	0.08	0.05	0.04						
	M&F	0.02	0.06	0.03	0.02	0.01	0.03	0.00	0.07	0.05	0.05						
75-84	M	0.04	0.03	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.01						
	F	0.07	0.06	0.06	0.01	0.07	0.00	0.00	0.04	0.02	0.02						
	M&F	0.06	0.05	0.04	0.00	0.05	0.00	0.00	0.04	0.01	0.01						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
≥85	M	0.00	0.03	0.00	0.00	0.00	0.00		0.03	0.00	0.02						
	F	0.00	0.03	0.00	0.00	0.00	0.00		0.01	0.00	0.01						
	M&F	0.00	0.03	0.00	0.00	0.00	0.00		0.01	0.00	0.01						
Unknown	M																
	F																
	M&F																
Total	M	0.04	0.03	0.05	0.03	0.03	0.04	0.04	0.04	0.03	0.04	0.03	0.01	0.02	0.02	0.03	0.04
	F	0.08	0.05	0.08	0.06	0.05	0.06	0.04	0.06	0.05	0.06	0.04	0.03	0.03	0.04	0.05	0.06
	M&F	0.07	0.04	0.07	0.05	0.04	0.05	0.04	0.05	0.04	0.05	0.04	0.02	0.03	0.03	0.04	0.05
<b>Average Scripts PMPY for Misc. Antibiotics of Concern</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10-17	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18-34	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35-49	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50-64	M	0.01	0.01	0.00	0.00	0.01	0.00	0.01	0.01	0.00	0.01						
	F	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.01						
	M&F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.01						
65-74	M	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.03	0.01	0.01						
	F	0.00	0.00	0.05	0.00	0.00	0.00	0.00	0.01	0.01	0.01						
	M&F	0.00	0.00	0.04	0.00	0.00	0.00	0.00	0.02	0.01	0.01						
75-84	M	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00						
	M&F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
≥85	M	0.00	0.00	0.00	0.00	0.00	0.00		0.03	0.00	0.00						
	F	0.00	0.01	0.00	0.00	0.00	0.00		0.02	0.01	0.00						
	M&F	0.00	0.01	0.00	0.00	0.00	0.00		0.02	0.01	0.00						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
Unknown	M																
	F																
	M&F																
Total	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>All Other Antibiotics Utilization</b>																	
<b>Average Scripts PMPY for Absorbable Sulfonamides</b>																	
0-9	M	0.06	0.04	0.05	0.05	0.04	0.05	0.10	0.05	0.04	0.05						
	F	0.10	0.07	0.07	0.09	0.07	0.08	0.15	0.08	0.07	0.07						
	M&F	0.08	0.05	0.06	0.07	0.05	0.06	0.12	0.06	0.05	0.06						
10-17	M	0.06	0.04	0.04	0.06	0.04	0.03	0.07	0.06	0.04	0.04						
	F	0.11	0.09	0.07	0.11	0.07	0.08	0.14	0.10	0.09	0.07						
	M&F	0.08	0.07	0.06	0.09	0.05	0.06	0.10	0.08	0.06	0.05						
18-34	M	0.10	0.08	0.06	0.07	0.06	0.06	0.07	0.08	0.08	0.06						
	F	0.21	0.15	0.17	0.15	0.16	0.14	0.11	0.15	0.14	0.13						
	M&F	0.17	0.14	0.15	0.13	0.13	0.12	0.09	0.13	0.13	0.11						
35-49	M	0.11	0.12	0.11	0.11	0.11	0.11	0.04	0.11	0.12	0.11						
	F	0.19	0.17	0.16	0.16	0.17	0.16	0.04	0.16	0.17	0.15						
	M&F	0.16	0.15	0.15	0.15	0.15	0.15	0.04	0.15	0.15	0.14						
50-64	M	0.11	0.15	0.11	0.12	0.11	0.11	0.09	0.14	0.16	0.10						
	F	0.14	0.17	0.12	0.15	0.14	0.14	0.09	0.17	0.20	0.14						
	M&F	0.12	0.16	0.11	0.13	0.13	0.13	0.09	0.16	0.18	0.12						
65-74	M	0.04	0.10	0.09	0.01	0.05	0.07	0.10	0.12	0.12	0.08						
	F	0.08	0.19	0.08	0.02	0.05	0.04	0.09	0.19	0.18	0.14						
	M&F	0.06	0.16	0.08	0.02	0.05	0.05	0.09	0.16	0.16	0.11						
75-84	M	0.00	0.18	0.11	0.00	0.00	0.08	0.00	0.10	0.07	0.04						
	F	0.02	0.18	0.11	0.01	0.09	0.00	0.00	0.13	0.08	0.06						
	M&F	0.01	0.18	0.11	0.00	0.07	0.02	0.00	0.12	0.08	0.06						
≥85	M	0.00	0.31	0.00	0.00	0.10	0.15		0.11	0.01	0.03						
	F	0.05	0.16	0.05	0.02	0.10	0.06		0.07	0.03	0.02						
	M&F	0.04	0.19	0.04	0.02	0.10	0.08		0.08	0.03	0.03						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
Unknown	M																
	F																
	M&F																
Total	M	0.07	0.06	0.06	0.07	0.05	0.05	0.08	0.07	0.06	0.06	0.05	0.03	0.04	0.05	0.06	0.08
	F	0.15	0.12	0.12	0.13	0.12	0.11	0.13	0.13	0.12	0.11	0.09	0.05	0.07	0.09	0.11	0.14
	M&F	0.12	0.09	0.10	0.10	0.09	0.09	0.10	0.10	0.09	0.08	0.08	0.05	0.06	0.07	0.09	0.11
<b>Average Scripts PMPY for Aminoglycosides</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10-17	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18-34	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35-49	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50-64	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65-74	M	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.00	0.00						
	F	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
75-84	M	0.04	0.00	0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.15	0.03	0.00	0.00	0.01	0.00	0.01	0.00	0.00						
	M&F	0.01	0.10	0.03	0.00	0.00	0.01	0.00	0.01	0.00	0.00						
≥85	M	0.00	0.03	0.00	0.00	0.00	0.00		0.02	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00		0.01	0.00	0.00						
	M&F	0.00	0.01	0.00	0.00	0.00	0.00		0.01	0.00	0.00						
Unknown	M																
	F																
	M&F																

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
Total	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<b>Average Scripts PMPY for 1st Generation Cephalosporins</b>																	
0-9	M	0.05	0.06	0.04	0.05	0.05	0.05	0.05	0.05	0.06	0.04						
	F	0.07	0.06	0.04	0.06	0.06	0.05	0.07	0.06	0.06	0.04						
	M&F	0.06	0.06	0.04	0.06	0.06	0.05	0.06	0.05	0.06	0.04						
10-17	M	0.07	0.06	0.04	0.06	0.05	0.05	0.05	0.06	0.05	0.04						
	F	0.08	0.07	0.05	0.07	0.06	0.06	0.07	0.07	0.07	0.05						
	M&F	0.07	0.07	0.05	0.07	0.05	0.05	0.06	0.06	0.06	0.04						
18-34	M	0.07	0.06	0.06	0.07	0.06	0.05	0.04	0.06	0.07	0.05						
	F	0.14	0.11	0.12	0.12	0.11	0.11	0.07	0.11	0.11	0.09						
	M&F	0.12	0.10	0.10	0.10	0.10	0.09	0.05	0.10	0.10	0.08						
35-49	M	0.08	0.09	0.08	0.09	0.08	0.09	0.03	0.09	0.09	0.09						
	F	0.11	0.11	0.11	0.12	0.10	0.11	0.03	0.11	0.12	0.09						
	M&F	0.10	0.10	0.10	0.11	0.10	0.10	0.03	0.10	0.11	0.09						
50-64	M	0.08	0.10	0.09	0.09	0.08	0.09	0.06	0.10	0.09	0.09						
	F	0.11	0.14	0.09	0.12	0.10	0.13	0.04	0.13	0.14	0.13						
	M&F	0.09	0.13	0.09	0.11	0.09	0.12	0.05	0.11	0.12	0.11						
65-74	M	0.04	0.13	0.07	0.01	0.03	0.04	0.10	0.10	0.09	0.13						
	F	0.15	0.16	0.08	0.04	0.02	0.13	0.18	0.17	0.13	0.12						
	M&F	0.11	0.15	0.08	0.03	0.03	0.11	0.14	0.14	0.12	0.13						
75-84	M	0.04	0.15	0.19	0.00	0.03	0.00	0.00	0.13	0.05	0.08						
	F	0.04	0.11	0.08	0.02	0.05	0.00	0.00	0.11	0.08	0.06						
	M&F	0.04	0.12	0.11	0.01	0.04	0.00	0.00	0.12	0.07	0.06						
≥85	M	0.00	0.14	0.00	0.13	0.41	0.00		0.11	0.04	0.04						
	F	0.05	0.14	0.10	0.00	0.16	0.00		0.07	0.04	0.04						
	M&F	0.04	0.14	0.08	0.02	0.21	0.00		0.07	0.04	0.04						
Unknown	M																
	F																
	M&F																
Total	M	0.06	0.06	0.05	0.06	0.06	0.05	0.05	0.06	0.06	0.05	0.06	0.04	0.05	0.06	0.07	0.09
	F	0.10	0.09	0.08	0.09	0.09	0.08	0.07	0.09	0.09	0.07	0.08	0.05	0.06	0.08	0.10	0.12
	M&F	0.09	0.08	0.07	0.08	0.07	0.07	0.06	0.08	0.08	0.06	0.07	0.04	0.06	0.07	0.09	0.11

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
<b>Average Scripts PMPY for Lincosamides</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10-17	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18-34	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35-49	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50-64	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65-74	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
75-84	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
≥85	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
Unknown	M																
	F																
	M&F																
<b>Total</b>	<b>M</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>										
	<b>F</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>										
	<b>M&amp;F</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>										
<b>Average Scripts PMPY for Macrolides (not azith. or clarith.)</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
10-17	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
18-34	M	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
35-49	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50-64	M	0.01	0.00	0.00	0.00	0.00	0.00	0.10	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.00	0.01						
	M&F	0.01	0.00	0.00	0.01	0.00	0.00	0.05	0.00	0.00	0.00						
65-74	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.01	0.09	0.00	0.00	0.01						
	M&F	0.00	0.00	0.00	0.00	0.00	0.01	0.05	0.00	0.00	0.00						
75-84	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
≥85	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
Unknown	M																
	F																
	M&F																
Total	M	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
<b>Average Scripts PMPY for Penicillins</b>																	
0-9	M	0.55	0.49	0.42	0.55	0.45	0.42	0.50	0.50	0.52	0.40						
	F	0.56	0.49	0.41	0.55	0.46	0.42	0.51	0.49	0.51	0.39						
	M&F	0.56	0.49	0.41	0.55	0.45	0.42	0.50	0.50	0.51	0.39						
10-17	M	0.25	0.18	0.17	0.22	0.17	0.15	0.19	0.20	0.19	0.15						
	F	0.32	0.24	0.22	0.28	0.21	0.19	0.25	0.26	0.24	0.19						
	M&F	0.28	0.21	0.19	0.25	0.19	0.17	0.21	0.23	0.22	0.17						
18-34	M	0.19	0.13	0.15	0.15	0.12	0.12	0.11	0.14	0.14	0.13						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
35-49	F	0.35	0.24	0.30	0.26	0.24	0.25	0.17	0.25	0.24	0.23						
	M&F	0.30	0.21	0.26	0.24	0.20	0.22	0.13	0.22	0.21	0.20						
	M	0.17	0.16	0.16	0.17	0.11	0.15	0.04	0.16	0.15	0.16						
	F	0.26	0.21	0.25	0.22	0.19	0.24	0.04	0.21	0.21	0.23						
50-64	M&F	0.22	0.19	0.23	0.20	0.17	0.22	0.04	0.19	0.19	0.21						
	M	0.12	0.14	0.12	0.12	0.11	0.14	0.05	0.13	0.16	0.17						
	F	0.15	0.18	0.18	0.16	0.14	0.20	0.04	0.17	0.18	0.22						
65-74	M&F	0.14	0.16	0.15	0.15	0.13	0.18	0.04	0.15	0.17	0.19						
	M	0.07	0.19	0.12	0.01	0.10	0.06	0.00	0.12	0.11	0.12						
	F	0.04	0.15	0.13	0.05	0.09	0.05	0.18	0.18	0.15	0.17						
75-84	M&F	0.05	0.17	0.13	0.04	0.09	0.05	0.09	0.16	0.13	0.15						
	M	0.04	0.03	0.00	0.00	0.03	0.00	0.00	0.07	0.07	0.07						
	F	0.02	0.13	0.09	0.01	0.06	0.00	0.00	0.09	0.08	0.07						
≥85	M&F	0.03	0.10	0.07	0.01	0.05	0.00	0.00	0.09	0.08	0.07						
	M	0.00	0.10	0.00	0.00	0.00	0.00		0.03	0.03	0.02						
	F	0.14	0.06	0.05	0.02	0.03	0.17		0.05	0.02	0.02						
Unknown	M&F	0.12	0.07	0.04	0.02	0.02	0.13		0.05	0.02	0.02						
	M																
	F																
Total	M&F																
	M	<b>0.33</b>	<b>0.31</b>	<b>0.27</b>	<b>0.34</b>	<b>0.27</b>	<b>0.27</b>	<b>0.28</b>	<b>0.29</b>	<b>0.32</b>	<b>0.26</b>	<b>0.28</b>	<b>0.18</b>	<b>0.24</b>	<b>0.28</b>	<b>0.33</b>	<b>0.40</b>
	F	<b>0.38</b>	<b>0.31</b>	<b>0.30</b>	<b>0.34</b>	<b>0.29</b>	<b>0.28</b>	<b>0.32</b>	<b>0.30</b>	<b>0.31</b>	<b>0.26</b>	<b>0.31</b>	<b>0.21</b>	<b>0.26</b>	<b>0.30</b>	<b>0.35</b>	<b>0.41</b>
<b>Average Scripts PMPY for Tetracyclines</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10-17	M	0.04	0.04	0.03	0.06	0.02	0.04	0.06	0.06	0.04	0.04						
	F	0.05	0.05	0.03	0.07	0.03	0.05	0.06	0.07	0.05	0.05						
	M&F	0.04	0.05	0.03	0.06	0.02	0.05	0.06	0.06	0.04	0.04						
18-34	M	0.04	0.05	0.05	0.05	0.03	0.05	0.08	0.06	0.06	0.06						
	F	0.07	0.06	0.08	0.07	0.05	0.07	0.06	0.08	0.06	0.07						
	M&F	0.06	0.06	0.08	0.06	0.05	0.07	0.07	0.07	0.06	0.07						
35-49	M	0.05	0.05	0.08	0.05	0.05	0.06	0.04	0.06	0.06	0.07						
	F	0.09	0.08	0.10	0.09	0.06	0.09	0.02	0.09	0.08	0.10						

**Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures**

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
50-64	M&F	0.08	0.07	0.09	0.08	0.06	0.08	0.03	0.08	0.08	0.09						
	M	0.06	0.08	0.07	0.08	0.06	0.08	0.13	0.10	0.08	0.09						
	F	0.09	0.11	0.08	0.10	0.07	0.10	0.09	0.14	0.11	0.10						
	M&F	0.08	0.09	0.08	0.09	0.07	0.10	0.11	0.12	0.10	0.10						
65-74	M	0.09	0.05	0.07	0.01	0.03	0.02	0.00	0.13	0.07	0.09						
	F	0.02	0.08	0.04	0.03	0.01	0.03	0.00	0.15	0.11	0.10						
	M&F	0.05	0.07	0.05	0.02	0.02	0.02	0.00	0.14	0.09	0.10						
75-84	M	0.00	0.08	0.00	0.00	0.00	0.00	0.00	0.09	0.07	0.03						
	F	0.07	0.11	0.08	0.02	0.00	0.00	0.00	0.09	0.06	0.05						
	M&F	0.04	0.10	0.05	0.01	0.00	0.00	0.00	0.09	0.06	0.04						
≥85	M	0.00	0.10	0.48	0.00	0.10	0.00		0.08	0.01	0.02						
	F	0.02	0.10	0.05	0.02	0.01	0.00		0.04	0.03	0.02						
	M&F	0.01	0.10	0.14	0.02	0.03	0.00		0.05	0.03	0.02						
Unknown	M																
	F																
	M&F																
Total	M	0.03	0.03	0.03	0.03	0.02	0.03	0.04	0.04	0.03	0.03	0.03	0.02	0.02	0.03	0.04	0.05
	F	0.05	0.04	0.05	0.05	0.04	0.05	0.04	0.06	0.05	0.05	0.05	0.05	0.03	0.04	0.05	0.07
	M&F	0.04	0.04	0.04	0.04	0.03	0.04	0.04	0.05	0.04	0.04	0.04	0.04	0.02	0.03	0.04	0.05
<b>Average Scripts PMPY for Misc. Antibiotics</b>																	
0-9	M	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	F	0.01	0.01	0.00	0.01	0.01	0.00	0.02	0.01	0.01	0.00						
	M&F	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.00						
10-17	M	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.00	0.00						
	F	0.05	0.05	0.05	0.06	0.04	0.05	0.10	0.05	0.05	0.04						
	M&F	0.03	0.03	0.03	0.03	0.02	0.03	0.04	0.03	0.03	0.02						
18-34	M	0.02	0.02	0.02	0.02	0.01	0.02	0.01	0.02	0.02	0.02						
	F	0.32	0.29	0.45	0.26	0.30	0.32	0.16	0.24	0.27	0.30						
	M&F	0.22	0.22	0.34	0.20	0.22	0.24	0.08	0.17	0.21	0.23						
35-49	M	0.03	0.03	0.05	0.03	0.04	0.04	0.01	0.02	0.04	0.03						
	F	0.17	0.20	0.27	0.17	0.18	0.25	0.04	0.16	0.20	0.22						
	M&F	0.12	0.15	0.21	0.13	0.14	0.21	0.03	0.12	0.14	0.17						
50-64	M	0.03	0.05	0.03	0.04	0.04	0.04	0.08	0.04	0.08	0.04						
	F	0.11	0.14	0.15	0.13	0.12	0.15	0.14	0.15	0.17	0.13						
	M&F	0.07	0.10	0.10	0.09	0.09	0.11	0.11	0.10	0.13	0.09						

Table A. HEDIS 2016 Plan-Specific Rates with HEDIS 2015 National Benchmarks: Utilization Measures

Measure by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	2015 National Medicaid Means and Percentiles					
												Mean	P10	P25	P50	P75	P90
65-74	M	0.03	0.02	0.04	0.01	0.16	0.01	0.00	0.06	0.07	0.05						
	F	0.13	0.09	0.09	0.03	0.03	0.08	0.46	0.19	0.15	0.12						
	M&F	0.09	0.06	0.07	0.02	0.08	0.06	0.23	0.14	0.12	0.10						
75-84	M	0.00	0.05	0.04	0.00	0.03	0.04	0.00	0.06	0.03	0.02						
	F	0.17	0.13	0.05	0.02	0.08	0.00	0.00	0.14	0.09	0.09						
	M&F	0.11	0.10	0.04	0.02	0.07	0.01	0.00	0.11	0.07	0.07						
≥85	M	0.09	0.07	0.00	0.00	0.00	0.00		0.07	0.01	0.02						
	F	0.48	0.23	0.07	0.11	0.09	0.06		0.07	0.09	0.04						
	M&F	0.42	0.20	0.06	0.10	0.07	0.04		0.07	0.07	0.04						
Unknown	M																
	F																
	M&F																
Total	M	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.01	0.01	0.01	0.02
	F	0.15	0.13	0.22	0.13	0.14	0.15	0.08	0.12	0.13	0.14	0.12	0.08	0.09	0.11	0.14	0.18
	M&F	0.09	0.08	0.13	0.08	0.09	0.10	0.04	0.07	0.08	0.09	0.07	0.04	0.05	0.07	0.09	0.10

## APPENDIX B | HEDIS 2015 National Medicaid Means and Percentiles

Table B. HEDIS 2015 National Medicaid Means and Percentiles						
Measure	Mean	10th	25th	Percentile 50th	75th	90th
<i>HEDIS Effectiveness of Care Measures</i>						
<i>Prevention and Screening</i>						
<b>Adult BMI Assessment (ABA)</b>	79.91%	66.51%	75.47%	83.45%	89.62%	92.94%
<b>Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC):</b>						
BMI Percentile: 3–11 years	63.61%	36.77%	50.72%	66.86%	77.48%	86.28%
12–17 years	64.71%	40.00%	52.05%	67.47%	79.49%	86.36%
<b>Total</b>	<b>64.05%</b>	<b>38.94%</b>	<b>51.27%</b>	<b>67.23%</b>	<b>77.98%</b>	<b>85.61%</b>
Counseling for Nutrition: 3–11 years	62.15%	43.25%	54.25%	63.00%	73.78%	80.29%
12–17 years	57.55%	36.76%	47.77%	58.33%	71.52%	77.85%
<b>Total</b>	<b>60.52%</b>	<b>41.36%</b>	<b>51.98%</b>	<b>61.44%</b>	<b>72.87%</b>	<b>79.56%</b>
Counseling for Physical Activity: 3–11 years	52.62%	34.84%	42.91%	53.36%	63.94%	71.81%
12–17 years	55.25%	35.75%	46.49%	56.34%	66.23%	75.42%
<b>Total</b>	<b>53.54%</b>	<b>35.77%</b>	<b>44.16%</b>	<b>53.89%</b>	<b>64.43%</b>	<b>71.53%</b>
<b>Childhood Immunization Status (CIS):</b>						
DTaP	77.98%	69.70%	74.45%	79.52%	83.45%	86.11%
IPV	88.96%	82.86%	87.31%	91.22%	93.00%	94.70%
MMR	89.98%	84.67%	87.83%	90.93%	92.95%	94.91%
HiB	89.30%	84.49%	87.35%	91.00%	93.30%	95.38%
HepB	89.31%	80.54%	87.35%	91.48%	93.67%	95.43%
VZV	89.72%	84.17%	87.59%	91.17%	92.76%	94.81%
PCV	78.32%	69.05%	75.23%	79.88%	83.70%	87.04%
HepA	83.39%	73.24%	78.35%	84.43%	89.29%	91.67%
RV	68.08%	55.23%	64.23%	69.91%	74.83%	79.08%

Table B. HEDIS 2015 National Medicaid Means and Percentiles

Measure	Mean	Percentile				
		10th	25th	50th	75th	90th
Influenza	51.10%	35.65%	42.04%	51.34%	58.57%	65.45%
Combination 2	73.79%	63.99%	70.14%	75.47%	79.40%	82.78%
Combination 3	70.42%	59.93%	66.19%	71.53%	76.50%	81.25%
Combination 4	66.17%	54.68%	61.54%	67.64%	73.24%	77.86%
Combination 5	57.21%	42.36%	51.62%	58.36%	64.48%	69.59%
Combination 6	43.56%	29.29%	35.74%	43.65%	51.09%	57.53%
Combination 7	54.73%	40.48%	48.81%	55.52%	62.04%	67.20%
Combination 8	42.10%	27.74%	34.55%	42.23%	48.42%	56.02%
Combination 9	37.13%	24.33%	29.20%	36.68%	43.55%	51.60%
Combination 10	36.10%	23.40%	28.70%	35.88%	42.13%	49.63%
<b>Immunizations for Adolescents (IMA):</b>						
Meningococcal	73.43%	57.99%	66.67%	75.69%	83.70%	88.32%
Tdap/Td	83.75%	72.13%	81.02%	86.26%	90.00%	93.29%
Combination 1	71.39%	56.27%	63.79%	73.15%	81.51%	87.71%
<b>Human Papillomavirus Vaccine for Female Adolescents (HPV)</b>	22.19%	13.87%	17.36%	21.90%	25.61%	31.43%
<b>Lead Screening in Children (LSC)</b>	66.78%	40.40%	58.39%	71.93%	79.67%	85.93%
<b>Breast Cancer Screening (BCS)</b>	58.76%	45.79%	51.59%	58.34%	66.02%	71.41%
<b>Cervical Cancer Screening (CCS)</b>	60.22%	45.81%	54.33%	61.05%	67.88%	73.08%
<b>Chlamydia Screening in Women (CHL):</b>						
16–20 years	51.27%	36.67%	44.46%	50.17%	57.64%	66.71%
21–24 years	60.16%	46.72%	54.36%	61.21%	67.25%	72.08%
<b>Total</b>	<b>54.63%</b>	<b>40.34%</b>	<b>48.66%</b>	<b>54.40%</b>	<b>61.98%</b>	<b>68.60%</b>
<b>Respiratory Conditions</b>						
<b>Appropriate Testing for Children With Pharyngitis (CWP)</b>	69.54%	50.99%	62.98%	71.48%	79.83%	85.25%
<b>Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)</b>	30.95%	21.05%	25.81%	30.77%	35.77%	40.54%

Table B. HEDIS 2015 National Medicaid Means and Percentiles						
Measure	Mean	10th	25th	Percentile 50th	75th	90th
<b>Pharmacotherapy Management of COPD Exacerbation (PCE):</b>						
Systemic Corticosteroid	65.30%	47.60%	58.52%	69.01%	74.76%	78.21%
Bronchodilator	78.90%	64.06%	76.07%	83.43%	87.07%	89.04%
<b>Medication Management for People With Asthma (MMA)</b>						
Medication Compliance 50%*: 5–11 years						
12–18 years						
19–50 years						
51–64 years						
<b>Total</b>						
Medication Compliance 75%: 5–11 years	26.62%	15.81%	19.55%	24.86%	32.80%	40.37%
12–18 years	24.34%	15.15%	18.14%	23.30%	28.99%	35.81%
19–50 years	35.46%	23.26%	30.82%	35.28%	41.11%	46.29%
51–64 years	48.10%	37.14%	42.30%	48.51%	53.74%	58.82%
<b>Total</b>	<b>30.34%</b>	<b>18.58%</b>	<b>23.72%</b>	<b>29.60%</b>	<b>34.84%</b>	<b>43.38%</b>
<b>Asthma Medical Ratio (AMR)</b>						
5–11 years	69.47%	58.99%	63.30%	70.41%	75.30%	81.18%
12–18 years	57.68%	46.90%	51.50%	58.44%	64.15%	68.06%
19–50 years	47.11%	33.63%	40.96%	48.28%	53.48%	57.68%
51–64 years	49.01%	34.78%	43.06%	50.19%	56.29%	61.65%
<b>Total</b>	<b>59.33%</b>	<b>48.29%</b>	<b>54.23%</b>	<b>60.76%</b>	<b>65.01%</b>	<b>70.43%</b>
<b>Cardiovascular Conditions</b>						
<b>Controlling High Blood Pressure (CBP)</b>	57.08%	43.55%	49.88%	57.53%	65.49%	70.32%
<b>Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)</b>	83.22%	71.43%	79.79%	84.15%	89.33%	92.31%
<b>Statin Therapy for Patients with Cardiovascular disease (SPC)**:</b>						
Received Statin Therapy: Males 21-75 years						
Females 40 -75 years						
<b>Total</b>						

Table B. HEDIS 2015 National Medicaid Means and Percentiles

Measure	Mean	10th	25th	Percentile 50th	75th	90th
Statin Adherence 80%: Males 21-75 years Females 40 -75 years						
<b>Total</b>						
<b>Diabetes</b>						
<b>Comprehensive Diabetes Care (CDC):</b>						
HbA1c Testing	86.30%	80.29%	83.19%	86.20%	89.55%	91.94%
HbA1c Control (<7.0%)	34.10%	21.70%	28.88%	36.47%	39.66%	41.74%
HbA1c Control (<8.0%)	46.47%	32.93%	40.00%	47.91%	54.01%	58.58%
Retinal Eye Exam Performed	54.30%	38.49%	47.06%	54.74%	63.23%	67.74%
Medical Attention for Nephropathy	80.93%	73.54%	77.95%	81.75%	84.88%	87.70%
Blood Pressure Control (<140/90 mm Hg)	61.92%	48.66%	56.45%	62.23%	69.16%	76.64%
<b>Statin Therapy for Patients with Diabetes (SPD)**:</b>						
Received Statin Therapy: 40–75 years Statin Adherence 80%: 40–75 years						
<b>Musculoskeletal Conditions</b>						
<b>Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)</b>	69.44%	57.61%	63.64%	69.68%	75.71%	82.04%
<b>Behavioral Health</b>						
<b>Antidepressant Medication Management (AMM):</b>						
Effective Acute Phase Treatment	52.25%	42.82%	46.71%	50.51%	56.15%	62.56%
Effective Continuation Phase Treatment	36.99%	27.44%	30.99%	34.02%	40.48%	48.39%
<b>Follow-Up Care for Children Prescribed ADHD Medication (ADD):</b>						
Initiation Phase	40.06%	25.56%	32.77%	40.79%	49.07%	53.99%
Continuation and Maintenance Phase	47.52%	24.37%	34.66%	50.61%	58.36%	65.20%

Table B. HEDIS 2015 National Medicaid Means and Percentiles						
Measure	Mean	10th	25th	Percentile 50th	75th	90th
<b>Follow-Up After Hospitalization for Mental Illness (FUH):</b>						
7-day follow-up	43.95%	20.87%	31.98%	46.22%	56.78%	63.85%
30-day follow-up	63.09%	39.35%	53.19%	66.64%	75.28%	80.17%
<b>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</b>	79.84%	72.69%	75.74%	80.10%	83.84%	86.96%
<b>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</b>	69.34%	57.86%	65.22%	69.61%	75.67%	79.31%
<b>Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)</b>	76.58%	64.68%	70.00%	79.07%	83.33%	87.88%
<b>Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)</b>	59.99%	43.71%	56.13%	60.68%	66.96%	74.32%
<b>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)***</b>						
1-5 Years						
6-11 Years						
12-17 Years						
<b>Total</b>						
<b>Medication Management</b>						
<b>Annual Monitoring for Patients on Persistent Medications (MPM):</b>						
ACE Inhibitors or ARBs	87.23%	82.11%	84.87%	87.72%	89.87%	92.01%
Digoxin	53.83%	44.90%	49.35%	53.85%	58.64%	61.04%
Diuretics	86.85%	81.82%	84.66%	87.04%	89.52%	91.78%
<b>Total</b>	86.75%	81.73%	84.46%	87.05%	89.17%	91.59%
<b>Overuse/Appropriateness</b>						
<b>Appropriate Treatment for Children With Upper Respiratory Infection (URI)</b>	87.00%	74.51%	84.24%	88.09%	92.51%	95.17%

Table B. HEDIS 2015 National Medicaid Means and Percentiles						
Measure	Mean	10th	25th	Percentile 50th	75th	90th
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	28.54%	19.29%	22.00%	26.30%	32.80%	40.38%
Use of Imaging Studies for Low Back Pain (LBP)	75.10%	67.84%	71.82%	74.95%	78.06%	82.86%
<i>Measures Collected Through CAHPS Health Plan Survey</i>						
Flu vaccinations for adults ages 18 to 64 (FVA)	39.49%	30.04%	35.14%	39.04%	44.83%	48.96%
<b>Medical Assistance With Smoking and Tobacco Use Cessation (MSC)</b>						
Advising Smokers and Tobacco Users to Quit	75.79%	67.57%	73.60%	76.74%	79.41%	81.91%
Discussing Cessation Medications	46.75%	36.31%	41.76%	46.70%	51.91%	57.45%
Discussing Cessation Strategies	42.46%	33.59%	38.18%	42.50%	47.60%	51.21%
% Current Smokers	32.84%	19.95%	26.40%	34.19%	39.60%	44.74%
<b><i>HEDIS Effectiveness of Care Measures Where Lower Rates Indicated Better Performance</i></b>						
<b><i>Diabetes</i></b>						
<b>Comprehensive Diabetes Care (CDC):</b>						
HbA1c Poor Control (>9.0%)	43.55%	59.05%	49.89%	42.22%	34.66%	29.68%
<b><i>Overuse/Appropriateness</i></b>						
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	3.84%	7.11%	5.04%	3.63%	2.09%	1.35%
<b>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)***</b>						
1-5 Years						
6-11 Years						
12-17 Years						
<b>Total</b>						
<b><i>HEDIS Access/Availability of Care Measures</i></b>						
<b>Adults' Access to Preventive/Ambulatory Health Services (AAP):</b>						
20-44 years	79.36%	68.33%	76.31%	81.37%	84.95%	87.38%
45-64 years	86.60%	79.48%	85.14%	87.84%	90.30%	92.29%

Table B. HEDIS 2015 National Medicaid Means and Percentiles

Measure	Mean	10th	25th	Percentile 50th	75th	90th
<b>Children and Adolescents' Access to Primary Care Practitioners (CAP):</b>						
12–24 months	95.50%	91.75%	94.23%	96.28%	97.43%	98.17%
25 months–6 years	87.78%	81.64%	85.41%	88.46%	91.22%	92.93%
7–11 years	90.95%	85.74%	88.89%	91.42%	93.90%	95.88%
12–19 years	89.32%	83.28%	87.25%	90.06%	92.46%	94.91%
<b>Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET):</b>						
Initiation of AOD Treatment: 13–17 years	41.35%	27.27%	36.50%	41.91%	47.37%	55.69%
≥18 years	38.01%	29.76%	33.07%	37.61%	41.96%	48.39%
<b>Total</b>	<b>38.25%</b>	<b>30.00%</b>	<b>33.54%</b>	<b>38.03%</b>	<b>42.17%</b>	<b>48.22%</b>
Engagement of AOD Treatment: 13–17 years	15.74%	5.11%	8.57%	14.99%	22.51%	26.37%
≥18 years	10.75%	3.76%	6.60%	9.83%	14.44%	18.96%
<b>Total</b>	<b>11.24%</b>	<b>4.20%</b>	<b>7.14%</b>	<b>10.07%</b>	<b>14.96%</b>	<b>18.95%</b>
<b>Prenatal and Postpartum Care (PPC):</b>						
Timeliness of Prenatal Care	82.43%	68.60%	77.44%	85.19%	88.66%	91.73%
Postpartum Care	61.79%	48.94%	55.47%	62.77%	68.85%	72.43%
<b>Call Answer Timeliness (CAT)</b>	<b>80.85%</b>	<b>61.29%</b>	<b>77.32%</b>	<b>85.37%</b>	<b>88.97%</b>	<b>92.69%</b>
<b>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) ***</b>						
1–5 Years						
6–11 Years						
12–17 Years						
<b>Total</b>						
<b>HEDIS Utilization and Risk-Adjusted Utilization</b>						
<b>Frequency of Ongoing Prenatal Care (FPC):</b>						
<21%	14.24%	2.66%	5.60%	8.63%	15.09%	32.44%
21–40%	7.64%	2.54%	3.77%	5.62%	10.46%	14.36%
41–60%	8.43%	4.38%	5.93%	7.82%	10.22%	13.38%

Table B. HEDIS 2015 National Medicaid Means and Percentiles

Measure	Mean	Percentile				
		10th	25th	50th	75th	90th
61–80%	14.46%	7.73%	11.7%	14.19%	17.61%	20.68%
≥81%	55.24%	27.48%	46.72%	59.49%	69.78%	75.35%
<b>Well-Child Visits in the First 15 Months of Life (W15):</b>						
0 Visits	2.17%	0.46%	0.96%	1.65%	2.94%	4.27%
1 Visits	2.11%	0.57%	1.10%	1.86%	2.91%	3.89%
2 Visits	3.29%	0.97%	2.03%	3.10%	4.38%	5.53%
3 Visits	5.53%	2.63%	3.94%	5.09%	6.81%	8.26%
4 Visits	10.39%	6.23%	7.89%	9.58%	11.81%	15.01%
5 Visits	17.65%	11.11%	14.66%	17.82%	20.44%	24.31%
6 or More Visits	58.86%	44.15%	51.76%	59.76%	66.24%	74.47%
<b>Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)</b>	71.89%	59.62%	65.54%	72.02%	78.46%	83.75%
<b>Adolescent Well-Care Visits (AWC)</b>	50.02%	35.52%	41.76%	49.15%	59.98%	66.58%

\*Benchmarks are not currently reported by Quality Compass for this rate.

\*\*First-year measure

\*\*\*Benchmarks are not reported by Quality Compass for 2015 first-year measures

## APPENDIX C | MCO Population in Member Months

Table C1. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—AG

Age Group	AGE			AGM			AGW		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
<1	19412	17481	<b>36,893</b>	41740	40762	<b>82,502</b>	20397	20149	<b>40,546</b>
1–4	87130	81445	<b>168,575</b>	148517	142888	<b>291,405</b>	101404	96988	<b>198,392</b>
5–9	113565	110401	<b>223,966</b>	160184	155862	<b>316,046</b>	115115	115877	<b>230,992</b>
10–14	108548	104004	<b>212,552</b>	115741	113877	<b>229,618</b>	93562	95331	<b>188,893</b>
15–17	36696	34747	<b>71,443</b>	68973	69330	<b>138,303</b>	37471	35840	<b>73,311</b>
18–19	34822	34266	<b>69,088</b>	30456	37407	<b>67,863</b>	32940	35641	<b>68,581</b>
<b>0–19 Subtotal</b>	<b>400,173</b>	<b>382,344</b>	<b>782,517</b>	<b>565,611</b>	<b>560,126</b>	<b>1,125,737</b>	<b>400,889</b>	<b>399,826</b>	<b>800,715</b>
	<b>68.55%</b>	<b>50.17%</b>	<b>58.14%</b>	<b>73.05%</b>	<b>53.42%</b>	<b>61.76%</b>	<b>74.49%</b>	<b>50.36%</b>	<b>60.11%</b>
20–24	40462	89104	<b>129,566</b>	35806	88709	<b>124,515</b>	39806	94767	<b>134,573</b>
25–29	26419	89237	<b>115,656</b>	20064	87773	<b>107,837</b>	15852	111667	<b>127,519</b>
30–34	24465	57459	<b>81,924</b>	25944	89236	<b>115,180</b>	14864	56955	<b>71,819</b>
35–39	21126	41158	<b>62,284</b>	26176	73413	<b>99,589</b>	13423	33046	<b>46,469</b>
40–44	16246	31900	<b>48,146</b>	23298	47839	<b>71,137</b>	9308	27785	<b>37,093</b>
<b>20–44 Subtotal</b>	<b>128,718</b>	<b>308,858</b>	<b>437,576</b>	<b>131,288</b>	<b>386,970</b>	<b>518,258</b>	<b>93,253</b>	<b>324,220</b>	<b>417,473</b>
	<b>22.05%</b>	<b>40.53%</b>	<b>32.51%</b>	<b>16.96%</b>	<b>36.90%</b>	<b>28.43%</b>	<b>17.33%</b>	<b>40.84%</b>	<b>31.34%</b>
45–49	14057	23767	<b>37,824</b>	18728	28430	<b>47,158</b>	8524	22398	<b>30,922</b>
50–54	15606	20798	<b>36,404</b>	19432	23829	<b>43,261</b>	11134	19274	<b>30,408</b>
55–59	15203	15336	<b>30,539</b>	18340	19704	<b>38,044</b>	13906	15914	<b>29,820</b>
60–64	8708	8540	<b>17,248</b>	12562	14295	<b>26,857</b>	8834	8714	<b>17,548</b>
<b>45–64 Subtotal</b>	<b>53,574</b>	<b>68,441</b>	<b>122,015</b>	<b>69,062</b>	<b>86,258</b>	<b>155,320</b>	<b>42,398</b>	<b>66,300</b>	<b>108,698</b>
	<b>9.18%</b>	<b>8.98%</b>	<b>9.07%</b>	<b>8.92%</b>	<b>8.23%</b>	<b>8.52%</b>	<b>7.88%</b>	<b>8.35%</b>	<b>8.16%</b>

Table C1. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—AG

Age Group	AGE			AGM			AGW		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
65–69	577	805	1,382	3970	5942	9,912	908	1614	2,522
70–74	253	417	670	2271	3663	5,934	304	699	1,003
75–79	135	230	365	1197	2333	3,530	226	500	726
80–84	166	322	488	534	1766	2,300	95	272	367
85–89	62	328	390	278	994	1,272	65	212	277
≥90	68	343	411	66	521	587	59	284	343
<b>≥65 Subtotal</b>	<b>1,261</b>	<b>2,445</b>	<b>3,706</b>	<b>8,316</b>	<b>15,219</b>	<b>23,535</b>	<b>1,657</b>	<b>3,581</b>	<b>5,238</b>
	<b>0.22%</b>	<b>0.32%</b>	<b>0.28%</b>	<b>1.07%</b>	<b>1.45%</b>	<b>1.29%</b>	<b>0.31%</b>	<b>0.45%</b>	<b>0.39%</b>
<b>Total</b>	<b>583,726</b>	<b>762,088</b>	<b>1,345,814</b>	<b>774,277</b>	<b>1,048,573</b>	<b>1,822,850</b>	<b>538,197</b>	<b>793,927</b>	<b>1,332,124</b>

Table C2. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—BC and TCS

Age Group	BCE			BCM			BCW			TCS		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
<1	48780	47466	96,246	31320	30345	61,665	36467	35705	72,172	6517	6615	13,132
1–4	151124	143266	294,390	118945	115463	234,408	118190	112559	230,749	51307	44358	95,665
5–9	167589	162846	330,435	151073	149803	300,876	134810	132974	267,784	88892	58541	147,433
10–14	132031	128806	260,837	137490	135633	273,123	110161	113201	223,362	100452	58388	158,840
15–17	78454	77731	156,185	47335	45482	92,817	63614	68091	131,705	72005	42231	114,236
18–19	37838	48781	86,619	40549	44750	85,299	31014	37816	68,830	49198	25553	74,751
<b>0–19 Subtotal</b>	<b>615,816</b>	<b>608,896</b>	<b>1,224,712</b>	<b>526,712</b>	<b>521,476</b>	<b>1,048,188</b>	<b>494,256</b>	<b>500,346</b>	<b>994,602</b>	<b>368,371</b>	<b>235,686</b>	<b>604,057</b>
	<b>73.12%</b>	<b>50.37%</b>	<b>59.71%</b>	<b>73.71%</b>	<b>52.08%</b>	<b>61.09%</b>	<b>77.63%</b>	<b>52.07%</b>	<b>62.26%</b>	<b>87.29%</b>	<b>80.45%</b>	<b>84.49%</b>

Table C2. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—BC and TCS

Age Group	BCE			BCM			BCW			TCS		
	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total
20–24	36572	112231	<b>148,803</b>	46333	114662	<b>160,995</b>	35275	85327	<b>120,602</b>	32792	24629	<b>57,421</b>
25–29	20508	105870	<b>126,378</b>	25163	109202	<b>134,365</b>	12579	75110	<b>87,689</b>	4057	9394	<b>13,451</b>
30–34	28225	100350	<b>128,575</b>	24638	73549	<b>98,187</b>	16791	90546	<b>107,337</b>	4255	8027	<b>12,282</b>
35–39	29926	82191	<b>112,117</b>	21227	55367	<b>76,594</b>	15468	74511	<b>89,979</b>	3405	5799	<b>9,204</b>
40–44	29013	57310	<b>86,323</b>	15537	39615	<b>55,152</b>	13562	43779	<b>57,341</b>	2729	3706	<b>6,435</b>
<b>20–44 Subtotal</b>	<b>144,244</b>	<b>457,952</b>	<b>602,196</b>	<b>132,898</b>	<b>392,395</b>	<b>525,293</b>	<b>93,675</b>	<b>369,273</b>	<b>462,948</b>	<b>47,238</b>	<b>51,555</b>	<b>98,793</b>
	<b>17.13%</b>	<b>37.88%</b>	<b>29.36%</b>	<b>18.60%</b>	<b>39.19%</b>	<b>30.61%</b>	<b>14.71%</b>	<b>38.43%</b>	<b>28.98%</b>	<b>11.19%</b>	<b>17.60%</b>	<b>13.82%</b>
45–49	22890	41901	<b>64,791</b>	14443	31111	<b>45,554</b>	11491	28331	<b>39,822</b>	1888	2158	<b>4,046</b>
50–54	22186	37247	<b>59,433</b>	14807	24390	<b>39,197</b>	12764	23656	<b>36,420</b>	1844	1488	<b>3,332</b>
55–59	20177	30445	<b>50,622</b>	14821	18442	<b>33,263</b>	13271	19926	<b>33,197</b>	1699	1125	<b>2,824</b>
60–64	13384	23843	<b>37,227</b>	9123	9917	<b>19,040</b>	9503	14952	<b>24,455</b>	814	800	<b>1,614</b>
<b>45–64 Subtotal</b>	<b>78,637</b>	<b>133,436</b>	<b>212,073</b>	<b>53,194</b>	<b>83,860</b>	<b>137,054</b>	<b>47,029</b>	<b>86,865</b>	<b>133,894</b>	<b>6,245</b>	<b>5,571</b>	<b>11,816</b>
	<b>9.34%</b>	<b>11.04%</b>	<b>10.34%</b>	<b>7.44%</b>	<b>8.38%</b>	<b>7.99%</b>	<b>7.39%</b>	<b>9.04%</b>	<b>8.38%</b>	<b>1.48%</b>	<b>1.90%</b>	<b>1.65%</b>
65–69	1605	3608	<b>5,213</b>	742	1110	<b>1,852</b>	979	2274	<b>3,253</b>	108	74	<b>182</b>
70–74	1099	2195	<b>3,294</b>	375	568	<b>943</b>	362	998	<b>1,360</b>	18	56	<b>74</b>
75–79	482	1220	<b>1,702</b>	241	499	<b>740</b>	165	487	<b>652</b>	30	17	<b>47</b>
80–84	168	882	<b>1,050</b>	187	528	<b>715</b>	122	387	<b>509</b>	7	1	<b>8</b>
85–89	80	434	<b>514</b>	127	475	<b>602</b>	68	131	<b>199</b>	0	0	<b>0</b>
≥90	12	198	<b>210</b>	109	351	<b>460</b>	12	77	<b>89</b>	0	0	<b>0</b>
<b>≥65 Subtotal</b>	<b>3,446</b>	<b>8,537</b>	<b>11,983</b>	<b>1,781</b>	<b>3,531</b>	<b>5,312</b>	<b>1,708</b>	<b>4,354</b>	<b>6,062</b>	<b>163</b>	<b>148</b>	<b>311</b>
	<b>0.41%</b>	<b>0.71%</b>	<b>0.58%</b>	<b>0.25%</b>	<b>0.35%</b>	<b>0.31%</b>	<b>0.27%</b>	<b>0.45%</b>	<b>0.38%</b>	<b>0.04%</b>	<b>0.05%</b>	<b>0.04%</b>
<b>Total</b>	<b>842,143</b>	<b>1,208,821</b>	<b>2,050,964</b>	<b>714,585</b>	<b>1,001,262</b>	<b>1,715,847</b>	<b>636,668</b>	<b>960,838</b>	<b>1,597,506</b>	<b>422,017</b>	<b>292,960</b>	<b>714,977</b>

Table C3. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—UHC									
Age Group	UHCE			UHCM			UHCW		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
<1	32303	29742	<b>62,045</b>	45914	42640	<b>88,554</b>	32960	31998	<b>64,958</b>
1–4	131314	126433	<b>257,747</b>	144712	141857	<b>286,569</b>	116449	111189	<b>227,638</b>
5–9	148291	143339	<b>291,630</b>	157142	153646	<b>310,788</b>	135786	134239	<b>270,025</b>
10–14	118965	115291	<b>234,256</b>	114956	111654	<b>226,610</b>	98277	98990	<b>197,267</b>
15–17	70271	72873	<b>143,144</b>	69645	69881	<b>139,526</b>	58884	63246	<b>122,130</b>
18–19	32838	39150	<b>71,988</b>	30752	36483	<b>67,235</b>	28395	33722	<b>62,117</b>
<b>0–19 Subtotal</b>	<b>533,982</b>	<b>526,828</b>	<b>1,060,810</b>	<b>563,121</b>	<b>556,161</b>	<b>1,119,282</b>	<b>470,751</b>	<b>473,384</b>	<b>944,135</b>
	<b>65.67%</b>	<b>47.76%</b>	<b>55.36%</b>	<b>72.47%</b>	<b>51.14%</b>	<b>60.03%</b>	<b>72.77%</b>	<b>50.69%</b>	<b>59.72%</b>
20–24	37915	84669	<b>122,584</b>	30597	84612	<b>115,209</b>	35013	89541	<b>124,554</b>
25–29	22265	78870	<b>101,135</b>	18908	88786	<b>107,694</b>	14231	69025	<b>83,256</b>
30–34	25507	83031	<b>108,538</b>	24576	92461	<b>117,037</b>	13170	69963	<b>83,133</b>
35–39	30474	78859	<b>109,333</b>	27494	74832	<b>102,326</b>	16984	67700	<b>84,684</b>
40–44	31394	58520	<b>89,914</b>	24530	49663	<b>74,193</b>	16899	43472	<b>60,371</b>
<b>20–44 Subtotal</b>	<b>147,555</b>	<b>383,949</b>	<b>531,504</b>	<b>126,105</b>	<b>390,354</b>	<b>516,459</b>	<b>96,297</b>	<b>339,701</b>	<b>435,998</b>
	<b>18.15%</b>	<b>34.81%</b>	<b>27.74%</b>	<b>16.23%</b>	<b>35.89%</b>	<b>27.70%</b>	<b>14.89%</b>	<b>36.37%</b>	<b>27.58%</b>
45–49	27357	39149	<b>66,506</b>	20859	31891	<b>52,750</b>	15171	26193	<b>41,364</b>
50–54	27621	36520	<b>64,141</b>	19878	27873	<b>47,751</b>	17495	22496	<b>39,991</b>
55–59	29438	32163	<b>61,601</b>	17955	24150	<b>42,105</b>	18022	20338	<b>38,360</b>
60–64	22030	25679	<b>47,709</b>	13013	18018	<b>31,031</b>	14306	14909	<b>29,215</b>
<b>45–64 Subtotal</b>	<b>106,446</b>	<b>133,511</b>	<b>239,957</b>	<b>71,705</b>	<b>101,932</b>	<b>173,637</b>	<b>64,994</b>	<b>83,936</b>	<b>148,930</b>
	<b>13.09%</b>	<b>12.10%</b>	<b>12.52%</b>	<b>9.23%</b>	<b>9.37%</b>	<b>9.31%</b>	<b>10.05%</b>	<b>8.99%</b>	<b>9.42%</b>

Table C3. HEDIS 2016 MCO Population Reported in Member Months by Age and Sex—UHC

Age Group	UHCE			UHCM			UHCW		
	Male	Female	Total	Male	Female	Total	Male	Female	Total
65–69	9247	15508	<b>24,755</b>	5071	9267	<b>14,338</b>	5681	8576	<b>14,257</b>
70–74	6425	11497	<b>17,922</b>	4144	7457	<b>11,601</b>	3780	7276	<b>11,056</b>
75–79	4110	9221	<b>13,331</b>	2828	5951	<b>8,779</b>	2130	5586	<b>7,716</b>
80–84	2648	8976	<b>11,624</b>	2019	5764	<b>7,783</b>	1697	5608	<b>7,305</b>
85–89	1676	6929	<b>8,605</b>	1272	5257	<b>6,529</b>	996	5158	<b>6,154</b>
≥90	979	6692	<b>7,671</b>	731	5347	<b>6,078</b>	583	4738	<b>5,321</b>
<b>≥65 Subtotal</b>	<b>25,085</b>	<b>58,823</b>	<b>83,908</b>	<b>16,065</b>	<b>39,043</b>	<b>55,108</b>	<b>14,867</b>	<b>36,942</b>	<b>51,809</b>
	<b>3.09%</b>	<b>5.33%</b>	<b>4.38%</b>	<b>2.07%</b>	<b>3.59%</b>	<b>2.96%</b>	<b>2.30%</b>	<b>3.96%</b>	<b>3.28%</b>
<b>Total</b>	<b>813,068</b>	<b>1,103,111</b>	<b>1,916,179</b>	<b>776,996</b>	<b>1,087,490</b>	<b>1,864,486</b>	<b>646,909</b>	<b>933,963</b>	<b>1,580,872</b>

## APPENDIX D | Measure Reporting Options

The reporting options are presented for each measure: administrative and/or hybrid. Currently, when the hybrid option is available, TennCare MCOs are required to use the hybrid method.

Table D. Measure reporting options: Administrative/Hybrid		
Measure	Administrative	Hybrid
<i>HEDIS Effectiveness of Care</i>		
<b>Prevention and Screening</b>		
Adult BMI Assessment (ABA)	✓	✓
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)	✓	✓
Childhood Immunization Status (CIS)	✓	✓
Immunizations for Adolescents (IMA)	✓	✓
Human Papillomavirus Vaccine for Female Adolescents (HPV)	✓	✓
Lead Screening in Children (LSC)	✓	✓
Breast Cancer Screening (BCS)	✓	
Cervical Cancer Screening (CCS)	✓	✓
Chlamydia Screening in Women (CHL)	✓	
<b>Respiratory Conditions</b>		
Appropriate Testing for Children With Pharyngitis (CWP)	✓	
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	✓	
Pharmacotherapy Management of COPD Exacerbation (PCE)	✓	
Medication Management for People With Asthma (MMA)	✓	
Asthma Medical Ratio (AMR)	✓	
<b>Cardiovascular Conditions</b>		
Controlling High Blood Pressure (CBP)		✓
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	✓	

<b>Table D. Measure reporting options: Administrative/Hybrid</b>		
<b>Measure</b>	<b>Administrative</b>	<b>Hybrid</b>
Statin Therapy for Patients with Cardiovascular Disease (SPC)	✓	
<b>Diabetes</b>		
Comprehensive Diabetes Care (CDC)	✓	✓
Statin Therapy for Patients with Diabetes (SPD)	✓	
<b>Musculoskeletal Conditions</b>		
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	✓	
<b>Behavioral Health</b>		
Antidepressant Medication Management (AMM)	✓	
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	✓	
Follow-Up After Hospitalization for Mental Illness (FUH)	✓	
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)	✓	
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	✓	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	✓	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	✓	
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	✓	
<b>Medication Management</b>		
Annual Monitoring for Patients on Persistent Medications (MPM)	✓	
<b>Overuse/Appropriateness</b>		
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	✓	
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	✓	
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	✓	
Use of Imaging Studies for Low Back Pain (LBP)	✓	
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)	✓	

<b>Table D. Measure reporting options: Administrative/Hybrid</b>		
<b>Measure</b>	<b>Administrative</b>	<b>Hybrid</b>
<b><i>Measures Collected Through CAHPS Health Plan Survey</i></b>		
Flu vaccinations for adults ages 18 to 64 (FVA)		
Medical Assistance With Smoking Cessation (MSC)		
<b><i>HEDIS Access/Availability of Care Measures</i></b>		
Adults' Access to Preventive/Ambulatory Health Services (AAP)	✓	
Children and Adolescents' Access to Primary Care Practitioners (CAP)	✓	
Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET)	✓	
Prenatal and Postpartum Care (PPC)	✓	✓
Call Answer Timeliness (CAT)	✓	
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	✓	
<b><i>HEDIS Utilization and Risk-Adjusted Utilization Measures</i></b>		
Frequency of Ongoing Prenatal Care (FPC)	✓	✓
Well-Child Visits in the First 15 Months of Life (W15)	✓	✓
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	✓	✓
Adolescent Well-Care Visits (AWC)	✓	✓